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1. MS in drug discovery 
The first main application of mass spectrometry (MS) in pharmaceutical analysis and 
in particular in drug discovery started in the 60’s, when it was used as an analytical 
tool for structure characterization of both synthetic and natural derived products and 
of their metabolites.  
We had to wait several decades before seeing a broader application of MS, not only 
limited to structure characterization, but also extended to the different branches of 
the drug discovery program, and this was due to some instrumental achievements: 
(a) the advent in the 90’s of ion sources (ESI and MALDI), able to ionize 
macromolecules, including peptides and proteins; (b) the commercial availability of 
high resolution mass analyzers, such as the Orbitrap in 2005; (c) the development of 
tandem and hybrid mass spectrometers as well as of bioinformatics tools for peptide 
sequence determination, even if contained in complex mixtures. [1] 
Nowadays, high-resolution mass spectrometry (HR-MS), coupled to an electrospray 
ionization (ESI) source, is an emerging and powerful analytical tool in the drug 
discovery field, applied for target and hit compound identification, protein-ligand 
characterization, lead optimization and this through a high-throughput screening 
(HTS) approach. [2] 
 
2. MS for the identification of bioactive molecules 
An emerging field of MS application in drug discovery regards the identification of 
large bioactive macromolecules, namely proteins, naturally existing in biological 
systems. The rationale of such a discovery approach is to consider natural matrices 
such as plant extracts or animal fluids characterized by a well-established 
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pharmacological/clinical activity and then identifying the proteins constituting the 
proteome. Bioinformatics tools are then used not only to address the biological 
activity of the identified proteins and to establish protein-protein interaction but also 
to predict the bioactivity of the digested peptides arising from gastro-intestinal 
digestion.  The aim of such an approach is to identify proteins or their clusters or 
peptides arising from their gastrointestinal digestion that are responsible of the 
pharmacological activity of the starting bioactive biological matrix. This knowledge 
permits not only the isolation of the bioactive fraction or its reproduction by 
recombinant technology, with the final goal of producing a standardized and high 
quality bioactive material, but also allows the set-up of suitable analytical protocols 
aimed at analyzing qualitatively and quantitatively the bioactive proteins. 
 
The large-scale study of proteins, particularly their structures and functions, falls 
within the scope of proteomics. Proteomics has evolved substantially over the last 20 
years; the term proteomics was first coined in 1997 [3] to make an analogy with 
genomics, the study of the genome.  
The rapidly emerging field of proteomics is strictly dependent on the success of whole 
genome sequencing projects, since it provides an essential support for more 
comprehensive characterization of the genes encoded within the genomes. In this 
respect, MS-based proteomics has established itself as the method of choice to 
interpret the information encoded in genomes.  
Traditional proteomics works aimed at characterizing individual proteins and 
understanding their functionality, and the amount of publicly available mass 
spectrometry-based proteomics data has grown substantially in recent years. 
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Proteomics could be considered as a field where researchers provide insights into 
cellular processes and functions by regrouping different pre-fractionation methods, 
mass spectrometry (MS), and bioinformatics. 
 
3. Mass spectrometry-based proteomic 
Although proteomics has enjoyed great success, it must still deal with significant 
technical challenges, including the dynamic nature of the proteome and its 
complexity. Recent development in mass spectrometry has improved the throughput 
in protein identification and quantification; most notably, enhancement of the 
sensitivity of mass spectrometers, as well as improved sample preparation and 
protein fractionation techniques have resulted over time in a more comprehensive 
analysis of proteomes.   
 
3.1. Sample preparation in proteomics 
Proteins present several striking analytical challenges, in particular the enormous 
dynamic range across which they are expressed. The analysis of complex biological 
matrices by MS is strictly dependent on off-line separation technologies that simplify 
such samples prior to mass analysis. Multiple separation methods can now, more 
easily, be combined for proteome analysis, and each approach available has its 
advantages and disadvantages. [4] 
“No proteome can be considered democratic, but rather oligarchic”, declared P.G 
Righetti, to introduce the very helpful invention regarding Protein Equalizer 
Technology, an enrichment method used to reduce protein concentration differences 
in a sample. This technique comprises a diverse library of combinatorial peptide 
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ligands coupled to spherical porous beads. In more detail, when these beads are 
added to a complex proteome characterized by a widely differing protein composition 
and relative abundance, they are able to “equalize” the protein composition, by 
sharply reducing the concentration of the most abundant protein components, and at 
the same time by enhancing the concentration of less abundant species. This 
innovation introduces a useful tool in bringing the “unseen proteome” within the 
detection capabilities of current proteomics detection methods. [5] 
Such an innovative technique has been largely applied with great success in this 
Ph.D work as described in the experimental part. 
 
3.2 Sources and MS analyzers for proteomics 
The production of ions of the molecules in the gas phase is an absolute requirement 
for successful mass spectrometric protein analysis. As reported above, the 
development of electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI), the two soft ionization techniques capable of ionizing 
peptides or proteins, revolutionized protein analysis using MS. For any MS 
experiment, more than one consideration should be mad about the instrumentation 
and fragmentation method best suited to the analytical strategy chosen (top-down, 
bottom-up or shotgun).  
The mass analyzer is central to MS experiments, and for proteomics research, four 
types of mass analyzer are commonly used: quadrupole (Q), ion trap (quadrupole ion 
trap - QIT, linear ion trap – LIT / LTQ), time-of-flight (TOF) mass analyzer, and 
Fourier-transform ion cyclotron resonance (FTICR) mass analyzer; they vary in their 
physical principles and analytical performance. In 1999, Makarov invented a new type 
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of mass analyzer, the Orbitrap. It is a “hybrid” instrument consisting of a LTQ coupled 
to a C-trap and the Orbitrap. It combines the robustness, sensitivity and MS/MS 
capability of the LTQ with the very high mass accuracy and the high-resolution 
capabilities of the Orbitrap, and, for all these characteristics, has become the 
instrument of choice for proteomic works. [6] 
The use of mass spectrometry for proteomics should not be considered as the 
application of a single technique for all purposes, since no instrument or existing 
method allows the identification and quantification of all the components of complex 
protein samples in a simple, single-step operation. 
The proteomic studies described in the present research work have been carried out 
by using an Orbitrap MS analyzer coupled to a Nano-LC system by a Nano-ESI 
source. The nano system together with a high-resolution MS analyzer represents a 
state of the art system for proteomics. 
 
3.3 The different stages of a proteomic experiment 
A typical proteomics experiment starts from the sample preparation stage, aimed at 
isolating proteins from the original sample (biological matrix, cell lysates or 
subcellular compartments). The second step consists of protein fractionation from 
complex mixtures using chromatographic or electrophoretic techniques.  
Each fraction can be directly analyzed by mass spectrometry, and the protein 
analysis carried out in the form of whole-protein analysis (top-down approach). Large 
proteins (>~50KDa), however, could not be readily analyzed, due to the increasing 
complexity of the gas-phase protein ion’s tertiary structure. [6] 
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The second approach, based on peptide detection to infer a protein sequence, 
implies protein digestion (shotgun approach). The obtained peptide mixture is 
consequently subjected to a chromatographic separation in order to reduce its 
complexity before it reaches the mass analyzer. Usually the resulting peptide mixture 
is extensively fractionated by a nanoscale reversed-phase high pressure liquid 
chromatography (RP-HPLC), easily hyphenated to a mass spectrometer. [7] The 
mass spectrometer scans the population of eluting ions, measures their m/z, and in 
the case of tandem MS experiments proceeds to the fragmentation step. Because 
peptides tend to fragment into recognizable patterns, peptide characterization can be 
achieved from this spectrum. [8] In this respect, due to the wide dynamic range of 
protein species in a complex biological matrix, the shotgun approach leads to the loss 
of information upon the conversion of intact proteins. Since the limited dynamic range 
of MS analysis only allows for the peptides present at high relative abundance to be 
preferentially sampled, the information regarding low abundant species is not 
commonly obtained. Alternatively, sodium dodecyl sulfate (SDS)-PAGE or 2D-PAGE 
separation methods can be applied prior to MS analysis; once proteins are separated, 
selected spots are excised and digested in-gel with a specific protease like trypsin, 
followed by MS measurement of the peptide mixture obtained (bottom-up approach).  
In each of these methods, the identified peptides are listed on a protein “hit list”, which 
is the typical output of a proteomics experiment. Since protein identifications rely on 
matches with sequence databases, in-depth proteome characterization is actually 
restricted to those species for which comprehensive sequence databases are 
available. [9] The computational peptide identifications are known to return both 
correct assignment against the experimental spectra, as well as a number of false 
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positives, strictly dependent on the introduction of many sources of errors through all 
experimental steps.  For instance, to solve the mass error introduced in the 
experimental observation of peaks, related to the mass spectrometer resolution, a 
mass error distribution is often used in the matching process. [8]  
The above described bottom-up approach has been used for protein identification 
together with suitable databases obtained by the genomes. 
 
3.4 Computational proteomics and system biology 
Proteomics has recently come to the forefront offering a new perspective to biological 
systems and promising to transform biology and medicine; it has revolutionized 
biological systems studies leading to advancements in the identification of some 
pathologies as well as a more exhaustive explanation of a given biological system. 
Proteins do not usually function in isolation; most interact non – covalently with other 
molecules of the same protein or with other proteins. Groups of interacting molecules 
for a specific function make up bio-modules whose interconnections give rise to 
networks.   
With the advent of system biology and more accurate computational modeling 
methodologies, it has been possible to realize biological networks aimed at 
elucidating both a system’s structure and functional dynamics, and to predict the 
behavior of such a biological system as a whole. [4] System biology approaches, 
including genomics, transcriptomics, and proteomics have now been adapted to 
update natural product discovery platforms. With ever more sequenced genomes in 
hand, it is possible now to use bioinformatics analysis to predict the biosynthetic 
potential of an organism, or more generally of a biological complex matrix. [10] 
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In particular, MS-based proteomics, to be biologically useful, should be interfaced 
well with different bioinformatics tools capable of accurate data elaboration. Although, 
bioinformatics for proteomics has developed with great speed and complexity many 
open source software are available with statistical methods and filtering algorithms 
for proteomic data validation, their usage can be problematic for researchers without 
programming experience. The main application in this regard is the generation of 
protein-protein linkage maps. STRING and similar platforms (Cytoscape) are useful 
tools that can provide integration of external databases with user data sets and 
present these elaborations in rich graphical formats.  
The current growth in the number of deep proteome studies means that the cell 
biology community needs consistent ways to process, analyze and share these large 
proteomic data sets.  
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The aim of the work is to set-up and apply an analytical approach based on 
proteomics for the identification of bioactive macromolecules contained in complex 
bioactive matrices, such as natural extracts and biological fluids. The approach starts 
with proteome characterization, followed by bioinformatics analysis aimed not only at 
addressing the biological activity of the identified proteins and at establishing protein-
protein interaction, but also at predicting the bioactivity of the digested peptides 
arising from gastro-intestinal digestion. We believe that the knowledge generated by 
such an approach permits not only the production of a safe and high 
quality/standardized bioactive matrix, obtained by isolating the bioactive fraction or 
by recombinant technology, but also the set-up of suitable analytical protocols aimed 
at analyzing qualitatively and quantitatively the bioactive proteins. 
The above mentioned strategy was applied for the identification of bioactive 
macromolecules contained in bovine colostrum and panax ginseng, two natural 
sources of nutraceutical and pharmaceutical interest. The goal was reached through 
an integrated analytical strategy based on a proteomic and bioinformatics approach 
and by applying innovative techniques for sample preparation, including affinity 
chromatography and the combinatorial peptide library technology (CPLL or PM, 
ProteoMiner), aimed at reducing the dynamic range of protein concentrations. 
Bovine colostrum (BC) is a mixture of diverse components, including proteins, fat, 
lactose, vitamins and minerals, providing the first nutritional components to newborn 
calves. Certain beneficial effects of BC may be shared across species and it could 
also benefit humans. Based on the presence of several bioactive components, BC 
has been included in several health products that are claimed to improve the immune 
system and treat gastro-intestinal infection as well as to maintain skin and mucous 
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membrane integrity, favoring their healing. Most of the beneficial effects of BC have 
been ascribed to protein components, and so far explained on the basis of the known 
components or by searching, through an intrinsically limited on target approach, only 
putative components whose activity would explain the effect of BC. In the first part of 
the work, an innovative proteomic approach was used to generate an exhaustive 
protein data bank of bovine colostrum, including the minor protein components. By 
using a bioinformatics approach, a cluster of bioactive proteins effective for treating 
wound healing was identified. Such an approach also permitted the exploration of 
novel biological functions of colostrum through the identification of novel bioactive 
proteins not yet reported as colostrum components. An integrated analytical strategy 
was then set-up for the quality control of the bioactive protein components of bovine 
colostrum.  
Asian ginseng (Panax ginseng C. A. Meyer), one of the most highly regarded of 
herbal medicines in the Orient, was selected as the second matrix to be studied; most 
of the health effects of such plant have been ascribed to ginsenosides. The aim of 
our research was to investigate the bioactive protein components and peptides 
arising from their gastrointestinal digestion, and to do this a comprehensive proteomic 
analysis was carried out together with a bioinformatics approach for protein/peptide 
bioactive constituents.  
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Part I-A 
 
Health benefits of bovine colostrum revealed by an in depth proteomic 
analysis 
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Abstract 
Bovine colostrum (BC), the initial milk secreted by the mammary gland immediately 
after parturition, is widely used for several health applications. We here propose an 
off-target method based on proteomic analysis to explain at molecular level the health 
benefits of BC. The method is based on the set-up of an exhaustive protein data bank 
of bovine colostrum, including the minor protein components, followed by a 
bioinformatics functional analysis. The proteomic approach based on ProteoMiner 
technology combined to a highly selective affinity chromatography approach for the 
immunoglobulins depletion, identified 1786 proteins (medium confidence; 634 setting 
high confidence), which were then clustered on the basis of their biological function. 
Protein networks were then created on the basis of the biological functions or health 
claims as input. A set of 93 proteins involved in the wound healing process was 
identified. Such an approach also permits the exploration of novel biological functions 
of BC by searching in the database the presence of proteins characterized by 
innovative functions. In conclusion an innovative approach based on an in depth 
proteomic analysis is reported which permits an explanation of the wound healing 
effect of bovine colostrum at molecular level and allows the search of novel potential 
beneficial effects. 
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1. Introduction 
Bovine colostrum (BC), the initial milk secreted by the mammary gland immediately 
after parturition, is a mixture of diverse components, such as proteins, fat, lactose, 
vitamins and minerals, providing the first nutritional components to the new-born 
calves [1, 2].  
Besides the nutritional effect, colostrum has a fundamental biological function in 
calves due to the presence of a complex mixture of proteins that actively participate 
in the protection of the neonate against pathogens and other postpartum 
environmental challenges (passive immune transfer) [3-6]. 
Certain effects of BC may be species specific, whereas other effects may be shared 
across species. Hence, the unique nutritional and biological activities of BC that 
benefit neonatal calves may also benefit humans and be effective for the treatment 
of some human pathologies [5, 7]. Most of the beneficial effects of BC have been 
ascribed to the protein components. For instance immunoglobulins, that represent 
the main protein class of colostrum, have direct antimicrobial and endotoxin-
neutralizing effects throughout the alimentary tract, playing a direct role in the defence 
of the gastro-intestinal (GI) tract [8-11]. BC also has growth-promoting effects on 
human epithelial cells, which is attributable to the combination of several growth 
factors, including insulin-like growth factors (IGFs), basic fibroblast growth factors 
and platelet-derived growth factor [5, 12, 13]. 
Based on the beneficial effects, as reported above, BC has been included in several 
health products making various claims such as supporting the immune system, 
treating gastro-intestinal infection and for the maintenance of the skin and mucous 
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membranes integrity, favouring their healing [9, 13] and also for the prevention and 
treatment of vaginal dryness [14]. 
Although several studies on the health applications have so far been reported, an in 
depth knowledge of the biological effects of BC at molecular level is still missing. Most 
of the beneficial effects of BC are explained on the basis of the known components 
or by searching, through an on target approach, putative components whose activity 
would explain the effect of BC [2, 15, 16]. This on target method has several limits 
and in particular it permits the identification of only known or putative components 
proposed on the basis of their biological activity but not of unknown compounds.  
We here propose an off-target method based on proteomic analysis. The method is 
based on the set-up of an exhaustive protein data bank of bovine colostrum, including 
the minor protein components. The proteins are then clustered on the basis of their 
biological function and protein networks created on the basis of the biological 
functions or health claims as input. Such an approach also permits the exploration of 
novel biological functions of colostrum by searching in the database for the presence 
of proteins characterized by innovative functions. 
Hence, an in depth proteome analysis of BC is required to generate such a workflow, 
aimed to better investigate the health benefits of BC and to find novel applications. 
From an analytical point of view, the complete BC proteome resolution represents a 
difficult challenge because, similarly to other body fluids, the proteins are contained 
in a large dynamic range, spanning up to 12 orders of magnitude. This hinders in-
depth proteomic analyses due to the lack of sensitivity in protein detection, primarily 
because of the influence of the dominating proteins (immunoglobulins and caseins). 
[17] [18] 
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Up to now several approaches have been reported and, to our knowledge, that 
proposed by Nissen et al., based on an extensive fractionation of colostrum prior to 
2D-LC-MS/MS analysis, which brought to the identification of 403 proteins, is, to date, 
the most extensive list of bovine colostrum proteins available in the literature [18]. 
We here report a strategy based on the combinatorial peptide library technology 
(CPLL or PM, ProteoMiner), aimed at reducing the dynamic range of protein 
concentrations, thus maintaining representatives of all proteins within the original 
sample under analysis [19]. The CPLL technology was also combined with a highly 
selective affinity chromatography approach, based on protein G stationary phase that 
binds specifically the Fc portion of the immunoglobulin and allows a removal of about 
95% of IgG.  
 
 
2. Materials and methods 
2.1. Chemicals 
ProteoMine (combinatorial hexapeptide ligand library beads, CPLL), Laemmli buffer, 
40% acrylamide/Bis solution, N,N,N',N'-tetramethylethylenediamine (TEMED), 
molecular mass standards and electrophoresis apparatus for one-dimensional 
electrophoresis were supplied by Bio-Rad Laboratories, Inc., Hercules CA. β-
mercaptoethanol, dithiothreitol (DTT), ammonium persulfate, 3-[3-cholamidopropyl 
dimethylammonio]-1-propanosulfonate (CHAPS), acetonitrile (ACN), trifluoroacetic 
acid (TFA), sodium dodecyl sulphate (SDS), iodoacetamide (IAA), formic acid (FA) 
and all other chemicals used throughout the experimental work were current pure 
analytical grade products and purchased from Sigma-Aldrich Corporation, St Louis, 
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MO. Water and acetonitrile (OPTIMA LC/MS grade) for LC/MS analyses were 
purchased from Fisher Scientific, UK. Complete protease inhibitor cocktail tablets and 
sequencing grade trypsin were supplied by Roche Diagnostics (Basel, CH). 
Decaseinated and defatted bovine colostrum was supplied by the company 
Advances in Medicine (AIM, Bologna, IT). According to the supplier, bovine colostrum 
was collected from Holstein cows until the fifth hour after birth and immediately frozen 
at -20°C. After a suitable dilution with demineralized water, the suspension obtained 
was introduced into a reactor (controlled continuous stirring), where it was heated at 
35-36°C for about 30 minutes. The suspension was then subjected to the skimming 
step, in a special cream centrifugal separator, and then  caseins were removed by 
precipitation by adjusting the pH at their isoelectric point. The product was then 
ultrafiltered on a ceramic membrane with cut-off 0.05 µm and the permeate 
concentrated (about 10/20 times) and dialyzed with demineralized water. The 
following steps consisted of the clarification through 0.45 and 0.22 µm filters followed 
by lyophilisation. 
 
2.2 Bovine IgG purification  
Affinity Chromatography – IgG depleted BC was prepared by removing the IgG 
fraction by affinity chromatography. The affinity column was prepared by packing 400 
mL of Protein G Sepharose 4 Fast Flow resin (GE Healthcare) in a column support 
HiScale 50 (GE Healthcare) which was connected to an FPLC system (ÄKTAprime 
plus, GE Healthcare).  
The chromatographic purification started by equilibrating the column with 5 volumes 
(5 x chromatographic bed volume) of buffer A (Binding Buffer: 20 mM sodium 
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phosphate, pH 7), and then the sample was loaded at a flow rate of 20 ml min-1. The 
absorbance  of the flow-through was monitored at 280 nm and the different fractions 
were automatically collected when the absorbance was > 0.01 A.U. . The subsequent 
step consisted of recovering the IgG fraction by eluting the column with 100% of 
Elution Buffer (1 M glycine hydrochloride pH 2.5).  
Tangential Flow Filtration – The collected fractions were mixed and subjected to 
concentration and desalting using hollow fibers cross flow filtration cartridges with 
3000 NMWC (Nominal Molecular Weight Cutoff) and a surface area of 650 cm2 (GE 
Healthcare) coupled to a tangential flow filtration system equipped with a peristaltic 
pump essential to keep the flow recirculation continuous (Kross Flo®- Tangential flow 
Filtration System Research III). The IgG depleted fraction was concentrated 20/30 
times, dialysed with 5 volumes and then lyophilized. Glass vials filled with 3mL 
dialyzed solution and partially stoppered with lyo-stoppers were placed on a pre-
cooled shelf at -20 °C inside the ice condenser chamber of an Alpha 1-4 LSC Christ 
freeze dryer (G). Once frozen (30 min), the samples were dried under the following 
condition. Main drying: the shelf temperature was ramped from -20 °C to 15 °C in 8 
h; afterwards the shelf temperature was kept constant over a 10 h period. The 
chamber pressure was set at 1.030 mBar; final drying: the chamber pressure was set 
at 0.001 mBar and the shelf temperature ramped to 25 °C in 2 h and then kept 
constant for 2.5h. 
2.3 Separative methods of proteins on polyacrylamide gel 
One-dimensional analysis (SDS-PAGE) - Protein separation was performed under 
both reducing and non reducing conditions; aliquots of 10 μL of samples containing 
20-25 µg of proteins were mixed with 10 μL of Laemmli sample buffer (containing 50 
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mM DTT in case of reducing conditions) and heated at 95°C for 5 minutes. Samples 
and the standard proteins mixture (Precision Plus Protein Standards) were loaded on 
precast gels (Any KD Mini Protean TGX), then placed in the electrophoresis cell (Mini-
PROTEAN Tetra) and run at 200 V until the samples reached the front of the gel. 
Gels were stained using Coomassie blue (Biosafe G250, Bio-Rad). Images were 
acquired by the GS800 densitometer and analyzed by software Quantity One (all Bio-
Rad). 
 
Two-dimensional gel electrophoresis - 150 µg of each sample were solubilised in the 
denaturing buffer (7 M Urea, 2 M thiourea, 40 mM Tris, 3% CHAPS) and incubated 
for one hour at room temperature with 5 mM TCEP in order to reduce the protein 
disulphide bonds. After spiking with DESTREAK (150 mM), Ampholine (0.5%) and 
Blue Bromophenol, samples were loaded on IPG strips (Bio-Rad 7 cm, pH gradient 
3-10); after incubation (4 hours) strips were laid in the strip housing for isoelectric 
focusing (IEF, I12 Protean IEF Cell-Bio-Rad) and covered with Mineral Oil (Bio-Rad) 
to prevent proteins oxidation and strip dehydration. The instrument was set to follow 
the voltage gradient reported in the Table 1.  
Voltage (V) Time (h) Voltage Ramping Method (Slope) 
100 1 Rapid 
1000 1 Rapid 
1000 1 Linear 
5000 1 Rapid 
5000 30 Linear 
 
Table 1- Isoelectric focusing voltage gradient. 
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Once the IEF was completed, strips were incubated with 2.5 mL of equilibration buffer 
(6 M Urea, 2% SDS, 0.05 M Tris-HCl pH 8.8 and  20% glycerol) on gentle shacking 
for 10 minutes. Proteins separation based on their molecular mass was obtained by 
one-dimensional electrophoresis (SDS-PAGE) using precast gel (Any KD ™ Mini 
Protean® TGX ™). The strips were laid on the top of the gel, orienting them so that 
pI followed an ascending order (from 3 to 10) from left to right, and coated with a layer 
of agarose (0.5%). The electrophoretic device was assembled as described above 
and the electrophoretic run was carried out at 200 V for 30 min. After electrophoresis, 
gels were washed, stained and acquired as image as described in the previous 
paragraph. 
 
2.4 Sample preparation for mass spectrometry analysis 
CPLL treatment (ProteoMiner) - 1.5 g of lyophilized colostrum (IgG depleted and non 
depleted) was dissolved in 50 mL of solubilization buffer (phosphate buffer 10 mM 
and 25 mM KCl pH≈7) in order to obtain a concentration of 3% w/v. The pH of the 
solutions was adjusted at pH 2.2, 4.0, and 9.0. The solutions at the different pH values 
(2.2, 4.0, 7.0, 9.0) were then incubated overnight with 100 µL of beads (ProteoMiner, 
Protein Enrichment Kit) under continuous stirring provided by a rotary mixer. All the 
beads were then recovered by filtering the solutions with Micro Bio-Spin 
chromatographic columns (Bio-Rad) connected to an Erlenmeyer flask coupled with 
a vacuum pump. Proteins bound to the beads, now trapped in the mesh of the 
chromatography column, were  eluted after two consecutive bead incubations with 
4% sodium dodecyl sulphate (100 µL first elution, 80 µL second elution) at 99°C. After 
each incubation the samples were centrifuged at 4000 rpm for two minutes. The first 
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and the second elution, maintained in separate eppendorf tubes, contained the 
enriched proteins. 
 
In-gel protein digestion – After gel separation by mono/bi-dimensional 
electrophoresis,  bands/spots of interest were excised and washed with 200 µL of 
MilliQ H2O. Gel pieces were destained using 100 µl of destaining solution (50% 
25 mM NH4HCO3/50% ACN) for 10 min and then with 100 µl of acetonitrile for other 
10 min.  
100 µl of reducing solution (10 mM DTT in 50 mM NH4HCO3) was added to gel pieces 
and incubated for one hour at 56 °C; after the removal of the solution and a washing 
step in Digestion buffer (50 mM ammonium bicarbonate), 100 µl of alkylating solution 
(55mm IAA in 50 mM NH4HCO3) were added to gel pieces and incubated in the dark 
for 45 minutes. After the removal of the alkylating solution, gel pieces were washed 
in Digestion buffer. Trypsin (sequencing grade, Roche) was diluted in Digestion buffer 
and added to gel pieces (about 1 µg of trypsin to each sample). After an overnight 
incubation at 37°C, the tryptic mixtures were acidified with 1 µl of formic acid and 
eluted using 70 µl of 3% TFA / 30% ACN in H2O MilliQ, which was added and 
incubated for 10 minutes at 37°C. This step was repeated once with the same solution 
and two times using acetonitrile; collected peptides were pooled for each sample. 
The peptide mixture was dried using a Speed Vac (Martin Christ) and stored at -20°C.  
 
2.5. Mass spectrometry analysis 
The peptide mixtures obtained by in-gel digestion were solubilized in 20 µl of buffer 
A (0.1% HCOOH). Five µl of each sample were injected on a C18 column (HALO 
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PicoFrit, 75 mM x 10 cm, 2.7 µ particles, 100 Å pore size, New Objective, USA) by a 
nano-chromatographic system (UltiMate 3000 RSLCnano System, Thermo 
Scientific) operating at a constant flow rate of 0.4 µl/min. The separating gradient 
ramped linearly from 1% acetonitrile to 35% acetonitrile in 90 min. The eluting 
peptides were on-line sprayed in a LTQ-Orbitrap XL mass spectrometer by a nano-
ESI source (all Thermo Scientific) set as follows: positive ion mode, spray voltage 1.8 
KV; capillary temperature 220°C, capillary voltage 35 V; tube lens offset 120 V. The 
mass spectrometer operated in data-dependent acquisition mode (DDA) to acquire 
both full MS and MS/MS spectra. Full MS spectra were acquired in a "profile" mode, 
by the Orbitrap (FT) analyzer, between 300-1500 m/z, AGC target = 5x105 and 
resolving power = 60000 (FWHM at 400 m/z). Tandem mass spectra MS/MS were 
acquired by the Linear Ion Trap (LTQ) in CID mode, automatically set to fragment the 
nine most intense ions in each full MS spectrum (exceeding 1x104 counts) under the 
following conditions: centroid mode, isolation width = 2.5 m/z, AGC target = 1x104 
and normalized CE = 35 eV. Dynamic exclusion was enabled for 45 seconds for ions 
already observed 3 times in 30 seconds. Charge state screening and monoisotopic 
precursor selection was enabled, singly and unassigned charged ions were not 
fragmented. Instrument control and spectra analysis were provided by the software 
Xcalibur 2.0.7 and Chromeleon Xpress 6.80. 
 
2.6. Data processing using different bioinformatics tools 
Protein identification - Proteins was identified using the software Proteome 
Discoverer 1.3 (Thermo Scientific) using the Sequest algorithm. The Bos Taurus 
database used for data analysis was downloaded from UniProt (released on October 
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16, 2013). Default settings were used for protein identification, with the following 
exceptions: mass range = 350 - 5000 Da, signal/noise threshold = 5, precursor mass 
tolerance = 5 ppm, fragment mass tolerance = 0.5 Da. Trypsin was set as the 
proteolytic enzyme, cysteine carbamidomethylation (+57.021 Da) and methionine 
oxidation (+15.995 Da) were set as variable modifications. Proteins were searched 
both in the Bos Taurus and in the Decoy Database. The false discovery rate of protein 
identification was set to FDR = 0.01 (Strict) or FDR = 0.05 (Relaxed). Two lists of 
proteins were obtained from Proteome Discoverer: the first list was generated by 
considering a medium-confidence identification (FDR = 0.05); the second one was 
generated by setting  a high-confidence identification (FDR = 0.01).  
These proteins were clustered on the basis of their cellular localization, molecular 
functions or biological processes by using the Annotation tool, that allows automatic 
information retrieval from the website Protein Center. 
 
Generation of protein-protein interaction network - STRING database (http://string-
db.org/) aims at providing a comprehensive understanding of biological processes, 
known or predicted, in which a group of proteins is involved, within a given organism. 
Functional analysis aimed at creating interaction and association protein networks 
was conducted subjecting the identified proteins (gene IDs), identified in all the 
colostrum samples analyzed, in STRING v.9.1, selecting Bos Taurus as organism 
reference. 
In the final interactive network view proteins are represented by nodes and 
interactions by connecting lines, continuous for direct interactions (physical), 
discontinuous for indirect (functional). Each connecting line is supported by at least 
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one bibliographical reference or by canonical information present in the dataset of 
STRING. The confidence value (score) was set to 0.4 (mean level). 
Based on functional annotations, including Gene Ontology, KEGG, Pfam and 
InterPro, proteins involved in selected biological processes were highlighted. On the 
basis of BC applications mentioned above, networks of protein interaction were 
enriched on the basis of the following biological processes: wound healing, 
bactericidal/bacteriostatic, neurogenesis, regulation of bone growth.  
 
3. Results 
3.1 SDS-PAGE analysis of bovine colostrum. Figure 1 displays the SDS-PAGE 
profile of BC in reducing and non-reducing conditions. As expected, the protein profile 
of native colostrum (non reducing conditions) shows a single, broad band of 
immunoglobulins centred at about 150 kDa, which disappears under reducing 
conditions in favour of two bands at about 50 and 25 kDa, representing the heavy 
and light IgG chains, respectively. Not many more bands can be detected, except for 
a few rather intense zones, which, upon cutting the gel into ten segments along the 
electrophoretic track, could be identified via MS as: α-lactalbumin (14.1 kDa), ß-
lactoglobulin (19.9 kDa), serum transferrin (77.7 kDa) and α2-macroglobulin (167.5 
kDa), i.e. the classical set of high-abundance species normally found in just about 
any type of milk of animal origin (although in colostrum IgGs alone represent about 
80% of the total protein mass). 
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Figure 1 - SDS-PAGE profiling of colostrum proteins. Mr: molecular mass ladder. Samples: 
Ctrl: control; red: reduced with 50 mM DTT. The two samples to the left have been dialyzed 
so as to remove sugars; the two to the right are untreated. Staining with colloidal Coomassie 
blue. 
 
The two lines are duplicated since they represent dialyzed vs. non-dialyzed 
colostrum. Although the pattern is superimposable, dialysis removes different sugars 
present in the fresh sample that, if not eliminated, upon storage form extensive 
adducts, producing, after Amadori rearrangement, stable glycated forms that would 
greatly increase the sample heterogeneity and produce a yellowish tinge, in turn 
diminishing the biological activity of originally active proteins [20] (all data presented 
hereafter were obtained using dialyzed colostrum).  
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3.2 Proteome treatment with CPLL. Given the impossibility of exploring to a deeper 
extent the colostrum proteome and so visualizing the low-abundance species whose 
signal is masked by the high-abundance proteins (especially IgGs), we resorted to 
sample treatment with combinatorial peptide ligand libraries (CPLL or PM, 
ProteoMiner), a technique well known to amplify the signal of less abundant species.  
The “democratic” extraction which occurred is shown in Figure 2, which shows the 
SDS-PAGE profiling of the control material (Starting – untreated sample) versus the 
sample captured with CPLLs at four different pH values (pH 2.2 with synthesis beads 
and pH 4.0, 7.0 and 9.0, with beads from ProteoMiner Kit).  
 
 
Figure 2 - SDS-PAGE profiling of colostrum proteins. Mr: molecular mass ladder. Samples: 
Start (control, untreated colostrum), 2.2 PM, 4.0 PM , 7.0 PM and 9.3 PM (colostrum 
captured with CPLL beads at pH 2.2, 4.0, 7.0 and 9.3, respectively). In these last 4 lanes 
notice the marked reduction of the 50 and 25 kDa chains of IgGs and the sudden 
appearance of a multitude of fine bands in the entire Mr region. Staining with colloidal 
Coomassie blue. 
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Two phenomena are immediately apparent: first of all, the massive amounts of heavy 
and light IgG chains present in the control are substantially reduced in the captured 
samples; concomitantly, a very large number of fine protein zones appears and 
carpets essentially the entire electrophoretic track between 10 to 250 kDa (and even 
higher).   
Just to give a visual impact of the large increment of novel protein species detected, 
the two-dimensional (2D) maps of Figure 3 show the pI/Mr distribution of the visible 
species in the control (first panel) versus the eluate from CPLL beads after pH 4.0 
capture (second panel). Many more spots are visible, especially in the acidic map 
region and in the Mr 10-40 kDa range.  
Although the CPLL Technology was found very effective in normalizing the protein 
abundance, the isoforms of the heavy and light IgG chains respectively were still 
predominant and for this reason, we combined the CPLL to IgG depletion by affinity 
chromatography. 
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Figure 3 - Two-dimensional maps of control (first panel) and CPLL captured colostrum at pH 
4.0 (second panel). Staining with colloidal Coomassie blue. 
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3.3 Immunoglobulin G (IgG) depletion by affinity chromatography. The affinity 
chromatogram displayed two peaks, the first, not retained, corresponding to the non-
immunoglobulin protein fraction and the second to IgG (data not shown). According 
to the relative abundance of IgG in colostrum (80%), the second peak was the most 
abundant, followed by a peak attributed to the immunoglobulin aggregates at high 
Mr. The electrophoretic patterns obtained for each collected fraction (data shown in 
the second part of the work), indicate a good depletion of immunoglobulins, whose 
characteristic bands at 160-50-25 KDa, are very weak in the aliquots eluted within 
the first peak, and clearly much more intense in the fractions of the second peak 
corresponding to the immunoglobulins.  
The efficiency of the depletion process was then confirmed by measuring the IgG 
content by enzyme immunoassay (ELISA assay) of the fractions collected and 
liophylized; the IgG content in the depleted fraction was less than 5% of the total 
amount of IgG (100%) as determined before the depletion. Data were confirmed by 
Western blot analyses (Figure 4), showing an intense dark spot referred to the large 
abundance of IgG in the untreated sample that almost disappears in the depleted 
colostrum (central lane) to be well evident in the IgG fraction.  
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Figure S1- Western blotting analysis using monoclonal antibody anti-bovine IgG. The 
marked reduced IgG content in the purified Bovine colostrum by Affinity Chromatography can 
be observed. Samples: Ctrl (untreated colostrum), IgG depleted colostrum and eluted IgG. 
Position of the molecular marker (in kDa) is indicated on the left. 
 
3.4 IgG depletion combined with CPLL Technology. IgG Depleted colostrum was 
treated with combinatorial peptide ligand libraries (CPLL or PM, ProteoMiner) under 
different pH conditions (pH 4.0 ,7.0, 9.3, 2.2) as described in Material and Methods 
section. Figure 5 shows the SDS-PAGE analysis, in which it is possible to appreciate 
the enrichment effect and in particular that the intensity of the characteristic bands of 
the IgG subunits (50 and 25 kDa) is extremely decreased while a very large number 
of fine protein zones appears. 
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Figure 4 - SDS-PAGE profiling of colostrum proteins. Mr: molecular mass ladder. Samples: 
Start (IgG depleted colostrum), 2.2 PM, 4.0 PM , 7.0 PM and 9.3 PM (IgG-depleted colostrum 
captured with CPLL beads at pH 2.2, 4.0, 7.0 and 9.3, respectively). In the first lane chains of 
IgGs are clearly reduced; while in the last 4 lanes notice the sudden appearance of a 
multitude of fine bands in the entire Mr region. Staining with colloidal Coomassie blue. 
 
 
The 1D SDS-PAGE was used for separation of the proteins prior to the protein 
identification by MS. Two distinct experiments, in which peptides extracted from a 
PAGE slices, were performed.  
The Venn diagrams on Figure 6 show the number of proteins identified by the CPLL 
treaments at different pH. It can be seen that only 156 proteins are common to all 
three different pH treatments and that each capture at each individual pH value gives 
a unique contribution in terms of detected proteins.  
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Figure 6 - Venn diagrams showing the separate contributions to protein discovery of the 
three different CPLL treatments at pH 4.0, 7.0 and 9.3. Yellow: Colostrum captured with 
CPLL beads at pH 4.0 (421 proteins); blue: Colostrum captured with CPLL beads at pH 9.3 
(435 proteins); Orange: Colostrum captured with CPLL beads at pH 7.0 (672 proteins). 
 
The largest contribution, though, appears to be the one produced by the pH 7.0 
treatment, which allows the identification of 326 unique proteins, followed by the pH 
9.3 (169 ID) and finally by the pH 4.0 capture (147 unique ID). It is of interest, here, 
to compare what can be found in untreated colostrum vs. the different CPLL 
treatments.  
This is shown in the Venn diagrams of Figure 7, in which the contribution of yet 
another capture at pH 2.2 (Figure 7 - panel A) is shown (this last capture is different 
from the other three, because here the mechanism of harvesting is largely induced 
by hydrophobic interaction, whereas at pH 4.0, 7.0 and 9.3 the main operative 
mechanism is based on ionically-driven interactions).  
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In general control colostrum allows identification of an average of 224 unique 
proteins, whereas, as shown in the four panels, the four CPLL treatments allow the 
detection of many more species. The newly found proteins obtained in the four 
captures can thus be summarized: 420 at pH 2.2 (panel A), 299 at pH 4.0 (panel B), 
539 at pH 7.0 (panel C) and 330 at pH 9.3 (panel D). Interestingly, in all cases, an 
average of only 20% detected proteins are in common between the control colostrum 
and each of the four treatments.  
Figure 7 - panel E summarizes the overall exploration of enriched colostrum 
proteome, the two Venn diagrams showing again, on the left side (small circle) the 
total IDs in control colostrum, while the large circle on the right represents the overall 
findings in all CPLL treatments, by subtracting the various redundant proteins present 
in more than one CPLL capture. It can be appreciated that, when comparing what 
can be seen in the control (224 proteins) vs. what has been found upon all four 
treatments (1167 proteins) a 5.5 fold increment of (550%) in protein visibility is 
obtained, this huge increase likely being due to low- to very-low abundance proteins 
present in colostrum, whose signal had been largely masked by that handful of 
proteins (5-6 major components), which alone constituted >95% of the protein mass 
in colostrum. 
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Figure 7 - Venn diagrams showing the separate contributions to protein discovery of four 
different CPLL treatments at pH 2.2 (panel A), 4.0 (panel B), 7.0 (panel C) and 9.3 (panel D) as 
compared to the proteome discovery of untreated colostrum samples; panel E summarizes the 
overall findings in all CPLL treatments against the total IDs in control colostrum; panel F shows 
the effect of IgGs depletion by affinity chromatography; against an average of about 371 IDs in 
the depleted colostrum, an additional 726 species are detected (representing the sum of all 
four CPLL treatments). 
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In order to investigate more deeply the colostrum proteome, we combined the 
depletion of the IgGs by affinity chromatography with the CPLL capture. The overall 
IDs are given in the Venn diagrams of Figure 7 – panel F: here too, against an 
average of about 371 IDs in the depleted colostrum, additional 726 proteins are 
detected (representing the sum of all four CPLL treatments). Interestingly, here too 
the overlap between the two samples is 20-25%.  
 The merging tool, available among the Proteome Discoverer options, automatically 
deletes the redundancies from different tabular reports; it was used to generate the 
final list of proteins identified in the different samples of bovine colostrum, which 
includes 1786 ID. This number was reduced to 634 proteins upon setting high peptide 
confidence as filter (Peptide RANK 1) [Table 2]. This list of proteins was used as input 
for functional analyses, as described above. 
 
SAMPLE 
N° EXCLUSIVE 
PROTEINS 
N° SHARED 
PROTEINS 
DIALYZED COLOSTRUM 73 
151 
DIALYZED COLOSTRUM + CPLLs 1016 
DIALYZED COLOSTRUM 117 
101 
IgG-DEPLETED - DIALYZED COLOSTRUM 257 
IgG-DEPLETED -DIALYZED COLOSTRUM 92 
281 
IgG-DEPLETED -DIALYZED COLOSTRUM + CPLLs 726 
 
Table 2 – Comparison of the number of proteins identified in all the fractions analyzed: 
dialyzed colostrum, colostrum treated with CPLLs, depleted colostrum, colostrum depleted 
and further treated with CPLLs. 
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3.5 Descriptive proteomic analysis.  The proteins identified by mass spectrometry 
were subdivided into specific clusters, grouped on the basis of their cellular 
localization, molecular function and the biological process in which they are involved. 
Regarding the biological process (Figure 8 – panel A) the largest clusters include: 
proteins involved in metabolic processes (19.5%) and in biological process regulation 
(14.4%) while fewer proteins are involved in cellular processes including cellular 
division, proliferation and differentiation. A group of proteins accounting for 11.3% 
resulted with no-annotation.  
Regarding the molecular function (Figure 8 – panel B), 27.03% of proteins are 
involved in protein binding, while fewer proteins are involved in metallic ions, 
nucleotides, DNA, RNA binding. It is also possible to find a great percentage of 
protein with catalytic activity. Whereas, with regard to intra/extra cellular localization 
(Figure 8 – panel C), we surprisingly found a high percentage of proteins localized in 
the cellular membrane (18.64 %), followed by those localized in the cytoplasm 
(18.34%) and extracellular proteins (17.19%).  
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Figure 8 – BC protein distribution based on the biological process (panel A), molecular function 
(panel B), and cellular localization (panel C), obtained by using enrichment tool by Proteome 
Discoverer. 
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3.6 Functional proteomic analysis. The first goal of the functional analysis was the 
generation of a protein-interaction network. The interaction network, consisting of a 
complex grid based on bibliographic evidence or canonical information within 
STRING database, was integrated with functional information obtained from others 
databases, namely Gene Ontology, KEGG, Pfam e InterPro, in order to create 
different biological process clusters. Moreover, the enrichment tool of STRING 
allowed us to highlight protein groups based on targeted biological process, 
molecular function, cellular component localization such as cytoskeletal binding, 
calcium ion binding, growth factor activity and antioxidant activity (Figure 8). Besides 
the above-mentioned clusters, it should be stressed that most of the identified protein 
(spheres) are not involved in protein-protein interactions and this is in agreement with 
the heterogeneous composition of colostrum, which is not associated with a well-
defined cellular system. The functional analysis was then focused on the wound 
healing process, which was selected since there is some evidence reporting the 
colostrum capacity to induce, enhance and promote wound healing in different animal 
models. To do this, the bovine colostrum database was filtered by considering the 
main physiological steps involved in the wound healing process such as: 
haemostasis, inflammation, proliferation and tissue re-modelling.  
  
47 
 
 
Figure 8- Protein interactome network for the bovine colostrum proteome using the STRING 
software. Thicker lines represent stronger associations. 
 
A set of 93 proteins involved in the wound healing process were identified (Table 3), 
which can clustered on the basis of their biological functions as follow: 17 involved in 
the haemostasis process, 9 in the inflammatory process; 9, 15, and 13 in 
angiogenesis, extracellular matrix organization and regulation of epithelial cell 
proliferation, respectively; 5 proteins involved in collagen synthesis and 25 acting in 
epithelial remodelling. 
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Vitamin K-dependent protein S 
Coagulation factor XIIIa  
Vitamin K-dependent protein C  
Coagulation factor V  
Plasma kallikrein  
Coagulation factor IX 
Prothrombin  
Kininogen-1  
Carboxypeptidase B2  
Fibrinogen alpha chain   
Fibrinogen beta chain  
Fibrinogen gamma-B chain   
Antithrombin-III 
Plasminogen  
Factor XIIa inhibitor    
Annexin A5  
Hermansky-Pudlak syndrome 1 protein 
IN
FL
A
M
M
A
T
IO
N
 
CD74 antigen  
Thrombospondin-4   
C-C motif chemokine 2  
Colony stimulating factor 1  
Prothrombin 
Inter-alpha-trypsin inhibitor heavy chain H4 
Alpha-2-antiplasmin   
Alpha-1-acid glycoprotein 
Fibronectin   
A
N
G
IO
G
E
N
E
S
IS
 
Angiogenin-1  
Fibronectin   
Thrombospondin-1  
Serine/threonine-protein kinase 4 
Lactadherin  (Milk fat globule-EGF factor 8)  
alpha 1 type XVIII collagen 
Nuclear receptor subfamily 4 group A member 1 
Glucose-6-phosphate isomerase 
Beta-1,4-galactosyltransferase 1 
Annexin A2 
Ephrin-A1 
72 kDa type IV collagenase  (Matrix metalloproteinase-2) 
E
C
M
 O
R
G
A
N
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A
T
IO
N
 Fibulin 1 
92 kDa type IV collagenase (Matrix metalloproteinase-9) 
Vitronectin   
Angiotensinogen  
Plasminogen    
Alpha-2-antiplasmin    
Collagen alpha-4(IV) chain   
Alpha 1 type XVIII collagen   
  
49 
 
Transforming growth factor beta-2  
Beta-1,4-galactosyltransferase 1 
Annexin A2 
 Galectin 3   
Pikachurin 
Collagen alpha-1(III) chain 
Melanoma-derived growth regulatory protein  
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Angiogenin-1  
Thrombospondin-1  
Thrombospondin-4 
Nuclear receptor subfamily 4 group A member 1   
Beta-1,4-galactosyltransferase 1 
NDP kinase A ;  
Pigment epithelium-derived factor 
Wingless-type MMTV integration site family, member 5A  
Annexin A1 
Desmoplakin 
Colony stimulating factor 1 
Cathepsin Z 
Cathepsin H 
C
O
LL
A
G
E
N
 
S
Y
N
T
H
E
S
IS
 92 kDa type IV collagenase (Matrix metalloproteinase-9) 
72 kDa type IV collagenase  (Matrix metalloproteinase-2) 
Collagen alpha-1(III) chain 
Prothrombin 
Fibrinogen gamma-B chain 
R
E
M
O
D
E
LL
IN
G
 
92 kDa type IV collagenase (Matrix metalloproteinase-9) 
72 kDa type IV collagenase  (Matrix metalloproteinase-2) 
Actin, cytoplasmic 2 (Gamma-actin) 
Myosin-10 
Inversin  
Serine/threonine-protein kinase 4 
Retinol-binding protein 4 
Alpha-2-antiplasmin  
Fibronectin 
Beta-1,4-galactosyltransferase 1  
Collagen alpha-1(III) chain 
Transforming growth factor beta-2 
Neuropilin 2 
Alpha 1 type XVIII collagen  
Lysosomal alpha-glucosidase  
Glucose-6-phosphate isomerase 
Lactadherin  (Milk fat globule-EGF factor 8) 
Troponin I, cardiac muscle 
Lymphocyte antigen 6 complex, locus E 
Annexin A2  
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Ephrin-A1 
LAMA4 protein 
Angiogenin-1  
Thrombospondin-1 
Plasminogen   
 
Table 3 - BC proteins involved in wound healing clustered on the basis of the physiological 
step involved in the process. 
 
 
The involvement of the identified proteins in each step of wound healing can be 
further explored on the basis of the detailed functional analysis of the proteins. As an 
example, Figure 9 shows the involvement of the identified proteins in the molecular 
events leading to haemostasis, which happens just before the inflammatory phase 
during wound healing. BC contains the main protein factors of the coagulation 
cascade and in particular the main coagulation factors (VIIIa, XII, V, IX), the Thrombin 
precursor and its corresponding inhibitor, and two serine-proteases (Protein C, 
Protein S), whose active form plays an important role in the regulation of blood 
coagulation.  
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Figure 9 - Haemostasis pathway; the gene products highlighted by a blue colour have been 
detected in bovine colostrum. 
  
The BC proteome was then used to search novel potential health applications of BC. 
To do this we created a list of proteins that are potentially useful for health and with 
an external use. Such proteins were sought with either recombinant or natural origin 
and using PubMed or patent search engines. The set of selected proteins was then 
sought in the database of BC. By using such an approach we found some proteins in 
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BC that are currently used or are potentially useful for treating some human diseases 
and mostly produced by recombinant technology. As an example we found Lumican, 
a 40 kDa keratan sulfate proteoglycan which is receiving growing interest since it is 
involved in corneal epithelial wound healing [21]. The content of Lumican in BC (as 
determined by ELISA) ranged between 10 and 30 pg mg-1. 
 
4. Discussion  
4.1. Off-target based proteomics to elucidate the bases of its biological 
activities 
The health benefits of bovine colostrum have been largely reported and partially 
demonstrated in some pharmacological models and clinical studies, but the 
molecular mechanisms are poorly understood [5, 22]. The health claims of BC are 
usually associated with the presence of a certain cluster of known proteins (i.e. 
growth factors for wound healing) whose well-defined biological function is taken into 
account to furnish the explanation for the BC activity. Another approach consists of 
searching for BC putative proteins whose presence would explain the BC activity. 
These approaches, based on selecting bioactive components a priori (on-target 
approach), are limited, since they do not permit the association of the biological 
function to unknown compounds, a very important issue to extend our knowledge of 
the molecular mechanisms of BC. To overcome such limit, we here propose an off-
target method based on proteomic analysis that consists of identifying proteins 
involved in a certain biological effect and not selected a priori. Clearly, to make such 
an approach reliable, an exhaustive protein data bank of BC, including the minor 
protein components is required and this represented the first step of the work.  
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4.2. Protein identification via mass spectrometry analysis 
Since bovine colostrum, in addition to being an extremely complex biological matrix, 
is characterized by the presence of abundant proteins (caseins and 
immunoglobulins), which limit the separation and identification of the minor protein 
components by conventional techniques, an innovative analytical approach was 
required. 
Traditional systematic proteomic approaches are essentially based on two 
consecutive analytical steps: protein separation followed by identification. The 
conventional approach was initially applied for our purpose, but it turned out to be 
severely limiting due to its failure to separate/identify the minor protein components, 
including growth factors present in trace amounts, presumably responsible for some 
of the biological activities. 
The need to solve a complex proteome, characterized by a wide dynamic range, has 
focused our attention on proteomic techniques able to reduce protein concentration 
differences and enrich the low-abundance species, among which the well-ingrained 
“CPLL technology” appears to offer the best solution, since it is the only one able to 
“normalize” a protein population, by sharply reducing the concentration of the most 
abundant components, while simultaneously enhancing the concentration of the most 
rare species [19].  
An important goal was to set-up the best working conditions of the "CPLL technology" 
in order to extract the largest number of proteins. Since in the capture process ionic 
interactions are the most prominent ones, the extraction was conducted at four 
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different pH values (2.2, 4.0, 7.0, and 9.3) to modulate the surface charge of both the 
proteins and the hexa-peptide baits. 
The one and two-dimensional electrophoretic analysis of extracts confirmed that the 
sample treatment with the CPLL technology greatly improved the resolution of the 
proteome. Moreover, both the one- and two-dimensional electrophoretic maps of the 
extracts corresponding to the four different pH are visibly different and characterized 
by an extremely heterogeneous protein composition. In this way the importance and 
advantage of the parallel incubations at different pH values was established.  
Although this technology enabled a significant improvement in the resolution of the 
colostrum proteome, the immunoglobulin component still represented the main 
component. The only partial reduction of this protein component can be explained 
considering the heterogeneity of the variable portion of the immunoglobulin, so that 
the class of immunoglobulins is not recognized as a single protein, and therefore 
normalized, but as a set of more heterogeneous proteins. 
Therefore, in order to achieve a more comprehensive “picture” of the bovine 
colostrum proteome, the next step was to analyze the IgG-depleted colostrum 
obtained by affinity chromatography. Immunoassays and electrophoretic analysis 
confirmed the efficiency and robustness of the depletion method.  
As we expected, our previous results showed that the IgG-depletion on the one hand 
allowed the enrichment of a unique set of proteins, and on the other led to the loss of 
an equivalent number of proteins. This concept is in agreement with what reported in 
the literature: the selective removal of very abundant proteins, at the same time, 
cause the co-depletion of many species associated to the proteins removed [23]. 
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Therefore, an in-depth analysis of the proteome cannot be achieved by considering 
only one sample preparation strategy, and/or a single extraction method, but through 
the integration of all the data obtained by using different approaches, since these are 
complementary. 
By applying specific tools provided by Proteome Discoverer software, we compared 
the number of proteins identified in the following conditions: dialyzed colostrum, 
colostrum treated with CPLLs, depleted colostrum, colostrum depleted and further 
treated with CPLLs (Table 2). 
An accurate analysis of the values in the Table 2 leads to the conclusion that every 
single treatment, in a different way, increases knowledge of the proteome, therefore, 
in order to achieve a complete and comprehensive database of proteins belonging to 
bovine colostrum, it was necessary to merge all the results obtained. 
By using such an approach a list of 634 proteins was obtained by setting a high 
peptide confidence and 1786 proteins by using a medium peptide confidence. The 
number of the identified proteins represents to our knowledge the most extensive list 
of bovine colostrum proteins available so far reported.  
 
4.3. Functional study 
The final database shown in Table S1 was then used for the functional investigation. 
It was firstly applied for the off-target analysis aiming at better understanding the 
health benefit activity of colostrum at molecular level. We firstly clustered the proteins 
based on their biological function and in turn on the health claims. We started by 
focusing on the effect of BC to modulate and furnish a support effect on the immune 
system, since it is definitely one of the most studied and well known health effects 
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exerted by BC [5]; besides immunoglobulins, we found a cluster of 4.02% proteins 
involved in the defensive response and which can contribute to such effect. Another 
important biological effect already demonstrated for BC is its ability to promote 
epithelial cell proliferation, wound healing, accelerated proliferation of keratinocytes, 
and its positive effect on the re-epithelialization. A set of 2.43% of BC proteins is 
involved in the proliferation processes and 12.57% and 12.51% of the total protein 
content, are involved in cell division and cell growth, respectively, which together with 
the proteins having a proliferative activity, are supposed to contribute actively to the 
widely demonstrated wound healing and regeneration process of BC. 
A more detailed function analysis was then carried out for the wound healing process. 
The off-target approach identified 93 proteins that were then clustered on the basis 
of the 7 biological events leading to wound healing. Most of the identified proteins in 
BC were not reported as acting in the wound healing process, which is usually related 
to the presence of growth factors. Besides an important insight into the molecular 
mechanism, such an approach can also be important in setting up suitable analytical 
procedures to guarantee the quality control. For instance if BC is used as a wound 
healing product then a panel of proteins involved in this biological process can be 
selected for the qualitative and quantitative analysis thus assuring the quality and 
safety of the final product. 
Finally, by cross searching the BC database with a list of proteins, natural or 
recombinant, claimed to have health benefits for external use, novel applications of 
BC can be explored. As an example, we found that BC contains lumican (10-30 
pg/mg) which is a keratan sulfate proteoglycan that may be beneficial for treating 
epithelial defects in the cornea [21, 24]. 
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5. Conclusions 
In conclusion this paper on the one hand highlights the importance of ProteoMiner in 
greatly expanding the visibility of low- to very-low abundance species and, on the 
other hand, underlines the importance of proteomics in the pharmaceutical field and 
in particular for clarifying the biological effects of a complex protein matrix. 
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Table S1 – List of the 634 unique gene products identified in bovine colostrum.  
 
Accession 
Number 
Protein Name Coverage N° Peptides 
F1MTE8 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 1.17 1 
Q2HJD7 3-hydroxyisobutyrate dehydrogenase, mitochondrial  5.36 1 
F1MKI5 45 kDa calcium-binding protein (Fragment)  25.59 4 
F1N2B5 4F2 cell-surface antigen heavy chain 22.04 7 
E1BMZ8 5'-3' exoribonuclease 1 1.80 1 
Q0IIG5 6-phosphofructokinase, muscle type  4.49 1 
F1MKH8 72 kDa type IV collagenase  4.69 2 
Q0VCX2 78 kDa glucose-regulated protein  9.92 5 
E1BK03 A disintegrin and metalloproteinase with thrombospondin motifs 6 1.25 1 
F1MP11 A disintegrin and metalloproteinase with thrombospondin motifs 8 1.33 1 
A4FUD5 ABI3 protein  2.79 1 
Q95M17 Acidic mammalian chitinase  3.18 1 
P60712 Actin, cytoplasmic 1  47.73 13 
Q58CQ2 Actin-related protein 2/3 complex subunit 1B  3.76 1 
G5E5R8 Activity-regulated cytoskeleton-associated protein 3.03 1 
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Q0VCZ8 Acyl-CoA synthetase long-chain family member 1  1.43 1 
Q3Y5Z3 Adiponectin  5.00 1 
G3MYZ3 Afamin 20.70 9 
F1MSI2 Agrin 0.69 1 
G5E5D8 A-kinase anchor protein 14 11.86 1 
Q2KJH7 Aldehyde dehydrogenase 18 family, member A1  1.38 1 
A7YY28 Alpha/beta hydrolase domain-containing protein 14B  4.76 1 
Q3SZR3 Alpha-1-acid glycoprotein  52.97 13 
P34955 Alpha-1-antiproteinase  46.15 23 
Q2KJF1 Alpha-1B-glycoprotein  55.07 19 
P28800 Alpha-2-antiplasmin  29.27 10 
P12763 Alpha-2-HS-glycoprotein  28.97 12 
Q7SIH1 Alpha-2-macroglobulin  59.34 67 
F1MRD4 Alpha-actinin-2 (Fragment)  1.88 1 
F1MJQ3 Alpha-amylase 2 24.07 10 
F1MB08 Alpha-enolase  17.28 5 
E1B725 Alpha-galactosidase A 5.69 2 
P00711 Alpha-lactalbumin  83.10 15 
F1N7T2 Alpha-mannosidase 2x - 1 12.31 11 
E1BGJ4 Alpha-mannosidase 2x -2  11.74 11 
Q1RMM9 Alpha-N-acetylgalactosaminidase  6.81 2 
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P02662 Alpha-S1-casein  37.85 8 
P02663 Alpha-S2-casein  19.37 3 
E1B958 Alstrom syndrome protein 1 0.49 1 
E1BJN3 Amine oxidase  12.10 7 
P10152 Angiogenin-1  57.43 13 
P80929 Angiogenin-2  45.53 6 
Q3SZH5 Angiotensinogen  54.95 15 
E1BFD1 Ankyrin repeat and LEM domain-containing protein 2 2.90 1 
F1N650 Annexin  57.51 20 
F6QVC9 Annexin  10.90 3 
P04272 Annexin A2  31.86 7 
P81287 Annexin A5  10.90 3 
P79134 Annexin A6  2.08 1 
F1MSZ6 Antithrombin-III  59.14 24 
Q3ZC13 AP-2 complex subunit mu  4.83 1 
G3N2W6 APOL3 protein 8.04 1 
P15497 Apolipoprotein A-I  61.89 20 
P81644 Apolipoprotein A-II  16.00 1 
F1N3Q7 Apolipoprotein A-IV  15.53 4 
E1BNR0 Apolipoprotein B (Fragment) 0.74 2 
Q32KY0 Apolipoprotein D  13.23 2 
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Q03247 Apolipoprotein E  37.34 9 
E1BLF5 Aryl hydrocarbon receptor nuclear translocator-like protein 1 2.88 1 
Q08DD1 Arylsulfatase A  11.83 3 
P33097 Aspartate aminotransferase, cytoplasmic  15.98 4 
P12344 Aspartate aminotransferase, mitochondrial  2.09 1 
F1MH20 Ataxin-10  3.37 1 
E1B7A9 ATP-binding cassette sub-family C member 11 1.99 1 
Q4GZT4 ATP-binding cassette sub-family G member 2  1.53 1 
G3N0Q8 Azurocidin 42.68 7 
F1MER7 Basement membrane-specific heparan sulfate proteoglycan core protein 0.30 1 
P08037 Beta-1,4-galactosyltransferase 1  46.52 13 
P17690 Beta-2-glycoprotein 1  55.65 14 
P01888 Beta-2-microglobulin  66.10 11 
P02666 Beta-casein  8.48 1 
Q0V8R6 Beta-hexosaminidase subunit alpha  3.21 1 
P02754 Beta-lactoglobulin  86.52 27 
A6QLB0 Beta-mannosidase  7.96 4 
F1MTT1 Bile acid receptor  2.28 1 
F1N2G1 Biorientation of chromosomes in cell division protein 1-like 1 1.61 2 
A6QQ07 Biotinidase  9.52 3 
P13753 BOLA class I histocompatibility antigen, alpha chain BL3-7  31.59 10 
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A7YWH4 BoLA protein  22.04 6 
F1N4Y5 BOLA-NC1 protein (Bos taurus) 38.60 11 
E1BNJ9 Brain-specific serine protease 4 43.53 7 
Q0IIA9 Breast carcinoma amplified sequence 4  8.54 1 
F1N6I8 Bromodomain adjacent to zinc finger domain protein 2A 0.79 1 
F1MTQ0 Bromodomain and WD repeat-containing protein 1 0.99 1 
P18892 Butyrophilin subfamily 1 member A1  23.00 8 
Q3SX46 C1GALT1-specific chaperone 1  3.14 1 
Q28065 C4b-binding protein alpha chain  2.46 1 
A8YXZ2 C8G protein  37.97 6 
Q6R8F2 Cadherin-1  8.73 6 
E1BHE0 Cadherin-9 3.39 1 
B5UBG1 Calcitonin  15.38 1 
F1MHU1 Calcium uptake protein 3, mitochondrial 3.00 1 
Q2KIG3 Carboxypeptidase B2  34.52 11 
Q17QK3 Carboxypeptidase Q  2.33 1 
A6QNS7 Cardiomyopathy-associated protein 2  2.24 1 
A4FUC8 CARS protein  3.97 1 
F1MFI4 Cartilage acidic protein 1 48.46 27 
P35445 Cartilage oligomeric matrix protein  3.57 2 
P22226 Cathelicidin-1  50.32 9 
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P19660 Cathelicidin-2  9.66 1 
P33046 Cathelicidin-4  20.83 2 
P07688 Cathepsin B  15.52 3 
E1BEQ4 Cathepsin G 3.61 1 
P25326 Cathepsin S  19.34 4 
P05689 Cathepsin Z  32.89 8 
P00760 Cationic trypsin  70.73 18 
P28291 C-C motif chemokine 2  12.12 2 
F1MHC3 CD44 antigen  9.29 3 
Q32PA1 CD59 molecule, complement regulatory protein  20.66 2 
F1N514 CD5L protein 36.64 18 
Q29630 CD74 molecule, major histocompatibility complex, class II invariant chain  15.20 1 
G3MYH4 CD81 antigen (Fragment)  16.82 2 
G8JKX6 CD9 antigen (Fragment)  31.37 5 
A4IFM5 CDCA8 protein  6.07 1 
G3X7L5 
cDNA FLJ54643, highly similar to Homo sapiens SET domain and mariner 
transposase fusion gene (SETMAR), mRNA 
5.97 1 
F1N3A0 cDNA FLJ60976 3.84 1 
F1MAX3 Centrosomal protein of 192 kDa  0.84 1 
F1N192 Centrosome and spindle pole-associated protein 1 2.26 1 
F1MDQ6 cGMP-dependent protein kinase 2 2.30 1 
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A8E648 CHERP protein  2.73 1 
G3X7D2 Chitinase-3-like protein 1  60.61 20 
F1N2J7 Chitobiosyldiphosphodolichol beta-mannosyltransferase 6.68 1 
P09611 Chorionic somatomammotropin hormone 1  11.44 1 
F1MPU0 Clathrin heavy chain (Fragment)  1.20 1 
P17697 Clusterin  32.80 13 
Q2HJ57 Coactosin-like protein  21.83 4 
F1MBC5 Coagulation factor IX  8.95 3 
Q28107 Coagulation factor V  1.04 2 
F1MW44 Coagulation factor XIII A chain  22.68 13 
Q17QL3 Coiled-coil domain containing 94  9.06 1 
Q2TA16 Coiled-coil domain-containing protein 65  2.21 1 
F1N2Y4 Collagen alpha-1(III) chain (Fragment)  1.72 1 
E1B7H2 Collagen alpha-1(VII) chain 1.74 3 
F1MZ30 Collagen alpha-1(X) chain  4.45 1 
G3MZI7 Collagen alpha-1(XI) chain 12.22 16 
F1N401 Collagen alpha-1(XII) chain  0.35 1 
F1N6W9 Collagen alpha-1(XVIII) chain 1.46 2 
F1N7Q7 Collagen alpha-2(IV) chain (Fragment)  2.00 1 
G3N3E4 Collagen alpha-3(VI) chain 2.47 2 
F1N474 Collagen alpha-4(IV) chain 1.30 1 
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Q29442 Collagen alpha-4(IV) chain (Fragment)  7.95 1 
P42916 Collectin-43  38.63 11 
Q5E9E3 Complement C1q subcomponent subunit A  13.93 2 
Q2KIV9 Complement C1q subcomponent subunit B  5.67 1 
Q0VCX1 Complement C1s subcomponent  5.81 4 
Q3SYW2 Complement C2  38.53 25 
Q2UVX4 Complement C3  79.11 152 
P01030 Complement C4 (Fragments)  34.13 22 
E1BH06 Complement C4-B 37.56 47 
F1MVK1 Complement C4-B 21.71 27 
A5D9E9 Complement component 1, r subcomponent  6.67 3 
Q29RU4 Complement component C6  47.10 31 
F1N045 Complement component C7  3.32 2 
F1MX87 Complement component C8 alpha chain 23.60 10 
Q3MHN2 Complement component C9  60.40 29 
P81187 Complement factor B  62.29 54 
Q3T0A3 Complement factor D  43.63 9 
F1MW79 Complement factor H 4.46 1 
Q28085 Complement factor H  69.66 71 
F1MC45 Complement factor H (Fragment)  65.80 48 
Q17QC8 Complement factor properdin  2.80 1 
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F1MPS0 Condensin-2 complex subunit D3 1.21 1 
C4T8B4 C-reactive protein  41.96 5 
Q0P5I9 CXCL12 protein  35.96 4 
F1MZC9 Cyclic nucleotide-gated cation channel beta-3 3.31 1 
E1BM19 Cyclin-dependent kinase-like 3 3.38 1 
F6QEL0 Cystatin-B  18.18 1 
P01035 Cystatin-C  64.19 9 
G3N3P6 Cystatin-M 32.86 1 
F6R3I5 Cysteine-rich secretory protein 1 21.49 7 
P62894 Cytochrome c  36.19 3 
Q0V896 Cytochrome P450, family 4, subfamily F, polypeptide 2  3.63 1 
A6QQS0 D4, zinc and double PHD fingers family 2  4.86 1 
F1MRG2 Death domain-containing protein 1 1.79 1 
F1MIX6 Dedicator of cytokinesis protein 1 1.07 1 
Q58DK5 Delta-aminolevulinic acid dehydratase  3.04 1 
F1N0M9 DENN domain-containing protein 1B 1.86 1 
F1MW13 Deoxyribonuclease (Fragment)  12.06 2 
E1BKT9 Desmoplakin 0.45 1 
Q3ZCJ8 Dipeptidyl peptidase 1  7.13 4 
Q5E982 Diphthine synthase  3.86 1 
F1N5I2 Disks large-associated protein 4 2.12 1 
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F1N2W9 DNA helicase MCM9  1.23 1 
Q3MHE4 DNA mismatch repair protein Msh2  1.82 1 
E1BFW7 DNA-binding protein RFX7 3.22 2 
F1MXS1 E3 SUMO-protein ligase RanBP2  0.56 1 
Q5E9N3 E3 ubiquitin-protein ligase RNF25  5.02 1 
F1MN61 Early endosome antigen 1 3.11 2 
F1N0Z9 Early lactation protein 19.42 2 
A5PJT7 ECM1 protein  5.42 2 
A1A4K5 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2  33.90 23 
E1B7P6 EF-hand calcium-binding domain-containing protein 5 1.66 1 
Q17QM6 EF-hand domain-containing protein D1  4.66 1 
A2VE41 EGF-containing fibulin-like extracellular matrix protein 1  17.67 5 
E1BED8 Elongation factor 1-alpha (Fragment)  3.16 1 
B8Y9S9 Embryo-specific fibronectin 1 transcript variant  16.38 23 
F1MU34 Endoplasmic reticulum aminopeptidase 2 14.33 11 
A6QPT7 Endoplasmic reticulum aminopeptidase 2  1.36 1 
Q2TBT3 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial  11.82 1 
Q3ZC64 Ephrin-A1  19.51 3 
P79345 Epididymal secretory protein E1  47.65 5 
F1MW08 ERO1-like protein alpha 5.10 1 
B0JYP5 Eukaryotic translation initiation factor 2C, 2  1.98 1 
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P31976 Ezrin  6.54 4 
E1BMJ0 Factor XIIa inhibitor 30.13 14 
P50448 Factor XIIa inhibitor  30.13 14 
P10790 Fatty acid-binding protein, heart  20.30 2 
A8DC37 Fc-gamma-RII-D  17.99 2 
F1MMZ2 Ferritin  5.79 1 
Q58D62 Fetuin-B  21.45 5 
Q3SZZ9 FGG protein  61.15 22 
A5PJE3 Fibrinogen alpha chain  30.57 20 
F1MAV0 Fibrinogen beta chain  53.94 26 
Q9MZ06 Fibroblast growth factor-binding protein 1  30.77 7 
F1MYN5 Fibulin-1 15.86 7 
Q0VCN9 Folate receptor 2 (Fetal)  37.94 6 
P02702 Folate receptor alpha  58.51 11 
E1BJL8 Folate receptor alpha  38.13 8 
Q6SJV6 Foveolin  8.11 1 
A6QLL8 Fructose-bisphosphate aldolase  9.62 4 
A5PKH3 Fumarylacetoacetase  5.97 2 
F1MLX0 Fumarylacetoacetate hydrolase domain-containing protein 2A 9.24 1 
G3N2N5 FYVE and coiled-coil domain-containing protein 1 1.25 1 
E1B9P1 FYVE, RhoGEF and PH domain-containing protein 4 2.03 1 
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Q1JPD9 G protein-coupled receptor, family C, group 5, member B  6.72 3 
Q1LZG6 G2/mitotic-specific cyclin-B1  2.34 1 
A6QLZ0 Galectin  23.02 5 
A7E3W2 Galectin-3-binding protein  7.39 3 
G3N2D8 Gamma-glutamyltranspeptidase 1 17.08 9 
A6QPN6 Gamma-interferon-inducible lysosomal thiol reductase  21.31 3 
F1MBQ5 Gamma-secretase-activating protein 1.83 1 
A5D7A2 GARS protein  3.11 1 
Q3SX14 Gelsolin  49.11 28 
G3X6N2 General transcription factor IIH subunit 3 (Fragment)  6.56 1 
E1BJE7 Germinal-center associated nuclear protein 0.76 1 
Q3ZBD7 Glucose-6-phosphate isomerase  16.16 6 
F1MGS8 Glutamate carboxypeptidase 2 1.22 1 
E1BKZ1 Glutathione reductase, mitochondrial 2.86 1 
P80195 Glycosylation-dependent cell adhesion molecule 1  30.07 6 
G3X745 Glypican-1  5.01 2 
F1MCX1 Glypican-4 28.32 10 
G5E6P1 Gm628 protein 6.13 1 
F1MSB5 Golgi reassembly-stacking protein 2 5.71 1 
F1MJV6 G-protein coupled receptor 126 3.53 3 
Q8WMP9 Group XV phospholipase A2  3.44 1 
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Q1RMW5 Growth factor receptor-bound protein 7  4.51 1 
O18836 Growth/differentiation factor 8  34.93 8 
Q9GK68 Growth/differentiation factor 9  4.86 1 
Q32L41 GTP cyclohydrolase 1 feedback regulatory protein  20.24 1 
E1BP75 Guanylate cyclase soluble subunit alpha-2 1.92 1 
E1BD63 H-2 class I histocompatibility antigen, D-P alpha chain 9.72 4 
G3X6K8 Haptoglobin  21.45 6 
F1MWU9 Heat shock 70 kDa protein 6 2.80 1 
E1B812 Heat shock factor protein 5 3.82 1 
G5E507 Heat shock protein HSP 90-beta  0.97 1 
F1MLM2 Helicase-like transcription factor 1.39 1 
P02081 Hemoglobin fetal subunit beta  33.79 6 
P01966 Hemoglobin subunit alpha  15.49 1 
P02070 Hemoglobin subunit beta  57.93 9 
Q3SZV7 Hemopexin  73.64 33 
Q2KII3 Hepatitis A virus cellular receptor 1 N-terminal domain containing protein  45.04 6 
E1BCW0 Hepatocyte growth factor activator 10.77 2 
E1B7M9 Hermansky-Pudlak syndrome 1 protein 2.42 1 
E1BGX8 HHIP-like protein 2 1.38 1 
E1B8L8 High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor 4.45 2 
F1MKS5 Histidine-rich glycoprotein  9.33 3 
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P33433 Histidine-rich glycoprotein (Fragments)  7.58 2 
F1N6G4 Histo-blood group ABO system transferase 34.35 8 
A1A4R1 Histone H2A type 2-C  21.71 2 
E1BGW2 Histone H2B  11.90 1 
E1BLK2 Histone H2B.2 9.77 1 
G3N081 Histone H4  10.64 1 
E1BKN0 Histone-lysine N-methyltransferase 2B 0.55 1 
G3MYV9 Histone-lysine N-methyltransferase SETMAR 7.01 1 
Q0VD24 Histone-lysine N-methyltransferase SETMAR  7.52 1 
F1MXQ1 Homeobox protein engrailed (Fragment)  7.53 1 
F1MCY3 HORMA domain-containing protein 1  4.65 1 
G3MZ19 HRPE773-like  14.65 2 
E1BC79 Hydroxyacid oxidase 1 5.66 1 
G3N0T0 Hypoxanthine-guanine phosphoribosyltransferase 4.59 1 
F1N2D5 Iduronate 2-sulfatase 15.02 4 
G3MXB5 Ig alpha-1 chain C region 25.51 4 
G3N342 Ig epsilon chain C region 19.72 5 
G3N0V0 Ig gamma-4 chain C region 71.47 17 
G3N3Q3 Ig heavy chain V region MC101 44.52 4 
G3MZH0 Ig heavy chain V region MC102 25.00 3 
G3MXG6 Ig heavy chain V-II region ARH-77 46.76 5 
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G3N1R1 Ig heavy chain V-II region SESS 24.09 4 
F1MZ96 Ig kappa chain C region 48.75 15 
G5E5H2 Ig lambda chain V-IV region Bau 36.69 3 
F1MLW7 Ig lambda-2 chain C regions 64.96 16 
F1MCF8 Ig lambda-2 chain C regions 49.15 15 
F1MLW8 Ig lambda-2 chain C regions 42.06 11 
G5E513 Ig mu chain C region 61.05 24 
Q3T101 IGL@ protein 15.00 2 
G5E604 IGL@ protein 63.55 5 
G3X7I5 IGL@ protein 15.60 1 
Q3SYR8 Immunoglobulin J chain  54.14 10 
E1BLF1 InaD-like protein 0.72 1 
F1MJZ4 Insulin-like growth factor binding protein, acid labile subunit 9.51 4 
P20959 Insulin-like growth factor-binding protein 3  2.75 1 
F1MPP2 Insulin-like growth factor-binding protein 7 52.13 11 
F1N157 Integrin alpha-11 1.20 1 
Q0VCM5 Inter-alpha-trypsin inhibitor heavy chain H1  51.10 40 
F1MNW4 Inter-alpha-trypsin inhibitor heavy chain H2  34.25 32 
F1MMD7 Inter-alpha-trypsin inhibitor heavy chain H4  40.61 27 
F1MLN4 Interleukin-17F 12.94 1 
A0JN59 Inversin  2.94 1 
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A4IFB8 IPO4 protein  1.39 1 
Q9XSG3 Isocitrate dehydrogenase [NADP] cytoplasmic  38.41 14 
G3N0D2 Isoform 2 of Maestro heat-like repeat-containing protein family member 9 3.52 1 
G3MWG4 Isoleucine--tRNA ligase, mitochondrial 1.95 1 
Q9XT56 Junctional adhesion molecule A  4.03 1 
P02668 Kappa-casein  42.63 5 
E1BHV7 Kelch domain-containing protein 8A 2.29 1 
A6QNZ7 Keratin 10 (Epidermolytic hyperkeratosis; keratosis palmaris et plantaris)  11.79 7 
A1A4M9 Keratin associated protein 13-1  7.32 1 
A1L595 Keratin, type I cytoskeletal 17  6.58 3 
Q0P5J4 Keratin, type I cytoskeletal 25  4.00 2 
A4FUZ0 Keratin, type II cuticular Hb3  13.79 6 
E1B898 Keratin, type II cuticular Hb6 13.99 6 
G3MZ71 Keratin, type II cytoskeletal 2 7.93 4 
M0QVZ6 Keratin, type II cytoskeletal 5  12.91 8 
M0QVY0 Keratin, type II cytoskeletal 6A 14.54 10 
Q148H5 Keratin, type II cytoskeletal 71  4.00 2 
Q08D91 Keratin, type II cytoskeletal 75  12.34 7 
P05786 Keratin, type II cytoskeletal 8  9.62 5 
G3N171 Kielin/chordin-like protein 0.92 1 
F6RB08 KIF17 protein 4.49 1 
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A6QPE8 KIF2C protein  1.66 1 
P01044 Kininogen-1  35.27 17 
P01045 Kininogen-2  26.01 13 
A6QQ95 KLK6 protein  52.44 7 
Q17QL7 KRT15 protein  9.49 4 
A4IFP2 KRT4 protein  9.11 5 
Q95114 Lactadherin  58.78 25 
G3MXZ0 Lactoperoxidase (Fragment)  58.76 25 
P24627 Lactotransferrin  80.93 97 
F1MYX9 Laminin subunit alpha-4 2.47 3 
Q95M12 Legumain  12.24 6 
Q2KIF2 Leucine-rich alpha-2-glycoprotein 1  41.62 12 
F1MV58 Leucine-rich repeat and calponin homology domain-containing protein 4 2.58 1 
E1BMH2 Leucine-rich repeat-containing protein 16B 2.48 1 
Q5E9X4 Leucine-rich repeat-containing protein 59  5.56 1 
O62644 Leukocyte cell-derived chemotaxin-2  20.53 2 
Q1JPB0 Leukocyte elastase inhibitor  30.77 10 
Q3SZH7 Leukotriene A-4 hydrolase  9.17 4 
G3MWK8 LGP2 protein 3.75 1 
F1MNN7 Lipopolysaccharide-binding protein  18.50 6 
E1BM42 LisH domain and HEAT repeat-containing protein KIAA1468 2.15 1 
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P19858 L-lactate dehydrogenase A chain  9.34 3 
Q5E9B1 L-lactate dehydrogenase B chain  31.14 10 
A6QPC7 LOC510340 protein (Fragment)  5.94 1 
A7Z077 LOC510651 protein  1.38 1 
A5PJJ4 LOC787225 protein  7.94 1 
A5PJH7 LOC788112 protein  17.44 2 
E1B9L0 Low affinity immunoglobulin gamma Fc region receptor II  22.73 2 
F1N6H1 Low-density lipoprotein receptor-related protein 2 14.59 51 
Q05443 Lumican  14.91 4 
Q1RMM2 Lymphocyte antigen 6 complex, locus E  8.46 1 
Q9MYM4 Lysosomal alpha-glucosidase  4.27 3 
Q29451 Lysosomal alpha-mannosidase  1.00 1 
Q6B411 Lysozyme C, milk isozyme  15.54 2 
F1MEC3 Lysozyme C, tracheal isozyme 34.69 5 
Q27996 Lysozyme C, tracheal isozyme  15.65 2 
F1MGS9 Macrophage colony-stimulating factor 1 1.99 1 
F1MWM8 Macrophage mannose receptor 1 0.82 1 
E1BJP1 Major urinary protein 3 8.79 1 
Q3T145 Malate dehydrogenase, cytoplasmic  13.77 3 
G3MY87 Maltase-glucoamylase 2.84 3 
Q08DW8 Mammary tumor virus receptor 2 homolog  14.06 1 
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G3N120 Mannose-binding protein C 7.00 1 
O02659 Mannose-binding protein C  13.25 2 
F1N1A7 MAP kinase-interacting serine/threonine-protein kinase 1  2.86 1 
A5PJP8 MAP2K4 protein  3.88 1 
E1BF55 MAP7 domain-containing protein 2 2.38 1 
P52176 Matrix metalloproteinase-9  6.74 3 
E1BFW3 Meiosis inhibitor protein 1 1.56 1 
F1MH18 Meiosis-specific nuclear structural protein 1  2.43 1 
Q0VC16 Melanoma inhibitory activity protein 3  1.05 1 
Q28038 Melanoma-derived growth regulatory protein  19.23 2 
E1BG25 Melanotransferrin 4.87 3 
A5PKJ4 Mitogen-activated protein kinase 7  1.92 1 
Q2HJ49 Moesin  5.55 3 
Q95122 Monocyte differentiation antigen CD14  46.92 11 
A6QP39 MSLN protein  2.98 1 
Q8WML4 Mucin-1  3.45 3 
E1BNL1 Multidrug resistance-associated protein 7 1.61 1 
Q2TBT6 Multiple inositol polyphosphate histidine phosphatase, 1  7.08 2 
Q27991 Myosin-10  0.61 1 
F1MYM9 Myosin-14 1.06 1 
E1BH94 N-acetylmuramoyl-L-alanine amidase 33.99 9 
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A6QM01 NAGLU protein  21.74 9 
E1BP93 Nephrocystin-3 1.05 1 
P31836 Neural cell adhesion molecule 1  3.28 2 
F1MCK2 Neuroblast differentiation-associated protein AHNAK 0.44 1 
Q0VD07 Neuronal membrane glycoprotein M6-a  5.76 1 
E1BEL6 Neuropilin-2 17.71 10 
E1B6Z6 Neutrophil gelatinase-associated lipocalin 60.50 14 
E1BDF0 Nexilin 2.07 1 
Q8WNW7 NF kappa B inhibitor alpha (Fragment)  8.28 1 
F1MT12 Nicastrin 1.53 1 
A7E306 NID2 protein 2.53 1 
E1BKI3 Nitric oxide synthase  2.19 1 
G3X6Z0 NMDA receptor synaptonuclear signaling and neuronal migration factor 2.00 1 
F1MGC2 Non-secretory ribonuclease 23.42 3 
F1MV74 Non-specific lipid-transfer protein  3.50 1 
F1MM55 Nuclear pore complex protein Nup133 2.16 1 
F1MH31 Nuclear pore complex protein Nup214 1.21 1 
F1MNL6 Nuclear pore membrane glycoprotein 210-like 1.08 1 
Q0V8F0 Nuclear receptor subfamily 4 group A member 1  2.68 1 
Q0IIH5 Nucleobindin 2  13.49 7 
Q0P569 Nucleobindin-1  52.53 30 
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Q5E996 Nucleolar protein 16  6.18 1 
F1MCZ7 Nucleolar transcription factor 1 1.59 1 
Q3T0Q4 Nucleoside diphosphate kinase B  44.74 5 
F1N3U7 Nucleosome-remodeling factor subunit BPTF 0.49 1 
Q32KV6 Nucleotide exchange factor SIL1  15.58 7 
Q0IIA2 Odorant-binding protein-like  48.26 7 
F1MQH5 Olfactory receptor 4.21 1 
E1BKS7 Olfactory receptor  4.81 1 
G3MZJ6 Olfactory receptor 51S1 11.18 1 
E1B9S7 OTU domain-containing protein 7B 2.85 1 
E1BLL9 Out at first protein homolog 6.03 1 
E1BBD8 Oxysterol-binding protein  1.78 1 
F1MH87 Paired box protein Pax-1 5.53 1 
F1N726 Pancreatic secretory granule membrane major glycoprotein GP2 12.17 5 
Q58CQ9 Pantetheinase  6.47 2 
Q8MJG1 PC4 and SFRS1-interacting protein  2.45 1 
Q2KIR5 PCYT1A protein  3.69 1 
A6QNL5 PDIA6 protein (Fragment)  3.09 1 
Q3T005 PDZ and LIM domain protein 4  6.34 1 
F1MXC4 Pecanex-like protein 1 0.56 1 
G3X6Q8 Pentraxin-related protein PTX3  7.59 1 
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Q8SPP7 Peptidoglycan recognition protein 1  73.68 12 
Q9BGI2 Peroxiredoxin-4  54.74 10 
A6QQ11 PGM2 protein (Fragment)  2.87 1 
E1BMD4 PH domain leucine-rich repeat-containing protein phosphatase 2 0.83 1 
G5E5M1 PHD finger protein 3 0.84 1 
P13696 Phosphatidylethanolamine-binding protein 1  67.91 10 
E1BE68 
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit 
alpha 
2.30 1 
F1MNM2 Phosphatidylinositol-glycan-specific phospholipase D  4.29 3 
Q08DP0 Phosphoglucomutase-1  17.08 5 
Q95121 Pigment epithelium-derived factor  63.22 24 
A3KN33 Pikachurin  1.47 1 
Q2KJ63 Plasma kallikrein  4.09 1 
Q9N2I2 Plasma serine protease inhibitor  21.53 5 
E1B726 Plasminogen  33.99 21 
P06868 Plasminogen  34.24 21 
F1MYX5 Plastin-2 31.42 12 
P26201 Platelet glycoprotein 4  16.95 8 
E1BJY4 Platelet-derived growth factor C 11.73 3 
A0JN47 Plexin domain containing 2  5.46 2 
P81265 Polymeric immunoglobulin receptor  58.26 43 
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P0CG53 Polyubiquitin-B  39.34 3 
F1MVI5 Potassium voltage-gated channel subfamily D member 2 1.90 1 
E1B760 Potassium voltage-gated channel subfamily H member 3 1.40 1 
F1MMF9 POU domain, class 2, transcription factor 1 1.85 1 
Q29437 Primary amine oxidase, liver isozyme  51.31 28 
Q3T0I2 Pro-cathepsin H  23.58 4 
Q2HJB6 Procollagen C-endopeptidase enhancer  12.42 3 
E1BHJ0 Profilin  31.43 3 
E1BKM4 Programmed cell death 6-interacting protein 7.77 6 
A5D7K8 Prostaglandin D2 receptor  4.16 1 
O02853 Prostaglandin-H2 D-isomerase  28.80 8 
Q2TBX6 Proteasome subunit beta type-1  7.47 1 
F1MMK9 Protein AMBP  45.45 23 
F1MX50 Protein CREG1 67.42 10 
F1MTI7 Protein CutA  9.09 1 
Q5E946 Protein DJ-1  7.94 1 
F1MIT7 Protein FAM102A 6.27 1 
Q2KJI3 Protein FAM49B  8.02 2 
F1N4N5 Protein FAM81A 4.38 1 
F1MYQ7 Protein furry homolog 0.40 1 
Q2KIT0 Protein HP-20 homolog  52.88 11 
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Q2KIX7 Protein HP-25 homolog 1  12.74 2 
Q2KIU3 Protein HP-25 homolog 2  20.93 3 
F1MX66 Protein NYNRIN 0.88 1 
F1MX65 Protein OS-9  1.65 1 
F1N580 Protein phosphatase 1E 2.33 1 
E1BPN5 Protein phosphatase Slingshot homolog 2 2.18 1 
F1MNT2 Protein RTF2 homolog 10.03 1 
F1MX83 Protein S100-A11 10.78 1 
P79105 Protein S100-A12  10.87 1 
P28782 Protein S100-A8  28.09 2 
F1N1D4 Protein tweety homolog  2.67 1 
A7E379 Protein tyrosine phosphatase domain-containing protein 1  2.01 1 
E1BDG5 Protein Wnt  6.05 1 
P00735 Prothrombin  60.32 48 
E1B949 Protocadherin Fat 4 0.42 1 
A8E4M9 PRPF39 protein  3.47 1 
F1ML88 Pseudouridylate synthase 7 homolog  2.28 1 
Q3ZBD3 Pterin-4-alpha-carbinolamine dehydratase  23.08 2 
G3X7G5 Putative helicase Mov10l1 1.89 1 
Q2KIY5 Putative phospholipase B-like 2  5.09 2 
A0JNC2 R3H domain-containing protein 2  1.62 1 
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P50397 Rab GDP dissociation inhibitor beta  11.69 3 
E1BKQ2 Rab11 family-interacting protein 1  1.23 1 
E1BDG6 Rab11 family-interacting protein 4 2.43 1 
F2Z4D5 Ras-related protein Rab-11A  6.02 1 
Q0IIG7 Ras-related protein Rab-5A  5.12 1 
F1MFJ3 Receptor-type tyrosine-protein phosphatase gamma 2.99 3 
P82943 Regakine-1  16.30 1 
Q762I5 Resistin  12.84 1 
O02740 Retinal guanylyl cyclase 2  1.99 1 
P18902 Retinol-binding protein 4  63.93 10 
Q9TU03 Rho GDP-dissociation inhibitor 2  12.50 1 
P61823 Ribonuclease pancreatic  42.00 5 
Q3T114 Ribonuclease UK114  32.85 3 
Q58DP6 Ribonuclease, RNase A family, 4  64.63 10 
F1N0L5 RNA binding motif protein 19 1.96 1 
F1MFZ9 RNA-binding protein 10 1.51 1 
F1MF93 RNA-binding protein 20 1.74 1 
Q3T042 RNA-binding protein NOB1  7.26 1 
A5PKC6 RNF12 protein 3.62 1 
F1MGE7 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  1.61 1 
A6QPK0 SCGB2A2 protein  28.26 2 
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A0JNP2 Secretoglobin family 1D member  8.82 1 
Q2KJ32 Selenium-binding protein 1  41.31 14 
F1N152 Serine protease HTRA1  28.54 12 
E1BDW7 Serine/threonine-protein kinase 4  18.82 8 
F1MH45 Serine/threonine-protein kinase MRCK alpha 2.21 2 
Q2TA25 Serine/threonine-protein kinase PLK1  3.16 1 
E1BP17 Serine/threonine-protein kinase PLK2 2.48 1 
F1N3E3 Serine-rich coiled-coil domain-containing protein 1  2.56 1 
Q29443 Serotransferrin  92.05 89 
Q2HJF0 Serotransferrin-like (Bos taurus) 13.34 7 
Q9TTE1 Serpin A3-1  66.91 23 
G8JKW7 Serpin A3-6 56.31 21 
A2I7N2 Serpin A3-6  45.65 16 
A2I7N3 Serpin A3-7  28.30 14 
A6QPQ2 Serpin A3-8  36.12 14 
Q3SYR0 
Serpin peptidase inhibitor, clade A (Alpha-1 antiproteinase, antitrypsin), 
member 7  
18.49 5 
A5PJ69 SERPINA10 protein  12.61 4 
A6QPZ4 SERPINB4 protein  79.65 20 
A6QPP2 SERPIND1 protein  28.43 9 
P02769 Serum albumin  92.09 99 
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Q8SQ28 Serum amyloid A protein  32.06 4 
Q3T004 Serum amyloid P-component  42.86 8 
G3N2I7 SET domain-containing protein 5 1.19 1 
A5PKC2 SHBG protein  8.48 2 
E1B7R3 Sialin 4.04 1 
F1MNJ2 Signal recognition particle receptor subunit alpha  4.18 1 
A6QQW3 Signal recognition particle subunit SRP68  3.37 1 
G3MYW5 Single-pass membrane and coiled-coil domain-containing protein 2 5.78 1 
A6QP52 SMTN protein  2.53 1 
G3MYM1 Sodium channel protein type 10 subunit alpha 1.22 1 
E1BPZ1 Sortilin-related receptor 8.19 13 
E1BD26 Sorting nexin-14 1.27 1 
F1MUD3 Sperm flagellar protein 2 0.82 1 
P29392 Spermadhesin-1  16.42 1 
A5D796 Spermatogenesis-defective protein 39 homolog  3.53 1 
Q3ZCF3 S-phase kinase-associated protein 1  9.20 1 
Q2KIW7 ST6GAL1 protein  4.33 1 
Q08E24 Store-operated calcium entry-associated regulatory factor  5.07 1 
Q3ZBZ8 Stress-induced-phosphoprotein 1  3.50 1 
F1MM32 Sulfhydryl oxidase 58.20 26 
F1N6P2 Surfeit locus protein 1 2.32 1 
  
87 
 
Q3SZA6 Syndecan binding protein (Syntenin)  39.93 8 
F1MI41 Synergin gamma 1.45 1 
F1MQI1 Talin-2 0.43 1 
O97790 TBC1 domain family member 1  1.29 1 
A6QPP5 TCF7 protein  4.35 1 
F1MTN5 Tctex1 domain-containing protein 3 7.73 1 
E1BB53 Telomerase protein component 1 1.26 1 
E1BMG7 Teneurin-4 0.82 1 
Q9GLM4 Tensin-1  1.40 1 
F1MND3 Testis-expressed sequence 10 protein 1.61 1 
Q2KIS7 Tetranectin  50.00 11 
A6QLV4 TFAP4 protein  7.46 1 
G1K152 Thioredoxin-related transmembrane protein 2  6.67 1 
F1N3A1 Thrombospondin-1  36.84 39 
Q3SWW8 Thrombospondin-4  3.95 3 
A5D7K2 THSD1 protein  4.12 1 
A6QPW7 TNFRSF6B protein  37.16 9 
A4FUY5 TOB2 protein  4.06 1 
Q2TBL6 Transaldolase  13.35 3 
F1MFD3 Transcription factor RFX4 2.81 1 
E1B8P2 Transcription factor Sp6 7.20 1 
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F1MF62 Transcription initiation factor TFIID subunit 1 1.06 1 
F1MIL2 Transducin-like enhancer protein 6 5.05 1 
F1MF47 Transferrin receptor protein 2 2.74 1 
P21214 Transforming growth factor beta-2  4.59 2 
F1MBS3 Transforming growth factor-beta-induced protein ig-h3 (Fragment)  13.01 4 
F1MWK1 Transient receptor potential cation channel subfamily M member 6 0.94 1 
A7E3W4 Transketolase  25.17 9 
A5D7E2 Transmembrane 9 superfamily member 4  2.65 1 
O46375 Transthyretin  71.43 10 
A6QLF4 TRIB1 protein  5.65 1 
E1BLK1 Trinucleotide repeat-containing gene 18 protein 0.56 1 
A6QQZ8 TRIO protein  1.92 1 
G5E5Y3 Tripartite motif-containing protein 5  4.26 1 
Q0V8B6 Tripeptidyl-peptidase 1  22.91 6 
P08057 Troponin I, cardiac muscle  7.55 1 
F1MMS7 Uncharacterized protein  13.11 6 
F1MI18 Uncharacterized protein  5.62 6 
E1BJV2 Uncharacterized protein  1.65 1 
Q5E9S8 Uncharacterized protein C15orf41 homolog  7.83 1 
Q2NL11 Uncharacterized protein C8orf74 homolog  8.19 1 
E1BJV3 Uncharacterized protein KIAA0895-like 6.16 1 
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E1BKW7 Unconventional myosin-IXa 0.99 1 
F1MLR9 Unconventional myosin-VIIb 0.65 1 
F1MIA0 UPF0544 protein C5orf45 homolog 5.15 1 
P62248 UPF0556 protein C19orf10 homolog  28.16 6 
F1N3A8 UPF0602 protein C4orf47 4.21 1 
E1BP05 Usherin 0.31 1 
F1MKQ9 Uveal autoantigen with coiled-coil domains and ankyrin repeats protein  1.50 1 
F1MX48 UV-stimulated scaffold protein A  4.82 1 
Q0VD30 Vacuolar fusion protein CCZ1 homolog  4.58 1 
F1N318 Vacuolar protein sorting-associated protein VTA1 homolog  3.58 1 
Q3MHN5 Vitamin D-binding protein  74.05 36 
P00745 Vitamin K-dependent protein C (Fragment)  9.43 3 
P07224 Vitamin K-dependent protein S  27.41 19 
Q3ZBS7 Vitronectin 11.13 4 
E1BC63 WD repeat-containing protein 72 1.33 1 
E1BGC3 Wings apart-like protein homolog 1.42 1 
F1MJU6 WSC domain-containing protein 1 3.65 1 
F6Q234 Xaa-Pro dipeptidase 7.71 3 
F1MUT3 Xanthine dehydrogenase/oxidase  58.71 65 
P80457 Xanthine dehydrogenase/oxidase  58.71 65 
F1N283 Xyloside xylosyltransferase 1 4.83 1 
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Q5QQ49 Xylosyltransferase 2  2.54 1 
E1BEG4 Zinc finger FYVE domain-containing protein 16 1.62 1 
F1MB55 Zinc finger protein 157 3.40 1 
Q3SZL2 Zinc finger protein 174 7.45 1 
G3X6V5 Zinc finger protein 208 1.64 1 
F1MJN7 Zinc finger protein 318 0.39 1 
A8SM77 Zinc finger protein 713 4.26 1 
F1N4Q9 Zinc finger protein 839 3.86 1 
F1MFU7 Zinc finger protein 862 1.71 1 
F1N447 Zinc finger protein basonuclin-2 2.15 1 
E1BBZ5 Zinc finger protein ZFPM2 1.79 1 
F1MWD7 Zinc finger protein ZXDC isoform 1 2.14 1 
Q3ZCH5 Zinc-alpha-2-glycoprotein  64.88 32 
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Part I-B 
 
Healing...is not a science but the intuitive art of wooing nature. 
W.H. Auden, "The Art of Healing" 
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WOUND HEALING IN BOVINE COLOSTRUM 
 
The initial idea was to highlight proteins group based on targeted biological process 
of pharmaceutical interest. Our functional analysis focused on wound healing 
process, since there are several evidences of colostrum capability to induce, enhance 
and promote the wound healing in different animal models. Wound healing process 
could be explained through four subsequently physiological step: hemostasis, 
inflammation, proliferation and tissue re-modeling (Figure 1).  
For each biological process concerning in the healing phase we defined the proteins 
involved in; each protein “positioning” (Table 3 – Part I-A) has been combined with a 
mechanistic explanation of its involvement through the manual annotation of known 
or predicted functions, literature research, and sequence similarity confirmation with 
other organisms (in particular with the Human). 
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Figure 1 – Biological processes concerning in the healing phase. 
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During wound healing, just before the inflammatory phase, there is the cascade of 
coagulation regulation to obtain the arrest of blood loss, the so-called hemostasis. It 
represents the local response to hemorrhage, caused by the blood vessels 
disruption, based on thrombocytes action and the local activation of coagulation 
factors in tissue. This phase is characterized by the formation of a clot, typical 
structure consisting of a fibrin network in which remain trapped the corpuscular 
elements of the blood, which occupies the wound. Figure 9 (part I) shows the pathway 
of blood coagulation, as described in the literature; all the proteins identified, with a 
good degree of reliability, are highlighted in red. 
Reasonably, the demonstrated presence of the main protagonists of the coagulation 
cascade could be a good starting point to explain the mechanism of action of all the 
processes concerning the wound healing.  
Once the blood loss has stopped, the body immediately sends fluids containing 
plasma proteins, blood cells (primarily neutrophils, lymphocytes, and macrophages) 
and antibodies to the wound site to ensure that the proper equipment is in place to 
promote the inflammation phase.  
Although the main “actors” of this phase are all the inflammatory cells, our proteomic  
work, as it has been set, does not allow to define the cell component, hence, we 
investigated on those pro-inflammatory factors (proteins) that can promote the 
chemotaxis, proliferation and activity enhancement of all the inflammatory cells 
involved (Figure 2).  
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Figure 2 – Panel of pro-inflammatory factors (proteins) that can promote the 
chemotaxis, proliferation and activity enhancement of all the inflammatory cells 
involved. 
 
The major pro-inflammatory protein is Fibronectin, since it promotes adhesion and 
migration of neutrophils, monocytes, into the wound region, enhances the 
phagocytosis of immune-opsonized particles by monocytes, and promote bacterial 
attachment and infection. [1] 
 Beside fibronectin, other pro-inflammatory factors showing a positive regulation of 
neutrophil monocytes/macrophages, B cells chemotaxis or exerts pro-proliferative 
effects on the same inflammatory cell lines are CD74 antigen, Thrombospondin-4 
(THBS4), C-C motif chemokine 2, colony stimulating factor 1). [2] [3]  
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Thrombin, whose role has been widely proved to go far beyond hemostasis, appears 
to play a key role in the early inflammatory phase, stimulating chemotaxis and 
production of inflammatory cytokines and chemokines. 
A different class of inflammatory proteins are the acute-phase proteins (APP): 
proteins whose plasma concentration changes by at least 25% following 
inflammatory stimulus since they are able to initiate, sustain or resolve the 
inflammatory response. Inter-alpha-trypsin inhibitor heavy chain H4 [4] and 
alpha-1-acid glycoprotein [5] appear to function in modulating the activity of the 
immune system during the acute-phase reaction (APR).  
The fibrinolytic system is closely linked to the system of inflammation control. 
Plasmin in addition to lysing fibrin clots, also cleaves the complement system 
component C3. The system of plasminogen activation is controlled at several levels: 
plasminogen activator inhibitors (PAI-1 – stabilized by vitronectin, and PAI-2) 
counteract the activity of plasminogen activators and alpha 2-antiplasmin inhibits 
directly the activity of plasmin. [6]  
Fibronectins is also involved in the angiogenesis pathway, by promoting the 
spreading of platelets at the site of injury, the adhesion and migration of fibroblasts, 
and endothelial cells into the wound region. [1] 
Angiogenesis, alias neovascularization, is part of the longer proliferation phase 
(Phase II in wound healing), also characterized by collagen deposition, granulation 
tissue formation, epithelialization, and wound contraction, which overall restore skin 
integrity by filling in the wound with new tissue. During angiogenesis, new blood 
vessels form within the wound by extending from the wound’s edges. Most notably, 
the process of angiogenesis occurs in overlapping phases in response to 
inflammation when endothelial cells migrate to the area of the wound.  
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As the wound macrophages switches from inflammatory to healing mode, it begins 
to secrete endothelial chemotactic and growth factors (Angiogenin-1 and 
Fibronectin).  
To migrate, endothelial cells need proteases able to break down existing vascular 
basal lamina: plasminogen activator and collagenases (92 kDa type IV 
collagenase, also known as matrix metalloproteinase-9 (MMP-9), 72 kDa type 
IV collagenase - matrix metalloproteinase-2 (MMP-2)) are essential to degrade 
the clot and part of the ECM (extra-cellular matrix). [7]  
On the other hand, it has been demonstrated that MMP2 also interacts with 
Thrombospondin 1 (TSP1) that is a known ligand for CD36 mediating anti-
angiogenic properties. [8] Thrombospondins (TSPs), adhesive glycoprotein family, 
during wound healing act as angiogenic switches and control the extent of 
revascularization (Figure 3). 
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Figure 3 – Thrompospondins during wound healing act as angiogenic switches and regulate 
the revascularization process. [9] 
 
Detached endothelial cells from pre-existing capillaries and post-capillary venues can 
divide and migrate chemotactically towards the wound, laying down new vessels in 
the process.  
Neuropilin 2 (NRP2), commonly over-expressed in regions of physiological wound-
healing, is a receptor for the vascular endothelial growth factor (VEGF) ligand family 
involved in angiogenesis by promoting endothelial cell survival.[10] [11]  
Lactadherin (Milk fat globule-EGF factor 8) seems to play a crucial role in vascular 
endothelial growth factor (VEGF) – dependent neovascularization, contributing in this 
phase to phagocytic removal of apoptotic cells.[12]  
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Angiogenesis is tightly regulated by diverse growth factors with angiogenic activity: 
beside the vascular endothelial growth factor (VEGF) there are the fibroblast growth 
factor (FGF), the nerve Growth factor IB (NGFIB), which in turn is an early response 
gene stimulated by FGF-2. [13] On the contrary pigment epithelium-derived factor 
(PEDF) is a multifunctional secreted protein with anti-angiogenic function interfering 
with VEGF signaling. Thrombospondins, antiangiogenic proteins, are upregulated by 
PEDF. [14] 
The endothelium of vessels mature by laying down new endothelial extracellular 
matrix, followed by basal lamina formation. When macrophages and other growth 
factor-producing cells are no longer in a hypoxic they stop producing angiogenic 
factors. Thus, when tissue is adequately perfused, migration and proliferation of 
endothelial cells is reduced. 
Simultaneously with angiogenesis, fibroblasts begin accumulating in the wound site 
becoming the main cells in the wound (fibroplasia). [15] Previous studies have shown 
that the constituent chains of fibrinogen and its thrombin-derived cleavage 
products have the potential to promote fibroblast proliferation. At this stage 
phagocytes release proteases (plasmin) that break down the ECM of neighboring 
tissue, permitting activated fibroblasts from the adjacent uninjured cutaneous tissue 
to proliferate and migrate towards the wound.   
Initially fibroblasts utilize the fibrin cross-linking fibers (well-formed by the end of the 
inflammatory phase) to migrate across the wound, subsequently adhering to 
fibronectin. Recently, it has been suggested that Angiotensin II (by-product from 
Angiotensinogen) and Inversin have a function in skin wound healing, in 
coordinating fibroblasts migration. [16] [17]  
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Fibroblasts then deposit ground substance (granulation tissue) into the wound bed, 
which consists of a provisional extracellular matrix (ECM). The ECM is a complex, 
highly organized three-dimensional structure that serves as a scaffold for tissue re-
growth, but also as a signaling, binding, and activating substrate that interacts with 
the wound healing process. Components of the ECM play key roles in stimulating cell 
proliferation and differentiation, guiding cell migration, and modulating cellular 
responses. 
Such components include structural proteins, primarily collagen, the most abundant 
proteins in the body. Collagen in the skin is primarily type I and type III (Collagen 
alpha-1(III) chain) and provide structure, strength, and integrity. In early granulation 
tissue collagen III is expressed at high levels, gradually replaced by collagen I in 
later phases of wound healing. [18] [38] 
Type IV (Collagen alpha-4(IV)) collagen is a component of epidermal basement 
membranes, where it forms complex protein networks which make up thin sheet-like 
structures, that separate and support cells in many tissues. While, an excess of 
endostatin (alpha 1 type XVIII collagen), and its precursor, in wound healing, leads 
to an increased fragility of the epidermal-dermal junction.[19] 
Cell-adhesive glycoprotein. bind to cells and multiple components of the ECM and 
serve as modulators for growth factor activity (fibronectin, laminin (laminin subunit 
alpha, LAMA4), fibulin (Fibulin -1) and vitronectin).  
Glycosaminoglycans draw large amounts of water into their structures, allowing 
them to resist compression forces, and interact with proteins (such as the adhesive 
protein fibronectin) in the ECM. Pikachurin (EGF-like, fibronectin type-III and 
laminin G-like domain-containing protein), for instance, binds to α-dystroglycan in 
the extracellular space and promotes matrix assembly and cell adhesiveness. 
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Proteoglycans serve as co-receptors for growth factors, participate in cell signaling, 
and help regulate the activity of many other molecules.  
Matricellular protein class include thrombospondins (THBS1 / THBS4), 
osteopontin, tenascins, and secreted protein acidic and rich in cysteine (SPARC), 
which modulate cell-matrix interactions and help regulate the response to certain 
growth factors. 
Growth factors (PDGF, TGF-β) together with fibronectin encourage proliferation, 
migration to the wound bed, and production of ECM molecules by fibroblasts.  
It has been largely demonstrated the presence of the isoform TGF-beta 2 in bovine 
colostrum; exogenous application of the growth factor to enhance healing has been 
already investigated: TGF-beta2 appears to be of value in shortening the time for 
gain of incisional wound strength in healthy rats. [20] 
Among all the duties of fibroblasts, the most important is the production of collagen 
(Figure 5), because collagen itself is essential to increase the wound strength. . 
 
Figure 5 – Proliferative phase picture. 
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Even as fibroblasts are producing new collagen, collagenases (Matrix 
metalloproteinase-9 / Matrix metalloproteinase-2) other factors degrade it. Shortly 
after wounding, synthesis exceeds degradation so collagen levels in the wound rise, 
but later production and degradation become equal so there is no net collagen gain 
signaling the onset of the later maturation phase.[21] At the end of the granulation 
phase, fibroblasts begin to commit apoptosis, converting granulation tissue in an 
environment rich in collagen; this is essential for the re-epithelialization phase, 
involving basal keratinocytes (highly specialized epithelial cells) migration across the 
new tissue to form a barrier between the wound and the environment. Epidermal cell-
derived factors (EDF), including the nerve growth factor, were found to stimulate 
the proliferation of keratinocytes, but to inhibit fibroblasts.  
Keratinocytes must dissolve their desmosomes and hemi-desmosomes, which 
normally anchor the cells by intermediate filaments in their cytoskeleton to other cells 
and to the ECM to detach from the basement membrane and enter the wound bed. 
[22] Like fibroblasts, migrating keratinocytes use the fibronectin cross-linked with 
fibrin.[23] Factors responsible of epithelial cells migration are the cellular proteins 
belonging to the protein family Annexins (Annexin A1, Annexin A2), up-regulated in 
migrating epithelial cells (IECs). [42] [24] [25] On the other hand, ephrin-A1, it has 
been found that attenuates cell migration when bound EphA2 receptor. [26] 
Epithelial cells climb over one another in order to migrate. This growing sheet of 
epithelial cells is often called the epithelial tongue (Figure 6). [27]  
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Figure 6 – Topography of human cutaneous wounds. (A) Macroscopic view of epithelial 
migration over the wound bed of a burn patient. (B)  A cross-sectional view of human skin30 
hr after incisional wounding. [28] 
 
Cells migrate in two different manners: the first one is chemotaxis; the second type 
relies on trans-differentiation or cellular transition, applied by epithelial cell migration. 
The tight junctions between cells have to be partially dissociated; then, epithelial cells 
build up migration machinery with mesenchymal characteristics, which includes ECM 
components (fibronectin, MMPs, integrins, intermediate actin filaments and myosin 
chains, etc.). Since, keratinocytes at this stage extensively expressed mesenchymal-
specific markers, they may be activated and mobilized by epithelial to mesenchymal 
phenotype transition (EMT), which is orchestrated by injury signals like inflammatory 
cytokines. [29] Several studies established the importance of some members of the 
cathepsin (cathepsin Z, cathepsin H) family in mediating this process. [30]  
Keratinocytes themselves also produce and secrete factors, including growth factors 
(e.g. Colony stimulating factor 1, Pigment epithelium-derived factor - PEDF) and 
basement membrane proteins, which regulate both epithelialization. [31] Most 
notably, it has been demonstrated that PEDF influences keratinocytes at sites of 
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injury enhancing their adhesion, therefore impairing migration, while having no effect 
on cell proliferation. [32] 
When keratinocytes have finished migrating, they reestablish desmosomes and 
hemi-desmosomes and become anchored once again to the basement membrane; 
[22] desmoplakin is a protein associated with desmosomes.[33] Basal cells begin to 
divide and differentiate in the same manner as they do in normal skin to reestablish 
the strata found in re-epithelialized skin. 
An interesting finding in the bovine colostrum insight regards Galectin-3, a widely 
studied protein for its broad biological functionality (cell adhesion, cell activation and 
chemo-attraction, cell growth and differentiation, cell cycle, and apoptosis). Several 
studies confirmed to be involved in a variety of processes, including tissue repair, 
playing a crucial role in modulating re-epithelialization of corneal, dermal, intestinal, 
kidney and skin wounds. Overall, these findings have broad implications for 
developing novel therapeutic strategies for the treatment of non-healing wounds. 
Contraction phase commences when fibroblasts have differentiated 
into myofibroblasts; such epithelial plasticity is accompanied by dramatic 
reorganizations of the actin cytoskeleton: γ-cytoplasmic actin (γ-CYA) regulates 
epithelial phenotype and suppression of EMyT. [34] 
Myofibroblasts are attracted at wound edges by fibronectin and growth factors and 
they form connections to the ECM at the wound edges by desmosomes, in order to 
pull the ECM when they contract, reducing the wound size. [23] [35]  
Myofibroblasts can contract by using smooth muscle type actin-myosin complex. 
Myosin X, found in bovine colostrum, is an unconventional myosin motor, well known 
to play an important role during cell spreading in cytoskeleton reorganization, focal 
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contacts formation, and lamellipodial extension. The contraction stage in proliferation 
ends as myofibroblasts stop contracting and commit apoptosis. [36]  
As the final phase of wound healing, the remodeling phase is responsible for final 
scar tissue formation, tightly controlled by regulatory mechanism maintaining a 
delicate balance between degradation of fibronectin and synthesis of collagen (type 
III collagen is replaced by type I collagen). Synthesis and breakdown of collagen, 
exerts by MMPs, take place continuously. [37] 
MMPs activity is regulated and synchronized by inhibitory factors. For instance, 
Vitamin A reduces matrix metalloproteinase expression and stimulates collagen 
synthesis; so that, vitamin A deficiency can impede wound healing. Human skin can 
specifically and efficiently take up vitamin A from holo-Retinol-binding protein 
(RBP). [38] 
As the wound heals, the density of fibroblasts and macrophages is further reduced 
by apoptosis. The result is a fully matured scar with a decreased number of cells and 
blood vessels and a high tensile strength. [37]  
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Part II 
 
Set-up and application of an analytical approach for the quality control 
of purified colostrum as food supplement 
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Abstract – A validated analytical procedure is here described for the quality control 
of the protein fraction of purified bovine colostrum used in food supplements. The 
proposed procedure starts with 1D and 2D-gel electrophoresis. The sample is then 
separated into two fractions by protein G affinity chromatography: the IgG enriched 
and the IgG depleted fraction (IgG-d). A size exclusion chromatography coupled to 
UV is then applied to the IgG and IgG-d fractions for the quantitative analysis of IgG 
and IgM, respectively. The IgG-d fraction is then analyzed by HPLC-MS analysis for 
the quantitative analysis of β-lactoglobulins and α-lactoalbumin. The following step 
consists of quantitatively measuring a set of bioactive proteins selected from the 
bovine colostrum data bank on the basis of the claimed health benefits. The 
enzymatic activities of lactoperoxidase and xanthine dehydrogenase/Oxidase 
(XDH/XO) is then tested as an index of protein functionality.  
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1. Introduction 
Bovine colostrum (BC) is the initial milk secreted by the mammary gland immediately 
after parturition and provides the first nutritional components to the new-born calves 
due to the presence of proteins, fat, lactose, vitamins and minerals [1]. 
Besides the nutritional effect, colostrum also has a key role in the protection of the 
newborn calves against pathogens and other postpartum environmental challenges, 
and this is due to the presence of a complex mixture of antimicrobial peptides and 
bioactive proteins (i.e. immunoglobulins, lactoferrin, lactoperoxidase and lysozyme) 
that can stimulate innate antiviral pathways [2, 3]. 
Some beneficial effects of BC may be shared across species making it effective for 
the treatment of some human pathologies [4]. Most of the beneficial effects of BC 
have been ascribed to the protein components consisting of more than 1200 proteins, 
as recently found by our team [5]. For instance immunoglobulins, which represent the 
main protein class of colostrum, have direct antimicrobial and endotoxin-neutralizing 
effects throughout the alimentary tract, playing the role of a direct GI tract defence 
[6]. BC also has growth-promoting effects on human epithelial cells, which is 
attributable to the combination of several growth factors, including insulin-like growth 
factors, basic fibroblast growth factors and platelet-derived growth factor [7].  
Based on the presence of several bioactive components, BC has been included in 
several health products that are claimed to improve the immune system, treat gastro-
intestinal infection as well as to maintain the skin and mucous membranes integrity, 
favouring their healing [8-11]. Moreover, clinical research has demonstrated that α-
Lactalbumin in addition to being a highly nutritive protein, plays a central biochemical 
role as the regulatory subunit for lactose synthesis in the growing neonate [12]; 
having 72% sequence homology with the human isoform, bovine α-lactoalbumin is 
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widely added to infant formula-feed [13, 14]. On a commercial level, different bovine 
colostrum based products are available and they can be differentiated either on the 
basis of the degree of purification or on the process technologies. For instance, some 
products derive from a minimally processed raw material in order to maintain the 
original ingredients, while others are subjected to several steps aimed at removing 
the major ingredients such as fats, caseins, and lactose. Commercially available 
bovine colostrum also differs because of the technological processes needed for 
water removal (spray drying or freeze drying) or inhibiting the growth of bacteria 
(pasteurization or filtration). Due to the quite heterogeneous matrix and to the 
different methods of production, the quality control of bovine colostrum used in health 
products is a quite complex matter. Some validated analytical methods have so far 
been reported for the qualitative and quantitative analysis of some bioactive 
ingredients. In general the proposed analytical procedures target specific analytes 
such as IgG, lactoferrin and growth factors [7] but no integrated assays are yet 
available and which would be required to give a comprehensive qualitative and 
quantitative picture of the BC proteome. Such an approach is clearly required not 
only to guarantee the efficacy but also the safety of the product. 
The aim of the present paper is the set-up of an integrated analytical strategy for the 
quality control of the protein components of bovine colostrum. The procedure we 
propose starts with 1D and 2D-gel electrophoresis in reducing and non-reducing 
conditions that permits the mapping of the main protein components and the 
presence of aggregates as well as of caseins. The sample is then fractionated by 
affinity chromatography to isolate the IgG purified and depleted fractions and IgG/IgM 
content is then determined in the two fractions by SEC-UV. The IgG-depleted fraction 
is then subjected to HPLC-MS analysis for the simultaneous quantitative analysis of 
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the main protein components, including α-lactoalbumin and β-lactoglobulins 
(isoforms A and B). The analysis then focuses on a set of bioactive proteins (Lumican, 
IL-17 and IGF-1) which are selected from the BC database based on the health claim 
made. Since such proteins are contained in life amounts, ELISA is proposed. Finally, 
the conformational protein functional integrity is assayed by evaluating the enzymatic 
activity of two representative enzymes: Lactoperoxidase (LPO) and Xanthine 
Dehydrogenase/Oxidase (XDH/XO).  
 
2. Materials and methods 
2.1 Chemicals 
Laemmli buffer, 40% acrylamide/Bis solution, N,N,N',N'-tetramethylethylenediamine 
(TEMED), molecular mass standards and electrophoresis apparatus for one-
dimensional electrophoresis were supplied by Bio-Rad Laboratories, Inc., Hercules 
CA. β-mercaptoethanol, dithiothreitol (DTT), ammonium persulfate, 3-[3-
cholamidopropyl dimethylammonio]-1-propanosulfonate (CHAPS), acetonitrile 
(ACN), trifluoroacetic acid (TFA), sodium dodecyl sulphate (SDS), iodoacetamide 
(IAA), formic acid (FA), ABTS (2,2'-azino-di-3-ethylbenzthiazoline-6-sulphonic acid) 
solution, hydrogen peroxide, all the protein standards used for quantitative analysis 
(Bovine α-Lactalbumin, β-Lactoglobulin, Immunoglobulin M, Lactoperoxidase, 
Xanthine Dehydrogenase/Oxidase) and all other chemicals used throughout the 
experimental work were current pure analytical grade products and purchased from 
Sigma-Aldrich Corporation, St Louis, MO. Water and acetonitrile (OPTIMA® LC/MS 
grade) for LC/MS analyses were purchased from Fisher Scientific, UK. Purified IgG 
were prepared in our laboratory from bovine colostrum collected from Holstein cows 
until the fifth hour after birth and immediately frozen at -20°C. After a suitable dilution 
  
 
114
with demineralized water, the suspension obtained was introduced into a reactor 
(controlled continuous stirring), where it was heated at 35-36°C for about 30 minutes. 
The suspension was then subjected to the skimming step, and then caseins were 
removed by precipitation by adjusting the pH at their isoelectric point (pH 4.6). The 
product was then ultra-filtered and IgG separated by affinity chromatography and 
using Protein G Sepharose 4 as stationary phase (see below). Purity of IgG was 
determined by measuring the water content (about 8.8%) by thermogravimetric 
analyses using a TGA 2050 thermogravimetrical analyser (TA Instruments, US). A 
sample of approximately 10 mg was heated in a platinum crucible at 5 K/min from 25 
°C to 250 °C under nitrogen atmosphere and the loss of weight was recorded. The 
densitometric analysis of a 1D-gel electrophoresis was used to determine the 
presence of protein impurities that accounted for 13.5%:  by considering the presence 
of 1.2% of inorganic material as determined by total ashes measurement, the purity 
of IgG prepared according our protocol accounted for 76.5%. 
Analyses were carried out on commercially available BC raw materials sold as 
ingredient for the formulation of healthy products/food supplement; according to the 
vendors’ data sheet the different BC raw materials were produced as follows: BC1 
produced by a low temperature pasteurisation and freeze-drying process without the 
removal of any components; BC2 was defatted and spray-dried; BC3 no information 
on processing furnished; BC4 and BC5 were skimmed, decaseinated, micro-iltered, 
concentrated and freeze-dried. We also considered not processed BC which was 
collected from Holstein cows until the fifth hour after birth and immediately frozen at 
-20°C (BC0). 
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2.2 Separative methods of proteins on polyacrylamide gel 
One-dimensional analysis (SDS-PAGE) - Protein separation was performed under 
reducing conditions; aliquots of 10μL of samples containing 20-25 µg of proteins were 
mixed with 10μL of Laemmli sample buffer containing 50 mM DTT and heated at 
95°C for 5 minutes. Samples and the standard proteins mixture (Precision Plus 
Protein Standards) were loaded on precast gels (Any KD ™ Mini Protean® TGX ™) 
and then placed in the electrophoresis cell (Mini-PROTEAN Tetra) and run at 200 V 
(constant) for a variable time of about 30-40 min. Staining was carried out using 
Coomassie blue stain (Biosafe G250 Stain, Bio-Rad) and the images acquired by 
using the Bio-Rad GS800 densitometer and analyzed by using the software quantity 
One 1-D. 
 
Two-dimensional gel electrophoresis - 150 µg of each sample were solubilised in the 
denaturing buffer (7 M Urea, 2 M thiourea, 40 mM Tris, 3% CHAPS) and incubated 
for one hour at room temperature with 5 mM TCEP in order to reduce the protein 
disulphide bonds. After spiking with DESTREAK (150 mM), ampholine (0.5%) and 
blue bromophenol, samples were loaded on IPG strips (Bio-Rad 7 cm, pH gradient 
3-10); after incubation (4 hours) strips were laid in the strip housing for isoelectric 
focusing (IEF, I12 Protean IEF Cell-Bio-Rad) and covered with mineral oil (Bio-Rad) 
to prevent proteins oxidation. The instrument was set to follow the voltage gradient 
reported in Table 1 (Part I). Once the IEF was completed, strips were incubated with 
2.5 mL of equilibration buffer (6 M urea, 2% SDS, 0.05 M Tris-HCl pH 8.8 and  20% 
glycerol) on gentle shacking for 10 minutes. Proteins separation based on their 
molecular mass was obtained by one-dimensional electrophoresis (SDS-PAGE) 
using precast gel (Any KD ™ Mini Protean® TGX ™). The strips were laid on the top 
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of the gel, orienting them so that pI followed an ascending order (from 3 to 10) from 
left to right, and coated with a layer of agarose (0.5%). The electrophoretic device 
was assembled as described above and the electrophoretic run was carried out at 
200 V for 30 min. After electrophoresis, gels were washed and stained, de-staining 
and acquisitions carried out as described in the previous paragraph. 
 
2.3 Bovine IgG purification  
Affinity Chromatography – IgG depleted BC was prepared by removing the IgG 
fraction by affinity chromatography. The affinity column was prepared by packing 400 
mL of Protein G Sepharose 4 Fast Flow resin (GE Healthcare) in a column support 
HiScale ™ 50 (GE Healthcare) which was connected to an FPLC system (ÄKTAprime 
plus, GE Healthcare line-up). The chromatographic purification started by eluting the 
column with five volumes (5 x chromatographic bed volume) of buffer A (binding 
buffer: 20 mM sodium phosphate, pH 7), followed by sample loading at a flow rate of 
20 ml min-1. The eluate was monitored at 280 nm and all the fractions characterized 
by a significant UV absorption were automatically collected. The subsequent step 
consisted of recovering the IgG fraction by eluting the column with 100% of elution 
buffer (1 M glycine hydrochloride pH 2.5).  
Tangential Flow Filtration – The collected fractions were mixed and subjected to 
concentration and desalting using hollow fibers cross flow filtration cartridges with 
3000 NMWC (Nominal Molecular Weight Cutoff) and a surface area of 650 cm2 (GE 
Healthcare) coupled to a tangential flow filtration system equipped with a peristaltic 
pump essential to keep the flow recirculation continuous (Kross Flo®- Tangential flow 
Filtration System Research III). The IgG depleted fraction was concentrated 20/30 
times, dialysed with 5 volumes and then lyophilized. 
  
 
117
2.4 Profiling most abundant species 
2.4.1 SEC-UV for IgG and IgM analysis 
A size exclusion chromatography (SEC) method was set-up for the quantitative 
analysis of high-MW proteins (IgG and IgM); the technique is based on the separation 
of molecules depending on their size. SEC was performed on a Thermo Finnigan 
Surveyor HPLC system (ThermoFinnigan Italia, Milan, Italy) equipped with a variable 
wavelength detector and an auto-sampler, controlled by Xcalibur software (version 
2.0.7 Thermo Fisher Scientific, Rodano, MI, Italy). The SEC separation was 
performed on a 4.6 × 300 mm Phenomenex Yarra™ 3u SEC-3000, with a 4 × 3 mm 
GFC4000 pre-column, by running an isocratic flow of mobile phase containing 0.1M 
sodium phosphate bibasic, 0.025% sodium azide pH 6.8, at a constant flow rate of 
0.5 mL min-1. The autosampler temperature was set at 8°C and UV detection was 
conducted at a wavelength of 280 nm, a typical wavelength for protein detection.  
 
Preparation of standard - the dipeptide Tyrosine-Histidine (TH) was chosen as 
internal standard (IS). For calibration standards preparation, IgG standard was 
weighed and dissolved in the mobile phase (0.1M sodium phosphate bibasic, 0.025% 
sodium azide, pH 6.8) to obtain a solution of 1mg mL-1. The stock solution was then 
diluted to obtain working solutions at concentrations of 0.05, 0.10, 0.25, 0.50, 1.00, 
2.00, and 4.00 mg mL-1. The IgM stock solution (nominal concentration of 1mg/mL) 
was diluted in mobile phase, to obtain working solutions at concentrations of 0.020, 
0.050, 0.125, 0.250, 0.375, 0.500, 0.750, and 0.900 mg mL-1. All the stock solutions 
were added by a fixed amount of the dipeptide Tyrosine-Histidine chosen as the 
internal (0.1 mg mL-1).  
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Sample Preparation - The two fractions eluted from the purification step (depleted 
and IgG purified) were used for the IgG and IgM quantification in the bovine 
colostrum. Prior to SEC analysis the fractions were spiked with a fixed amount of the 
internal standard, 0.1 mg mL-1 TH.  
 
Method validation - The method was validated for linearity, lower limit of quantification 
(LLOQ), precision, and accuracy, by using as standard proteins the bovine IgM 
purchased from Sigma Aldrich, and lyophilized IgG (purified by affinity 
chromatography from bovine colostrum as above described). 
 
Linearity and carry over effect - To evaluate the linearity of the method eight 
calibration standards for each analyte were studied over a calibration range of 0.05-
4.00 mg mL-1 (IgG) and 0.02-0.90 mg mL-1 (IgM). Each calibration curve was built 
considering a blank sample, a zero sample (TH 0.1 mg mL-1 ) and eight calibration 
levels, among which blank and zero samples were necessary to confirm the absence 
of interferences. The calibration curves were realized by plotting peak area ratios of 
calibration standards to the IS versus the nominal molarity of analytes. Carry-over 
effects were assessed, with relevant criteria by injecting samples followed by the 
calibration standard at the highest concentration. The limit of detection (LOD) was 
calculated using a signal to noise (S/N) ≤ 3.  
 
Precision and accuracy - The precision of the method was given by the coefficient of 
variation (CV). The acceptable limit of CV was <20% for the LLOQ (corresponding to 
the low quality control, LQC), and ≤15% for medium quality control (MQC) and high 
quality control (HQC) samples. The acceptable limit of BIAS % (accuracy) should not 
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exceed ±20% and ±15%for the LLOQ (LQC) and all the other concentrations, 
respectively. To investigate the intra- and inter-day precision and accuracy, for IgG 
quantitation seven calibration standards in the range of 0.05-4.00 mg mL-1 and three 
quality control samples LQC (0.1 mg mL-1), MQC (1.0 mg mL-1), and HCQ (4.0 mg 
mL-1) were prepared separately in 6 replicates of each concentration, using 
chromatography for three consecutive days. The same procedure was used for IgM 
quantitation: in the range of 0.02-0.90 mg mL-1 and three quality control samples LQC 
(0.125 mg mL-1), MQC (0.250 mg mL-1), and HCQ (0.900 mg mL-1) were prepared 
separately in 6 replicates. Both the accuracy and CV should be respect the imposed 
limits, as above reported. The data obtained for the intra-day assay accuracy and 
precision were re-analyzed for inter-day assay accuracy and precision using all three 
days’ data for each concentration. 
 
2.4.2 Profiling intact proteins by HPLC-MS - TOF as MS analyser 
The BC sample (lyophilized) was solubilized in 50% of mobile phase A (0.1% formic 
acid in H2O) and 50% of mobile phase B (0.1% HCOOH in CH3CN) to obtain a 
solution with an approximate concentration of 2µg/µl. Aliquots of 10 µl of sample were 
injected on a ProSwift RP-H4 column, 1 x 250mm and using a Dionex Ultimate 3000 
RSLC as HPLC system. The rate of sample infusion into the mass spectrometer was 
300μL min-1, and the separating gradient ramped linearly from 5% to 95% of mobile 
phase B in 30 min. The eluting proteins were on-line sprayed in a Bruker maXis plus 
– Time of flight - mass spectrometer by an-ESI source; the profile spectra were 
acquired in positive ion mode in the mass ranges 750-5000 m/z and 300-3000 m/z, 
with a resolving power of 50,000. External mass calibration was performed prior to 
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each run. Data were analyzed with the instrument software Bruker Daltonics Data 
Analysis.  
 
2.4.3 Profiling intact proteins by HPLC-MS - Ion trap as MS analyzer 
Reversed phase LC-UV/MS experiments were performed on a Thermo Finnigan 
Surveyor HPLC system (ThermoFinnigan Italia, Milan, Italy) equipped with an online 
degasser, a gradient pump, an autosampler, and a variable wavelength detector, 
coupled to an LCQ Advantage mass spectrometer through a Finnigan IonMax 
electrospray ionization (ESI) source. Separation was conducted on a Jupiter C4 300A 
column (2 × 150 mm, 5 μm) with a Widepore C4 pre-column (4 x 3.0mm), at a flow 
rate of 0.25 mL min-1 with the column temperature set at room temperature. Mobile 
phase A was 0.1% formic acid in water and B is 0.1% formic acid in acetonitrile. Total 
run time was 24 min for each sample injection; gradient elution was set as follows: 
mobile phase B from 30% to 45% in 3 min and from 45% to 60% mobile in 13 min. 
At the end of the analysis, the column was washed by using 95% B for 3 min, followed 
by re-equilibration using 30% B for 5 min. The UV detection wavelength was set to 
acquire in a range 200-600nm (channel A 280 nm). MS experimental conditions were: 
the capillary temperature was 275°C, source voltage 3.5kV, sheath gas flow was 35 
arb and sweep gas flow was 10 arb. The profile spectra were acquired in positive ion 
mode in the mass range of 300-2000 m/z in profile mode. Mass calibration was 
performed prior to all the analysis. Full instrument control and data analysis were 
provided by Xcalibur software (version 2.0.7, Thermo Fisher Scientific, Rodano, MI, 
Italy). For each analysis 5µl of sample solution was injected by an autosampler.   
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Preparation of standard – For the preparation of the calibration standard solutions, 
α-lactoalbumin, β-lactoglobulins ,A/B and the internal standard, were separately 
weighed and dissolved in the mixture of 0.1% HCOOH in water and 0.1% HCOOH in 
CH3CN (70/30 v/v) to obtain a stock solution of 60 µM. These stock solutions were 
then diluted and mixed to obtain working solutions at concentrations of 0.5, 1.0, 2.0, 
5.0, 10.0, 15.0, and 20.0 µM. All the stock solutions were added by a fixed amount of 
ubiquitin (11.6 µM) chosen as internal standard.  
 
Sample Preparation - All the BC fractions obtained by the IgG depletion conducted 
on 4 different batches were spiked with 11.6 µM of IS. Samples were desalted and 
filtered by using Amicon Ultra-0.5 mL Centrifugal Filters (MWCO 3000Da) prior the 
LC-MS analysis.  
 
Linearity and carry over effect -  Calibration curves were built considering a blank 
sample, a zero sample (ubiquitin 11.6µM) and seven calibration levels (5-50µM for 
β-lactoglobulins  and 0.5-20.0 µM for α-lactoalbumin), among which blank and zero 
samples were necessary to confirm the absence of interferences. To simplify the 
method and to reduce the time of analysis we resorted to a combined calibration 
curve obtained by adding both the proteins in the same calibration standards over a 
range of 0.5-20.0 µM. The calibration curves were obtained by plotting peak area 
ratios of calibration standards to the IS versus the nominal molarity of analytes. Carry-
over effects were assessed, with relevant criteria by injecting samples followed by 
the calibration standard at the highest concentration. The limit of detection (LOD) was 
calculated using a signal to noise ratio (S/N) ≤3.  
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Precision and accuracy - The precision of the method was given by the coefficient of 
variation (CV%). The acceptable limit of CV was <20% for the LLOQ (corresponding 
to the LQC), and ≤15% for medium quality control (MQC) and high quality control 
(HQC) samples. Accuracy was determined as the percentage of difference between 
the mean calculated concentration and the theoretical value (BIAS %). The 
acceptable limit of BIAS percentage (%) should not exceed ±20% and ±15% for the 
LLOQ (LQC) and all the other concentrations, respectively. To investigate the intra- 
and inter-day precision and accuracy, precision seven calibration standards in the 
range of 0.5–20.0 µM and three quality control samples LQC (0.5µM), MQC (2.0µM), 
and HCQ (20.0µM) were prepared separately in six replicates of each concentration. 
Both the accuracy and CV should be respect the imposed limits, as above reported. 
The data obtained for the intra-day assay accuracy and precision were re-analyzed 
for inter-day assay accuracy and precision using all three days’ data for each 
concentration. 
 
2.5 Targeting bioactive proteins by ELISA assay 
Lumican, IL-17 and IGF-1 contents in BC were measured using a commercially 
available ELISA kits (Cell Biolabs Inc. Valter Occhiena S.R.L.) according to the 
manufacturer's instructions. Spectrofluorimetric readings were performed using a 
Wallac Victor 2 reader (Perkin Elmer).  
 
2.6 Protein Functionality 
2.6.1 Lactoperoxidase Activity Assay - Spectrophotometric method 
Lactoperoxidase activity was determined according to the method previously 
described by Shindler et al [15].. Briefly, 10 μL of the sample (standards and unknown 
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samples) were added to 2.0 ml of substrate solution (1 mM ABTS in 0.1 M acetate 
buffer pH 4.4) and mixed thoroughly. A 570µL portion was transferred to each of two 
wells (replicates) in the multiplate, which was put in the spectrophotometer. The 
experiment was controlled that a stable and straight base line is obtained. Then, 5μΙ 
of 5mM H2O2 solution, prepared fresh, were added to the sample and mixed carefully 
in the multiwall reader Wallac Victor 2 reader (Perkin Elmer). The increase in 
absorbance was then measured for 3 to 5 min at 413 nm (405±15nm filter). The 
increase in absorbance/min (ΔA413 min-1) was calculated drawing the tangent to the 
initial activity (1 minute). The activity of the enzyme is defined as: 1 unit (U) of 
lactoperoxidase activity is the amount of enzyme catalysing the oxidation of 1 μ-mole 
of substrate per min. The calibration curve was prepared by considering six standard 
concentrations of the enzyme (0.3, 0.4, 0.5, 0.6, 0.8 and 1.0U). The calibration curve 
was realized by plotting the ΔA413 min-1 (measured in the first minute of the reaction), 
versus the nominal concentration of the enzyme. The linearity was assessed 
considering the coefficient of linear regression obtained.  
 
2.6.2 Determination of Xanthine Dehydrogenase/Oxidase Activity - Fluorimetric 
Assay 
Xanthine Dehydrogenase/Oxidase (XDH/XO) efficiently metabolizes pterin (2-amino 
4-hydroxypteridine) into a fluorescent product, isoxanthopterin (2-amino-4,7-
pterinediol), which enables the highly sensitive quantitation of the enzyme’s activity.  
Since the enzymatic activity of XDH/XO can greatly depends on the sample’s matrix, 
a quantitative method based on standard addition was employed. For the analysis 
four different samples were prepared and analyzed simultaneously by using a four 
positions cuvettes holder. Samples were prepared by mixing BC with pterin as 
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substrate (40μM final concentration), in absence and presence of three increasing 
amounts of the enzyme standard solution to obtain the following concentrations: 
0.005, 0.010 and 0.020 U ml-1. Samples were then diluted to a final volume of 2.2ml 
of tris buffer (pH 7.8, 50 mM). The reaction mixtures were monitored for 30 min to 
measure the amount of isoxanthopterin produced, whose fluorescence intensity was 
measured by using the Luminescence Spectrometer LS 50B (Perkin Elmer) and 
setting the excitation and emission wavelengths at 345 nm at 390 nm, respectively.  
 
2.6.3 Determination of Xanthine Dehydrogenase/Oxidase Content - ELISA Assay 
Quantitative measurement of XDH/XO was carried by ELISA according to the 
suppliers’ manuals (Cloud-Clone Corp., Houston, USA).  
 
3. Results 
3.1 Profiling intact proteins by electrophoresis and MS 
3.1.1 1D and 2D gel electrophoresis of commercially available BC raw materials 
Figure 1 displays the SDS-PAGE profile (non-reducing conditions) of a set of 5 
commercially available BC raw materials used in healthy products, differing on the 
basis of the process technology and final composition, as reported by the suppliers.  
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Figure 1 – SDS-PAGE profiling of colostrum proteins. Mr: molecular mass ladder. Samples: 
BC commercial products (BC1, BC2 and BC3 claimed to be minimally processed thus 
maintaining the original composition, BC4 and BC5 were defatted and decaseinated); gel 
was run in non-reducing conditions and stained with colloidal Coomassie blue. 
 
In particular, samples BC1, BC2 and BC3 are claimed to be minimally processed thus 
maintaining the original composition while samples BC4 and BC5 were defatted and 
decaseinated. The mono-dimensional gel electrophoresis of all the samples shows a 
main single, heavy band of IgG centered at ca. 150 kDa, which in reducing conditions 
disappears in favor of two bands at ca. 50 and 25 kDa, representing the heavy and 
light IgG chains, respectively (data not shown). Low intensity bands at higher MW are 
also observed which can be attributed to IgA (mol. wt. about 410.000) and IgM (mol. 
wt. about 900.000). Samples BC1, BC2 and BC3 but not BC4 and BC5 show two 
intense bands between 25 and 30 kDa attributed to caseins. Sample BC4 depleted 
by caseins and defatted was then analyzed by 2D-gel electrophoresis.  
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Figure 2 - Two-dimensional map of BC4 (casein-depleted and defatted bovine colostrum). 
The 21 numbered and circled spots have been cut out and subjected to MS analysis after 
trypsin digestion. Staining with colloidal Coomassie blue. Identified proteins are listed in table 
2. 
 
The sample is characterized by few rather intense zones in addition to all those spots 
corresponding to the isoforms of immunoglobulin subunits, which, upon cutting the 
gel (Figure 2) were identified via MS as the following well known milk proteins: α-
lactalbumin (14.1 kDa), ß-lactoglobulin (19.9 kDa),  serum transferrin (77.7 kDa) and 
α-S1-casein (24KDa) in traces. All the identified gene product are reported in table 2. 
Sample 4 was then used for further analysis as here below reported. 
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SPOT PROTEIN NAME 
ACC. 
NUM. 
SCORE COVERAGE N° PEPT.  MW P.I. OMOLOGY  
1 
serum albumin  P02769 76.63 26.19 10 69KDa 6.18  
Ig heavy chain V-II 
region ARH-77 
G3MXG
6 
17.63 38.85 3 15KDa 9.45 
50% 
Human 
2 
serum albumin  P02769 176 43.82 18 69KDa 6.18   
Ig gamma-4 chain 
C region 
G3N0V
0 
68.44 9.2 3 36KDa 7.84 
50% 
Human 
Ig heavy chain V-II 
region ARH-77 
G3MXG
6 
21.19 23.74 2 15KDa 9.45 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MCF
8 
18.47 21.37 3 24KDa 7.58 
50% 
Human 
3 
Ig gamma-4 chain 
C region 
G3N0V
0 
  39.57 10 36KDa 7.84 
50% 
Human 
Ig heavy chain V-II 
region ARH-77 
G3MXG
6 
  23.74 2 15KDa 9.45 
50% 
Human 
Polymeric 
immunoglobulin 
receptor 
P81265   8.72 4 82KDa 7.27   
4 
Ig gamma-4 chain 
C region 
G3N0V
0 
56.79 24.23 7 36KDa 7.84 
50% 
Human 
Beta-lactoglobulin  P02754 18.76 32.58 4 20KDa 5.02  
Ig heavy chain V-II 
region ARH-77 
G3MXG
6 
14.72 25.9 2 15KDa 9.45 
50% 
Human 
5 
Ig gamma-4 chain 
C region 
G3N0V
0 
24.7 15.64 3 36KDa 7.84 
50% 
Human 
6 
Ig gamma-4 chain 
C region 
G3N0V
0 
27.88 20.86 5 36KDa 7.84 
50% 
Human 
Beta-lactoglobulin  P02754 14.2 15.73 2 20KDa 5.02   
7 
Beta-lactoglobulin  P02754 123.7 54.49 13 20KDa 5.02   
Zinc-alpha-2-
glycoprotein  
Q3ZCH
5 
30.45 12.37 4 34KDa 5.24  
Actin, cytoplasmic 
1  
P60712 22.97 20 4 42KDa 5.48  
8 Beta-lactoglobulin  P02754 182 62.92 17 20KDa 5.02   
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Zinc-alpha-2-
glycoprotein  
Q3ZCH
5 
84.71 31.77 13 34KDa 5.24   
9 Beta-lactoglobulin  P02754 275.7 77.53 18 20KDa 5.02   
10 Beta-lactoglobulin  P02754 163.1 54.49 13 20KDa 5.02   
11 Beta-lactoglobulin  P02754 165.1 60.67 15 20KDa 5.02   
12 
Ig kappa chain C 
region 
F1MH4
0 
70.79 36.67 8 26KDa 5.94 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
7 
62.75 31.2 5 24KDa 7.62 
50% 
Human 
Beta-lactoglobulin  P02754 35.85 41.57 5 20KDa 5.02  
Complement C3  G3X7A5 35.28 3.73 6 187KDa 7  
Prostaglandin-H2 
D-isomerase  
O02853 11.53 13.61 2 21KDa 6.90   
13 
Ig kappa chain C 
region 
F1MZ9
6 
134.2 42.5 11 26KDa 6.90 
50% 
Human 
Complement C3  G3X7A5 76.36 6.2 12 187KDa 7  
Ig lambda-2 chain 
C regions 
F1MLW
7 
70.32 31.2 4 24KDa 7.62 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
8 
56.87 22.32 2 24KDa 5.91 
50% 
Human 
Beta-lactoglobulin  P02754 25.14 32.58 4 20KDa 5.02  
Prostaglandin-H2 
D-isomerase  
O02853 13.91 13.61 4 21KDa 6.90   
14 
Ig lambda-2 chain 
C regions 
F1MLW
7 
409.8 58.97 10 24KDa 7.62 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
8 
229.2 22.32 5 24KDa 5.91 
50% 
Human 
Ig kappa chain C 
region 
F1MZ9
6 
193.1 42.5 12 26KDa 6.90 
50% 
Human 
Complement C3  G3X7A5 34.61 4.7 6 187KDa 7  
Beta-lactoglobulin  P02754 17.65 24.72 3 20KDa 5.02  
15 
Ig kappa chain C 
region 
F1MH4
0 
106.1 38.33 9 26KDa 5.94 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
7 
68.66 34.62 7 24KDa 7.62 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
8 
40.63 17.6 5 24KDa 5.91 
50% 
Human 
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Beta-lactoglobulin  P02754 16.62 21.35 3 20KDa 5.02  
Ig gamma-4 chain 
C region 
G3N0V
0 
15.68 11.96 3 36KDa 7.84 
50% 
Human 
16 
Ig lambda-2 chain 
C regions 
F1MLW
7 
143.5 31.2 7 24KDa 7.62 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MCF
8 
137.6 27.78 7 24KDa 7.58 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
8 
106.6 22.32 4 24KDa 5.91 
50% 
Human 
Beta-lactoglobulin  P02754 16.47 32.58 4 20KDa 5.02  
Ig kappa chain C 
region 
F1MH4
0 
15.11 14.58 2 26KDa 5.94 
50% 
Human 
17 
Ig lambda-2 chain 
C regions 
F1MLW
7 
96.71 29.91 10 24KDa 7.62 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
8 
57.04 22.32 5 24KDa 5.91 
50% 
Human 
Ig kappa chain C 
region 
F1MH4
0 
30.66 14.58 3 26KDa 5.94 
50% 
Human 
18 
Ig lambda-2 chain 
C regions 
F1MLW
7 
129 33.33 8 24KDa 7.62 
50% 
Human 
Ig lambda-2 chain 
C regions 
F1MLW
8 
114.7 22.32 5 24KDa 5.91 
50% 
Human 
Beta-lactoglobulin  P02754 90.81 46.07 11 20KDa 5.02  
Ig kappa chain C 
region 
F1MH4
0 
16.08 14.58 2 26KDa 5.94 
50% 
Human 
Alpha-S1-casein  P02662 9.05 10.28 2 24KDa 5.02  
19 Beta-lactoglobulin  P02754 770.8 86.52 24 20KDa 5.02   
20 
Alpha-lactalbumin  P00711 76.14 38.73 8 16KDa 5.14   
Beta-lactoglobulin  P02754 71.36 46.07 11 20KDa 5.02   
21 Beta-lactoglobulin  P02754 8.48 17.42 2 20KDa 5.02    
 
Table 2 - BC proteins identified by trypsin digestion and MS analysis of the spots circled in 
the 2D gel electrophoresis shown in Fig. 2. 
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3.1.2 Profiling intact proteins by LC-ESI-MS 
Profiling of intact proteins of BC4 was then carried out by LC-ESI-TOF. Figure 3a 
shows the average MS spectrum relative to the Total Ion Chromatogram (TIC) which 
is characterized by a not resolved broad peak from m/z 2740 to 4250 as magnified in 
Figure 3b, absent in the IgG depleted fraction, and attributed to the polyclonal 
immunoglobulins. From such a broad peak a series of more defined peaks arises 
and, as determined by the deconvoluted spectrum (Figure 3c), were assigned to 
proteins with an MW from 112 kDa to 163 kDa. Several abundant proteins that we 
identified in colostrum fall into this MW range such as two different isoforms of 
xanthine dehydrogenase/oxidase (146.6Kda), thrombospondin-1/2 (129Kda), 
complement factor H (140KDa), two different isoforms of alpha-mannosidase 
(130KDa), G-protein coupled receptor 126 (132KDa), aldehyde oxidase (147KDa) 
[5]. Figure 4a reports the TIC of BC4 depleted of IgG determined by LC-ESI-MS-TOF, 
which identifies at least 9 peaks.  
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Figure 3 – LC-ESI-MS-TOF analysis of BC4 (casein-depleted and defatted bovine 
colostrum). Panel a) average MS spectrum relative to the Total Ion Chromatogram (TIC); 
panel b) magnified MS spectrum; panel c) deconvoluted MS spectrum. 
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Figure 4 – LC-ESI-MS-TOF analysis of BC4 depleted of IgG. Panel a) Total ion current 
(TIC); panel b) MS spectrum relative to the peak eluting at 9.6 – 9.7 min (peak 3); panel c) 
deconvolution analysis of the MS spectrum showed in panel b) and referred to transferrin. 
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The MS spectrum of each peak was then analyzed and the corresponding 
deconvoluted spectrum determined to retrieve the proteins’ MW. Figure 4b shows the 
MS spectrum relative to peak 3 eluting between 9.6 and 9.7 min and characterized 
by well-defined multicharged ions. Deconvoluted analysis (Figure 4c) showed an MW 
centered at 78 kDa and assigned to lactotransferrin. Analyzing all the peaks in the 
chromatogram (TIC - Fig. 4a) by using the same approach other proteins were 
identified, namely: cytochrome c (11.7KDa), proline-rich protein 9 (12.8KDa), β-2-
microglobulin (13.6KDa), α-lactalbumin (16 Kda - active form 14KDa), β-lactoglobulin 
(isoform B 18.2KDa, isoform A 18.3KDa), serotransferrin (77.7KDa). Notably by using 
an ion trap analyzer or an Orbitrap system only proteins with an MW lower than 30 
kDa were identified.  
 
3.2 Affinity chromatography – IgG and IgG-depleted BC fractions  
As shown in Figure 1 relative to 1D-gel electrophoresis, IgG are the main components 
of BC with a relative concentration as determined by densitometry analysis of more 
than 80%. Due to such a high content, IgG were found to interfere with the 
quantitative analysis of minor analytes such as IgM, β-lactoglobulin and α-lactalbumin 
(data not shown). For this reason, an affinity chromatography based on protein G was 
carried out to prepare an IgG depleted fraction to be used for the quantitative analysis 
of the minor protein components. Moreover, the IgG enriched fraction was used for 
quantitative analysis of IgG. 
The affinity chromatogram displayed two peaks, the first, not retained, corresponding 
to the non-immunoglobulin protein fraction and the second to the IgG fraction (Figure 
5).  
 
  
 
134
 
 
Figure 5 – IgG purification by affinity chromatography. Panel a) FPLC-UV chromatogram of 
BC4 (casein-depleted and defatted bovine colostrum) obtained by using protein G as affinity 
stationary phase; peaks 1 and 2 are attributed to the IgG-depleted and IgG fractions as 
demonstrated by the SDS-gel electrophoresis patterns. Panels b) and c) report the gel 
electrophoretic pattern of peak 1 and 2 run in reducing conditions. The characteristic bands 
at 25 and 50 KDa are well evident in peak 2 and only in negligible amounts in peak 1. 
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According to the relative abundance of IgG in colostrum (80%), the second peak was 
the most abundant. The electrophoretic patterns obtained for each collected fraction 
(Figure 5) indicate a good depletion of immunoglobulins, whose two characteristic 
bands in reducing conditions at 50 and 25 kDa are very weak in the aliquots eluted 
within the first peak, and clearly much more intense in the fractions of the second 
peak corresponding to the immunoglobulins.  
 
3.3  IgG and IgM analysis by SEC-UV 
After optimization of the chromatographic conditions, a suitable separation of IgG and 
IgM in BC was achieved by SEC-UV.  
 
3.3.1 Immunoglobulin G analysis 
Figure 6 a-b-c represents typical SEC-UV chromatograms relative to IgG standard at 
different concentration levels (LOD 0.05, MQC 1.00, HQC 4.00 mg mL-1), spiked with 
TH as IS (0.1 mg mL-1).  
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Figure 6 – IgG and IgM analysis by SEC-UV; Panels a), b), c) show the SEC-UV 
chromatogram of purified IgG at different concentrations (LOD 0.05 mg mL-1, MQC 1.00 mg 
mL -1, HQC 4.00 mg mL-1), using TH as internal standard; panel d) shows the SEC-UV 
chromatogram of IgG purified fraction from BC4 sample; panel e) shows the SEC-UV 
chromatogram of IgG depleted fraction of BC4; IgM peak elutes at 6.12±0.01 min. 
 
IgG eluted at 9.15±0.01min, flanked by a less intense peak eluting at a lower retention 
time (8.4 min) and attributed to IgG aggregates (the 1D gel electrophoresis pattern in 
reducing condition of the collected peak shows the typical IgG subunits at 50 and 25 
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kDa). TH eluted at 11.57±0.02min. The calibration curve relative to the IgG monomer 
eluting at 9.15 min was built (y = 2.1129x + 0.0012, R2= 0.9998) using a concentration 
range of 0.05-4.00 mg mL-1 (Figure  7). 
 
 
Figure 7 - IgG Calibration Curve 
 
The LLOQ was evaluated by analyzing six replicates at the concentration of 0.1 mg 
mL-1. The LOD was 0.05 mg mL-1. As reported in Table 3, intra- and inter-day 
precisions were determined by analyzing six replicates of quality control samples 
(LQC= 0.1 mg/mL, MQC= 1.0 mg/mL and HQC = 4.0 mg/mL) on the same day and 
on three different days. 
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Table 3 - IgG and IgM quantitative analysis by SEC-UV: precision and accuracy. 
 
 
Satisfactory precision, accuracy and reproducibility were obtained: the intra- and 
inter-day precisions (CV%) were <5.0% and the accuracies (BIAS%) were <10%. No 
significant carry-over from the analyte or IS was observed in the double blank after 
subsequent injection of the highest calibration standard at the retention time of 
analyte. 
The method was then applied to a commercially available decaseinated and defatted 
BC sample (sample BC4). The typical SEC-UV chromatogram (Figure 6d) displays 
the peak referred to TH at 11.56±0.02 min and the peak of IgG at 9.15±0.01min, 
flanked, as in the case of standard samples, by a minor peak at lower retention time 
and attributed to IgG aggregates. IgG content for the analyzed batch samples 
accounted for 77.6 mg/100 mg (mean content) of BC raw material (Table 4). 
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Table 4 - IgG, IgM, α-lactalbumin and β-lactoglobulin contents measured in four different 
batches of BC4 (casein-depleted and defatted bovine colostrum). 
 
 
3.3.2 Immunoglobulin M analysis 
The IgM quantification by HPLC-SEC-UV was validated as reported for IgG 
(concentration levels: LQC 0.125, MQC 0.375, HQC 0.900 mg mL-1) and using TH as 
IS (0.1 mg mL-1). Typical retention time for IgM was about 6.1 min, and a typical 
calibration curve is shown in Figure 8 (y = 2.9997x + 0.0057, R2= 0.9997).  
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Figure 8 - IgM Calibration Curve 
 
 
The LLOQ was evaluated by analyzing six replicates at a concentration of 0.125 mg 
mL-1. The intra- and inter-day precisions (CV%) were <5.0% and the accuracies 
(BIAS%) were <20% (Table 3), confirming the repeatability and reproducibility of the 
method. The method was then applied to the analysis of IgM in a commercially 
available BC raw material (sample BC4). The corresponding SEC-UV chromatogram 
(Figure 6e) is characterized by a main peak at 11 min attributed to β-lactoglobulin as 
determined by comparing the RT of a genuine standard flanked by an unknown peak. 
The IgM peak eluted at 6.12±0.01 min. As shown in Table 4 the IgM content 
measured in different batches was of 1.7 mg corresponding to 2.5 % of the total 
immunoglobulin content.  
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3.4 β-lactoglobulin and α-lactalbumin analysis by LC-ESI/MS 
As revealed by the protein MS identification on the 2D-gel analysis (Table 2), besides 
IgG, β-lactoglobulin (18KDa) and α-lactalbumin (14KDa) represent the most 
abundant whey proteins. Both proteins were analyzed by LC-ESI-MS and using 
ubiquitin (8.5KDa) as internal std. Suitable HPLC conditions were achieved by using 
a mixture of CH3CN/H2O (70/30 v/v) spiked with 0.01% HCOOH to improve efficiency 
and peak symmetry. Figure 9 reports the total ion current (TIC) of the standards 
mixture containing β-lactoglobulin A and B, and α-lactalbumin and ubiquitin as IS, 
revealing 3 peaks. 
 
 
Figure 9 - β-lactoglobulin and α-lactalbumin analysis by LC-ESI/MS. Total ion current (TIC) 
of the standards mixture containing β-lactoglobulin A and B, α-lactalbumin and ubiquitin as 
IS. 
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The multi-charged ions and the corresponding deconvoluted spectra for each peak 
revealed that the first peak at 5.38±0.01min corresponds to ubiquitin (Figure 10a); 
the second one (RT 9.08±0.06 min), corresponds to the co-elution of the isoform B 
of β-Lactoglobulin and α-Lactalbumin (Figure 10b); the last one (RT 9.43±.05 min) is 
attributed to the isoform A of β-Lactoglobulin (Figure 10c).  
To selectively monitor the elution of the three analytes, selected ion chromatograms 
(SIC) were reconstituted by monitoring for each analyte the characteristic 3 most 
intense ions and in particular m/z 714.45, 779.36, 857.11 for ubiquitin, m/z 1223.77, 
1310.79, 1412.09 for the isoform A of β-lactoglobuiln, m/z 1218.06, 1305.09, 1404.95 
for the isoform B of β-lactoglobuiln and m/z 1418.51, 1575.44, 1772.32 for α-
lactoalbumin. 
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Figure 10 - β-lactoglobulin and α-lactalbumin analysis by LC-ESI/MS. Panel a) MS spectrum of 
the peak at 5.38±0.01min corresponding to ubiquitin; panel b) MS spectrum of the peak at 
9.08±0.06 min, corresponding to the co-elution of the isoform B of β-Lactoglobulin and α-
Lactalbumin; panel c) MS spectrum of the peak at RT 9.43±.05 min attributed to the isoform A of 
β-Lactoglobulin. The inlets of panels b, c and d show the deconvoluted spectra. 
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Calibration curves for β-lactoglobulin A/B and α-lactalbumin Figure 11 (panel a-b-c) 
ranged from 0.5 to 20.0 µM with R2= 0.9998 ±0.0001.  
 
Figure 11 - Panel a) β-lactoglobulin B calibration curve; panel b) β-lactoglobulin A calibration 
curve; panel c) α-lactalbumin calibration curve. 
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Figure 12a shows the TIC relative to BC4 sample spiked with the IS.  SIC traces 
relative to ubiquitin, α-Lactalbumin, β-Lactoglobulin A and B are displayed in panels 
b, c, d, e, respectively. 
 
Intra- and inter-day precisions were determined by an assay of quality control 
samples at low, medium and high concentrations (six replicates each) on the same 
day and on three different days; precision and accuracy were within ±20% for LLOQ 
(LQC) and ±15% for all the other concentrations, indicating satisfactory accuracy and 
precision (Table 5). 
 
 
Table 5 - β-lactoglobulin and α-lactalbumin quantitative analysis by HPLC-ESI-MS: precision 
and accuracy. 
 
The method was then applied to the IgG depleted fraction of BC sample. Analytes 
were easily identified and quantitatively determined. Results are summarized in Table 
4. 
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Figure 12 – β-lactoglobulin and α-lactalbumin analysis in BC4. panel a)  TIC relative to BC4 
sample spiked with the IS. SIC traces relative to ubiquitin, α-Lactalbumin, β-Lactoglobulin A 
and B are displayed in panels B, C, D, Eb, c, d, e, respectively. 
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3.5 Targeting bioactive proteins by ELISA assay  
ELISA analyses were performed to measure the content of three functional proteins 
involved in wound healing as previously identified by proteomic analysis of BC 
conducted by our team: lumican (37KDa), IL-17 (14 kDa) and IGF-1 (7.5 kDa) [5]. 
Quantitative measurements of BC4 were carried out according to the suppliers’ 
manuals. IL-17, Lumican and IGF-1 content was 2.25, 14.10 and 1.54 pg mg-1 
calculated on the dry matter, respectively.  
 
3.6. Protein Functionality 
3.6.1 Lactoperoxidase Activity Assay - Spectrophotometric method 
The LPO activity was measured by setting a calibration curve built by plotting the 
enzymatic activity, reported as the increase of absorbance at 413 nm min-1, in respect 
to the enzyme standard concentrations (four levels) (Figure 13).  
 
Figure 13 - LPO Activity calibration curve: the enzymatic activity is reported as the increase 
of absorbance at 413 nm per minute, in respect to the enzyme standard concentrations (four 
levels). 
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LPO activity was measured on BC, decaseinated/defatted BC and purified BC. 
Enzymatic activity in genuine BC accounted for 0.122±0.01 U mL-1, which is much 
lower than in bovine milk (1.2 to 19.4 U mL-1). However, considering that the minimum 
amount of LPO in milk required to activate the LPO system is 0.02U mL-1, the activity 
found in untreated BC is enough to be effective. No LPO activity was measured in 
processed BC up to a concentration of 100 mg ml-1. 
 
3.6.2 Determination of Xanthine Dehydrogenase/Oxidase Activity - Fluorimetric 
Assay 
The enzymatic activity of Xanthine Dehydrogenase/Oxidase (XDH/XO) was initially 
measured in BC0. An aliquot of 10 µl of colostrum (corresponding to 1.428 mg 
protein) was able to generate a well detectable increase of fluorescence, whose slope 
was automatically calculated by using the available arithmetic tool within the FL 
WinLab™ software (Perkin Elmer). The enzymatic activity was determined by using 
a quantitative method based on adding the standard of XDH/XO to BC0 at three 
different concentration levels (0.0005, 0.0010, and 0.0020 U mL-1). Figure 14 shows 
the fluorescent time course and the calculated slopes of BCO (panel a) spiked in the 
absence and presence of the three concentrations of standard enzymes.  
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Figure 14 - Determination of 
Xanthine 
Dehydrogenase/Oxidase Activity 
by fluorescence - fluorescent 
time courses and calculated 
slopes of BCO (panel a) and 
BC4 (panel b) spiked in the 
absence and presence of the 
three concentrations of standard 
enzymes (0.002 U ml-1 blue line; 
0.001 U ml-1 red; 0.0005 U ml-1 
green). The XDH/XO activity in 
the tested samples was 
determined by setting y=0 in the 
y=mx+b equation determined by 
considering the linear calibration 
curve obtained by considering 
the slopes of the three 
concentration levels. 
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The XDH/XO activity in BC0 was determined by setting y=0 in the y=mx+b equation 
determined by considering the linear calibration curve obtained by considering the 
slopes of the three concentration levels (Figure 14b). A similar approach was then 
applied to BC samples. The enzymatic activity was determined in only two samples 
(BC4 and BC5) when dissolved at a final concentration of 50 mg (30 mg of protein 
mL-1) and characterized by a significant difference in terms of slope. The other 
samples did not provide a detectable slope up to a concentration of 1.5 mg ml-1. 
Higher concentrations were not tested due to the formation of a cloudy suspension 
due to the presence of caseins. For each sample the amount of the enzyme was 
determined by ELISA thus permitting the reporting of enzymatic activity in respect to 
the amount of the enzyme. As shown in Table 6 the ratio reduced between 10 and 
100 times in processed colostrum in respect to frozen colostrum.     
 
 
Table 6 - XDH enzymatic activity and protein content measured in BC0, BC4 and BC5. 
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Discussion 
Bovine colostrum components in addition to their well-established nutritional 
properties also exhibit specific biological activities that make bovine colostrum, and 
its derivatives, a valuable ingredient for several food supplements and health 
products [4, 16]. Most of the beneficial effects of BC have been ascribed to the 
proteins [7]. By using an in depth proteomic and bioinformatic approach, we recently 
identified more than 1200 proteins and among these we selected protein clusters that 
on the basis of their biological activity can explain some claimed health benefits. For 
instance, BC is used as a functional ingredient in products claimed to better help the 
wound healing process and we identified 93 proteins involved in the different steps 
of the wound healing process [5]. 
On the one hand, BC is an amazing natural resource of bioactive protein components, 
on the other it is a very complex and oxidizable matrix that requires high 
standardization and in depth quality profiling for its usage as ingredient in food 
supplement products, to guarantee safety and a reproducible efficacy. We here report 
a suitable analytical platform for the quality control of the protein components of raw 
materials. 
Analysis starts with a 1D and 2D gel electrophoresis in both reducing and non-
reducing conditions. This is quite an easy analysis that permits the establishment of 
the presence of high molecular aggregates as well of caseins that in some 
commercial products are intentionally removed. Densitometry analysis can also 
furnish a draft semi-quantitative analysis of the most abundant proteins including IgG, 
IgM, lactoalbumins and lactoglobulins.  
The immunoglobulins fraction represents a very important antimicrobial component 
of BC. Ig antibodies express multifunctional activities, including complement 
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activation, bacterial opsonisation and agglutination, and act by binding to specific 
sites on the surfaces of the most infectious agents or products, either inactivating 
them or reducing infection [6]. In bovine colostrum, immunoglobulin G (IgG; 
subclasses IgG1 and IgG2) is the major immune component, and is accompanied by 
low levels of IgA and IgM [17]. 
As critically evaluated by Rathe et al. [4] evidence suggests that bovine colostrum 
has immunity-modulating capabilities that may be utilized in maintaining or improving 
host defences under different detrimental conditions or immune system exposures. 
Such effects are due to the Ig fraction and hence an accurate qualitative analysis is 
needed for this class of bioactive components. Several analytical methods have so 
far been reported for the quantitative analysis of Ig, including radial immunodiffusion, 
reversed-phase liquid chromatography, ion exchange chromatography, capillary 
electrophoresis, SEC, and ELISA, the latter representing the most widely used 
method [18]. ELISA kits have different positive aspects such as ease of use, 
sensitivity, speed of analysis and they do not require complex instruments or skilled 
operators. However, ELISA kits also have some drawbacks such as high cost and 
limited accuracy. 
We here propose a validated SEC-UV method that measures both IgG and IgM. The 
method was found to be accurate and precise with a LOD/LLOQ of 0.05 mg mL-1/0.10 
mg mL-1, and 0.125 mg mL-1/0.250mg mL-1, for IgG and IgM respectively. Analyses 
were carried out on two fractions prepared by an affinity chromatography based on 
protein G as stationary phase. IgG are analysed in the IgG enriched fraction while 
the IgM are analysed in the IgG depleted fraction. The SEC-UV method was found 
not to be sensitive enough for the measurement of IgA that can be measured by 
ELISA test. 
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The IgG depleted fraction is then analysed by HPLC-MS for measuring other major 
protein components. The identified intact proteins clearly depend on the type of MS 
analyser. The ion trap was limited because it was unable to detect proteins with a 
MW greater than 30 kDa which by contrast were easily detected by the TOF analyser. 
Besides the two isoforms of β-lactoglobulin A/B and the α-lactoalbumin easily 
identified by LC-ESI ion trap, LC-ESI-q-TOF system also identified intact 
lactotransferrin, cytocrome C, β2-microglobulin, bovine serum albumin, 
lactoperoxidase. Quantitative analysis of β-lactoglobulins A/B and the α-lactoalbumin 
were then carried out applying a validated HPLC-MS method by using the Ion Trap 
as mass analyser. Notably the number of proteins quantified by the intact protein 
assay can be significantly increased by using a TOF MS analyser. The intact protein 
analysis is also suitable to measure isoforms and post-translational modifications 
such as lactosylation. 
The strength of the proposed method is the simultaneous analysis of both the 
isoforms of β-lactoglobulins and of α-lactoalbumin in colostrum samples. We used 
the IgG-depleted fractions for the α-lactalbumin and β-lactoglobulin content 
measurement, since immunoglobulins have been found to interfere with the MS 
analysis and reduce the chromatographic column performance. Although we set-up 
a method that enables the simultaneous quantification of the two isoforms of β-
lactoglobulin, we here reported the values measured for the total content of the 
protein, since the standard of β-lactoglobulin we used is a not-defined mixture of both 
the isoforms. However, by assuming that the two isoforms have a similar ionic 
response a semi-quantitative measurement can be considered (in BC4 the isoforms 
A and B accounted for the 61.3 and 38.7 %, respectively).  
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Besides immunoglobulins and the other most abundant proteins, the quality control 
of BC should also target the bioactive proteins responsible for the claimed BC health 
properties. Selection of such bioactive proteins can be carried out by selecting them 
from the database of BC proteins recently identified by us using a proteomic and 
bioinformatics approach [5]. Sensitive and selective analytical methods are then used 
for their quantitative measurement, such as ELISA. As an example, three proteins 
involved in the re-epithelisation and wound healing process were selected: Lumican, 
IL-17 e IGF-1 and their quantitation was carried out by ELISA assay.  
Biological potency is a very important parameter for the quality control of biological 
products, such as recombinant proteins. Such a test is well integrated with the 
chemical analysis which furnishes detailed data regarding the structural integrity of 
the protein (primary sequence, MW, disulphide bonds and some PTM) but it is limited 
when assessing the correct biological activity of the analyte. The biological activity 
would be of great value also for testing the efficacy of BC because the chemical 
analysis cannot clearly cover all the bioactive constituents and their intrinsic activity. 
Moreover, the conformational integrity of bioactive proteins is a parameter that should 
be carefully evaluated due to the fact that BC is subjected to several purification steps 
including the lyophilization that can affect conformational integrity and consequently 
protein function. However, in vitro tests to evaluate the biological activity of BC are 
far from being devised particularly because the biological activity of BC results from 
the combined action of several constituents and hence it cannot be easily surrogated 
to an in vitro test. Based on these facts we propose to measure the enzymatic activity 
of some representative enzymes, which are contained in colostrum, and for this 
purpose, we considered Lactoperoxidase and Xanthine Dehydrogenase/Oxidase. 
The enzymatic activity can be considered as an index of protein functional integrity; 
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in other words if bioactive proteins are denaturated, even partially, during any step of 
the process (colostrum conservation, transfer, processing, lyophilisation) then also 
the target enzymes are affected and this can be determined by measuring their 
activity. Lactoperoxidase was well detected in the raw material but not in any of the 
commercial products tested. By contrast, XDH/XO activity, besides being significantly 
measured in the raw material, was also determined in some commercial products 
and its activity was used as a marker of protein functional integrity. Since the overall 
XDH/XO activity is due to both the intrinsic enzyme activity and to the absolute 
amount and since this latter clearly depends on several uncontrolled variables, the 
amount of XDH/XO was determined by ELISA test, thus expressing the XDH/XO 
activity in respect to the absolute amount of the enzyme. XDH/XO activity in 
colostrum was well detectable reaching 0.8 U mg of protein. In processed colostrum 
the activity was found to be very variable since in a set of samples it was not detected 
and in another samples it was found reduced between 10 and 100 fold. This loss of 
activity clearly depends on several parameters including the process technology and 
such results clearly indicate that XDH/XO activity could be a useful parameter to set-
up each step of the process and also to monitor the shelf-life of the powder.   
 
Conclusions 
In summary a comprehensive method for the quality control of the protein fraction of 
BC has been proposed and then applied to some commercial BC derivatives. The 
method permits, after a suitable fractionation by affinity chromatography, the 
quantitative determination of the Ig components as well as of the most abundant 
protein components including β-lactoglobulin and α-lactoalbumin. Functional proteins 
selected from the database on the basis of the health claim made are then 
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determined by ELISA. Finally, protein functional integrity is assayed by measuring 
the XDH/XO activity. In conclusion the here proposed method is suitable for the 
quality control of protein fractions of BC which are needed to guarantee safety and 
biological activity of such a complex matrix. 
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Part III 
 
The secrets of Oriental panacea: Panax ginseng 
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Abstract 
The Panax ginseng root proteome has been investigated via capture with 
combinatorial peptide ligand libraries (CPLL) at three different pH values. Proteomic 
characterization by SDS-PAGE and nLC-MS/MS analysis, via LTQ-Orbitrap XL, led 
to the identification of a total of 207 expressed proteins. This quite large number of 
identifications was achieved by consulting two different plant databases: Panax 
ginseng and Arabidopsis thaliana. The major groups of identified proteins were 
associated to structural  species (19.2%), oxidoreductase (19,5%), dehydrogenases 
(7.6%) and synthases (9.0%). For the first time, an exploration of protein-protein 
interactions was performed by merging all recognized proteins and building an 
interactomic map, characterized by 196 nodes and 1554 interactions. Finally a 
peptidomic analysis was developed combining different in-silico enzymatic digestions 
to simulate the human gastrointestinal process: from 661 generated peptides, 95 
were identified as possible bioactives and in particular 6 of them were characterized 
by antimicrobial activity. The present report offers new insight for future invesigations 
focused on elucidation of biological properties of Panax ginseng proteome and 
peptidome. 
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1. Introduction 
Asian ginseng (Panax ginseng C. A. Meyer) has a history of herbal use going back 
over 5,000 years as described in Chinese traditional medicine textbooks. It is one of 
the most highly regarded of herbal medicines in the Orient, where it has gained a 
reputation for being able to promote health, general body vigour and also to prolong 
life [1-3]. The genus name Panax is derived from the Greek word meaning "panacea" 
or "all-healing": the species ginseng is said to mean "wonder of the world". Both terms 
refer to the medicinal virtues of the plant belonging to Araliaceae family. Ginseng is 
traditionally used as an aid during convalescence and as a prophylatictic to build 
resistance, to reduce susceptibility to illness and to promote health and longevity [4]. 
Panax ginseng is a slow-maturing perennial herb native to the mountain forests of 
northeastern China, Korea and Russia. Seven major species of ginseng are 
cultivated extensively in China, Japan, Korea, Russia, Canada and Wisconsis in the 
US. The three mostly studied species are: Panax ginseng (Asian ginseng), Panax 
quinquefolius (American ginseng) and Panax japonicas (Japanese ginseng). 
Ginseng usually starts flowering at its fourth year and the roots take four to six years 
to reach maturity. Therefore, productivity of Panax ginseng can be significantly 
affected by various environmental factors such as temperature, condition of soil, light 
intensity, content of water and diseases [5-10]. Ginseng root consists of dried main 
root, lateral roots and root hairs or “tailings” of Panax ginseng C. A. Meyer, used as 
a tonic to revitalize and replenish vital energy. The bioactivities of ginseng roots, 
which include hypotensive [11], anticancer [12-14], antioxidant [15], anti-inflammatory 
activities as well as improving impaired memory [16-18] and anti-cardiovascular 
diseases [19, 20], are due to the presence of main pharmacologically active 
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components like ginsenosides. To understand these effects, the components of 
ginseng have been subjected to extensive analysis. Its saponins, known as 
ginsenosides, are considered to be the main active pharmacological compunds in P. 
ginseng. The distribution of ginsenosides varies from species to species [2] and each 
ginsenoside has different pharmacological effects even if it could produce multiple 
effects in the same tissue [3]. 
Although many reports have been published regarding the pharmacological effects 
of ginsenosides, little is known about biochemical pathways involving different 
proteins. High-throughput and high-sensitive proteomic techniques, such as gel 
electrophoresis and mass spectrometry, allow the separation of complex protein 
mixtures, which makes possible to charcterize protein profiles in plant roots. 
Recently, proteomic studies have been performed on ginseng roots: the first 
proteomic profiles were provided by Lum et al. [21], subsequently improved by Kim 
et al. by identifying several high-abundance proteins [22]. Most of highly abundant 
proteins in ginseng root are root-specific RNase-like proteins that function as 
vegetative storage proteins for survival in the natural environment [23, 24]. 
Subsequently, proteomic analysis was used on different varieties of ginseng, such as 
Panax ginseng and Panax quinquefolium [25-27]. However, to date, no systemic 
research has been reported for a deep investigation focused to identify the entire 
ginseng root proteome. 
Therefore, in this study, a proteomic approach was applied to identify proteins  of 
Panax ginseng C. A. Meyer root, contributing to understand their role in metabolic 
processes. Previously, a method for sample preparation of dried roots was 
established [28] and a suitable technology, called combinatorial peptide ligand 
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libraries (CPLLs) was used to capture the entire proteome by enriching trace proteins 
and concomitantly reducing the concentration of abundant species [29]. Ginseng 
proteins were identified by nLC-MS/MS, using an Orbitrap mass spectrometer, in 
order to extensively map the proteome for a consequent exploration of protein 
functions via Gene Ontology analysis. Moreover, also an interactomic investigation 
was performed merging all the proteins, by exploiting the STRING v.9.1 software, 
which was integrated with the analysis of peptides, obtained after an in-silico human 
gastrointestinal digestion. 
These results provide insight into the proteome and peptidome of Panax ginseng 
roots and contribute to a more comprehensive understanding of biological functions. 
 
 
2. Materials and methods 
2.1 Chemicals 
ProteoMiner™ (combinatorial hexapeptide ligand library beads, CPLL), Laemmli 
buffer, 40% acrylamide/Bis solution, N,N,N',N'-tetramethylethylenediamine 
(TEMED), molecular mass standards and electrophoresis apparatus for one-
dimensional electrophoresis were from Bio-Rad Laboratories, Inc., Hercules CA. β-
mercaptoethanol, dithiothreitol (DTT), ammonium persulfate, 3-[3-cholamidopropyl 
dimethylammonio]-1-propanosulfonate (CHAPS), acetonitrile (ACN), trifluoroacetic 
acid (TFA), sodium dodecyl sulphate (SDS), iodoacetamide (IAA), formic acid (FA) 
and all other chemicals used all along the experimental work were current pure 
analytical grade products and purchased from Sigma-Aldrich S.r.l, Italy. Water with 
0.1% formic acid  and acetonitrile with 0.1% formic acid  LC/MS grade were also 
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purchased from Sigma Aldrich S.r.l, Italy Complete protease inhibitor cocktail tablets 
and sequencing grade trypsin were from Roche Diagnostics (Basel, CH). 
 
2.2 Panax ginseng root treatment 
Dried powdered roots of Panax ginseng C. A. Meyer were used in this experiments. 
The dry radix was from Martin Bauer group (Vestenbergsgreuth, Germany). The drug 
was identified and ground by mill knives by the Phytochemistry Research Laboratory 
of Aboca s.p.a. (Sansepolcro, Arezzo, Italy).   
Samples were stored at room temperature until required and they were prepared as 
described by Wang et al. [28]. Briefly Panax ginseng powder (3 g) was washed firstly 
with 20 mL of 10% TCA/ice-cold acetone, secondly with 20 mL of 80% MeOH/H2O 
and finally with with 20 mL of 80% ice-cold acetone/H2O. After drying at 25°C 
overnight, powder was incubated with 30 mL of extraction buffer (50 mM Tris-HCl 
pH=8.0, 200 mM DTT, 0.3% SDS, 1 protease inhibitor tablet for 50 mL buffer) 
overnight at room temperature. After centrifugation at 14000 rpm for 30 min, the 
supernatant was precipitated with 10% TCA solution for 1 h at -20°C. The protein 
pellet thus obtained was washed with ice-cold acetone to remove contaminants and 
resuspended into 60 mL buffer for CPLLs incubation (50 mM Tris-HCl pH=7.2, 50 
mM NaCl), added with one tablet of proteases inhibitors cocktail. This solution was 
divided into three, twenty mL fractions: one of them was equilibrated into the same 
pH 7.2 buffer, the other two fractions were titrated, respectively, to pH 9.0 by addition 
of NaOH solution and to pH 2.2 by addition of 0.1% TFA and formic acid to mimic 
reverse phase conditions for the capture of hydrophobic proteins. All fractions were 
loaded onto 100 µL of CPLL beads at the three different pH values [30] and the 
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capture was performed batch-wise, gently rocking on a rotating platform for 2 hours. 
After that, the beads were rinsed twice with the incubation buffers, so as to remove 
any excess of non-adsorbed proteins (see the scheme of Figure 1).  
Desorption was implemented by washing the beads twice (each time with 80 µL) with 
a boiling 4% SDS solution containing 20 mM DTT, 12.5 % (v/v) glycerol, 0.005% (m/v) 
bromophenol blue, and 62.5 mM Tris-HCl (pH 6.8) [31].  
 
 
Figure 1 - Scheme of complete treatment protocol of Panax ginseng root’s powder. The 
capture with CPLLs is performed at three pH values, namely 2.2, 7.2 and 9.0. 
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2.3 SDS-PAGE analysis and trypsin digestion 
Ten µL of the above eluates (labelled as 2.2, 7.2 and 9.0) and ten µL of the non-
treated sample (CTRL) were loaded onto an SDS-PAGE gel, composed by a 4% 
polyacrylamide stacking gel (125 mM Tris-HCl, pH 6.8, 0.1%, m/v, SDS) over a 12% 
resolving polyacrylamide gel (in 375 mM Tris-HCl, pH 8.8, 0.1%, m/v, SDS buffer). 
The cathodic compartment was filled with Tris-glycine buffer, pH 8.3, containing 
0.1%, m/v, SDS whereas Tris buffer, at pH 8.8, was present at the anode. 
Electrophoresis was performed at 100 V until the dye front reached the bottom of the 
gel and at 150 V until the end of the separation. Staining and distaining were 
performed with Colloidal Coomassie Blue and 7% (v/v) acetic acid in water, 
respectively. For each lane of the gel, subsequent gel pieces in the range of 200-15 
kDa were excised to perform in-gel digestion, accordingly to a standardized protocol 
[32]. Thirteen gel pieces were cut from each sample, rinsed with pure water, 
destained for 10 min with 50% acetonitrile/25 mM ammonium bicarbonate and 
incubated at 56 °C with 10 mM dithiothreitol in 50 mM ammonium bicarbonate for 
cysteine reduction. After 60 min incubation, the solution was discarded and the gel 
pieces were incubated with 55 mM iodoacetamide in 50 mM ammonium bicarbonate 
for 45 min, in the dark, for cysteine alkylation. After discarding the iodoacetamide 
solution, gel pieces were rinsed with 50 mM ammonium bicarbonate and incubated 
in 100% acetonitrile for dehydration. Each gel slice was incubated with 1 µg of 
sequencing grade trypsin (Roche) dissolved in 50 mM ammonium bicarbonate. After 
overnight digestion at 37°C, the solutions containing the digested peptides were 
collected. Gel pieces were incubated for 10 min with 30% acetonitrile, 3% 
trifluoroacetic acid, and the solution was collected and pooled with the initial peptide 
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mixture. Gel pieces were incubated for an additional 10 min with 100% acetonitrile, 
and the solution was pooled with the previous one. Eluted peptides were evaporated 
on a vacuum concentrator (Christ) and stored at -20°C. 
 
2.4 Mass spectrometry analysis 
The dried peptides were solubilized in 15 µL of 0.1% formic acid. Five µL of sample 
were injected on a C18 column (picoFrit column, C18 HALO, 90Å, 75 µm ID, 2.7 μm, 
10.5 cm length, New Objective) by a constant flow rate of 0.4 µL/min delivered by a 
nano-chromatographic system (UltiMate 3000 RSLCnano System, Thermo 
Scientific). The separating gradient ramped linearly from 1% acetonitrile to 40% 
acetonitrile in 30 minutes; the eluting peptides were on-line sprayed in a LTQ-Orbitrap 
XL mass spectrometer by a nano-ESI source (all Thermo Scientific). Full scan mass 
spectra were acquired in the Orbitrap cell in the mass range 300 to 1500 m/z (positive 
polarity, profile mode, AGC = 5×105). The nine most intense ions (minimum charge 
state 2+, minimum intensity 10000 cps) were automatically selected and fragmented 
in the ion trap by collision-induced dissociation (CID). After two subsequent 
occurrences in less than 30 s, target ions already selected for fragmentation were 
dynamically excluded for 45 s.  
 
2.5 Protein identification 
The MS data were analyzed by the Proteome Discoverer software (v. 1.3.0.339 
Thermo), using the Sequest algorithm. The database of proteins belonging to 
different types of Panax (640 entries, downloaded on 02 July 2014 from Uniprot) and 
the database of Arabidopsis thaliana proteins (31760 entries, downloaded on 18 
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February 2014 from UniProt) were used for spectra matching. Cysteine 
carbamidomethylation and methionine oxidation were set as variable modifications. 
Peptide mass tolerance was set to 10 ppm, fragment mass tolerance to 0.5 Da and 
maximum number of missed cleavages = 2. The false discovery rate (FDR) for 
peptide identification was set at 0.05; only proteins identified by at least two peptides 
were considered as genuine identifications and further analyzed.  
 
2.6 Analysis of identified proteins  
In order to describe the functional classes of identified proteins, a Gene Ontology 
(GO) analysis was performed by using the web available software QuickGo 
(www.ebi.ac.uk/QuickGo). 
An interactomics map was built up by means of STRING (Search Tool for the 
Retrieval of Interacting Genes) v.9.1 software (http://stringdb.org/), set on 
Arabidopsis thaliana as organism database. This is a large database of known and 
predicted protein-protein interactions. Proteins were represented with nodes and the 
interactions with continuous lines to represent direct interactions (physical), while 
indirect ones (functional) were presented by broken lines. All the edges were 
supported by at least a reference from the literature or from canonical information 
stored in the STRING dataset. Cluster networks were created by using the K-means 
algorithm which is included in the STRING website and a value of 7 was selected for 
all the analyses. The pathways classification was done after the automatic 
enrichment in STRING, based on the information provided by the KEGG-Pathway 
Database.  
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2.7. Analysis of proteolytic peptides obtained by simulated gastrointestinal 
digestion 
Bioactive peptides encrypted in the Panax proteome were predicted by combining 
different in-silico enzymatic digestions in order to simulate the human gastrointestinal 
process: pepsin (stomach) and intestinal enzymes (trypsin, chymotrypsin, elastase, 
carboxypeptidase A and B and aminopeptidases). In order to perform the simulated 
gastrointestinal digestion, a global protein database was created by merging all MS 
tabular report, obtained by searching MS spectra of initial protein extract and all 
CPLLs eluates, against an Arabidopsis Thaliana database. All the digestions were 
performed in-silico using the MS-Digest software which is included in the 
ProteinProspector v 5.10.1 website 
(http://prospector.ucsf.edu/prospector/mshome.htm). To evaluate the results, all the 
potential peptides were ranked by using the PeptideRanker software 
(http://bioware.ucd.ie/~testing/biowareweb/), using the N-to-1 neural network 
probability to predict which peptides could be more bioactive. In addition, all the 
potential bioactive peptides were compared with the CAMP database, which includes 
known antimicrobial bioactive peptides  (http://www.bicnirrh.res.in/antimicrobial/). 
 
 
3. Results 
Figure 1 shows a complete scheme of protein extraction, CPLLs enrichment, proteins 
separation by SDS-PAGE electrophoresis and their identification by MS analysis.  
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Figure 2 - SDS-PAGE separation of the untreated (Raw) sample vs. the eluates of CPLL 
capture at the three different pH values (tracks E2.2, E7.2 and E9.0). Each lane has been cut 
into segments, the proteins digested and sent to MS analysis. Mr: molecular mass ladder. 
Staining with micellar Coomassie blue. 
 
In order to increase the knowledge on the Panax ginseng proteome, we have 
performed the most efficient protocol able to extract proteins from a dried root 
powder. After testing  various extraction procedures reported in literature [21], we 
have applied the initial steps of the protocol described by Wang et al. [28], which 
required preliminary washes of dried powder in order to eliminate interferences and 
contaminants until the plant powder became colorless. The protein extraction was 
performed by using a sample buffer previously described [22]. The final combination 
of TCA and acetone is commonly used to precipitate proteins and to remove any 
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remained contaminants. By using a combination of different methods, we were able 
to extract about 300 mg of soluble proteins from 3 g of sample, quantified by the 
BioRad protein assay with BSA as standard [33]. The extracted protein quantity was 
appropriate for incubation with bead-based libraries of combinatorial peptide ligands 
(CPLLs), a protein enrichment technology which simultaneously dilutes high-
abundance proteins and concentrates low-abundance ones [34]. The CPLLs 
technology was originally optimized for use with human biological samples [35], but 
it was recently adopted with other sample types like plants and foodstuffs within the 
recommend total protein range (>50 mg of proteins for 100 µL beads volume) [36-
38]. So in order to aim to a very large protein discovery, a sample overloading, as 
well as a capture at three pH values, are recommended. 
The CPLLs treatment has contributed to increase protein capture, as seen by the 
SDS-PAGE profiling in figure 2 where the untreated sample (Raw) is characterized 
by three major protein bands, while CPLLs beads eluates from the three pH values 
(lanes E 2.2, E 7.2 and E 9.0) exhibit additional bands, particularly increased in the 
regions of the gel corresponding to 75-30 KDa and 20-15 KDa. In fact, while the 
electrophoretic profile of the raw extract has displayed only 3 or 4 evident protein 
bands, probably corresponding to high-abundance proteins, the CPLLs eluates 
profiles have revealed more intense and much more resolved protein bands, referred 
both to high-abundance proteins and to low-abundance ones. The efficiency and the 
potentiality of CPLLs treatment has been demonstrated by mass spectrometry 
analysis. 
Figure 3 shows the number of proteins identified by matching the experimental 
spectra to two different databases: Arabidopsis thaliana and Panax ginseng.  
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Figure 3 - MS data of the identified proteins. Upper panel: table of  protein IDs as obtained in 
a raw extract and all CPLLs eluates by using both Panax ginseng and Arabidopsis thaliana 
databases, respectively. The total unique IDs were 152 for Arabidopsis thaliana database 
and 55 for Panax ginseng. Lower panel: Venn diagrams comparing the number of identified 
proteins in all CPLLs eluates with those recognized in the raw extract, considering both 
databases. In reagard to the Panax ginseng db, 37 proteins were found both in untreated and 
eluted samples, while 13 were specifically of CPLLs eluates. Moreover a quite high number 
of identifications was specific of each beads capture (e.g. 8 specific proteins for CPLLs 
treatment at pH 7,2). Also for Arabidopsis Thaliana db 81 were common identifications from 
all samples, while 43 were exclusive proteins of three eluates. The higher number of 27 
specific proteins was obtained after beads capture at pH 9,0. 
 
The use of two different databases was prompted by the necessity to increase the 
number of identified proteins. In fact while the Panax ginseng database is most 
specific, it’s characterized by a large number of unreviewed entries. Moreover, the 
lack of complete DNA sequencing cause the incompleteness of the Panax ginseng 
proteome. The choice of Arabidopsis thaliana database is due to many reasons: first 
of all its database is complete and characterized by a higher number of entries than 
the Panax ginseng database (31706 vs. 640); in fact, the full proteome of Arabidopsis 
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thaliana is available at the UniProt depository as reference proteome.  Secondly, 
Arabidopsis thaliana is commonly used as model organism for studying plant 
sciences and biology, after its complete genetic mapping and sequencing in 2000. 
The table displays the IDs obtained in the untreated sample (raw extract) and in all 
CPLLs eluates: many species are recognized in all samples so, in order to know the 
correct number of unique gene products, the last column reports the total distinct IDs 
without redundancies. The Venn diagrams, in the lower panel of figure 3, compare 
the identified proteins in CPLLs eluates vs. those recognized in raw extracts 
considering both types of databases. 13 and 43 more proteins, belonging to the 
Panax ginseng and the Arabidopsis thaliana database respectively, could be 
identified only after CPLLs treatment. Finally the different contributions of each 
CPLLs incubation were considered for a deep investigation of Panax proteome: for 
both databases, CPLLs treatments at different pH values were successful for capture 
of specific proteins, undetectable applying only the standard protocol. Concerning the 
Panax ginseng database, the most performant incubation condition was at 
physiological pH, able to capture 8 unique ginseng's proteins. Considering the 
Arabidopsos thaliana database, the beads incubation at pH 9,0 has identified the 
higher number of specific proteins (27) than other two pH conditions (15 at pH 7,2 
and 9 at pH 2,2). 
Figure 4 depicts a pie chart of Gene Ontology (GO) analysis applied to all 207 
identified species in order to understand /categorize the belonging protein classes.  
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Figure 4 - Biological funtional categorization of 207 unique proteins expressed in ginseng 
dried root powder via GO analysis. The pie chart shows the percentage distribution of 
reported GO terms. 
 
 
Figure 5 displays the general workflow for the analysis of the peptides obtained after 
an in-silico human gastrointestinal digestion: the software simulates digestion of 
pepsin, trypsin, chymotrypsin, elastase, carboxipeptidases (A and B) and 
aminopeptidases,  using the MS-Digest program.  
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Figure 5 - In-silico simulation scheme of human gastro-intestinal digestion, performed on all 
proteins identified via the Arabidopsis thaliana database. All the listed digestive enzymes 
generated a total number of 661 peptides. 
 
All generated peptides (661) were ranked on the basis of their predicted bioactivity 
by software the PeptideRanker, which was able to select 95 bioactive peptides 
focusing our attention on their potential antimicrobial action as reported in Figure 6.  
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Figure 6 - Representation of 95 proteins releasing bioactive peptides, clusterized by 
KMeans; bioactive peptides have been ranked on the bases of their a Peptideranker score 
>0.5 calculated by the corresponding software. All nodes in interactomic map were proteins, 
showing different activities like antimicrobial or defensive functions. 
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4. Discussion  
 
4.1. Protein identification  
The deep proteome identification was performed by using two different databases, 
Arabidopsis thaliana and Panax ginseng, in order to increase the number of panax 
species discovered. In fact a total number of 206 proteins were identified by merging 
all unique IDs obtained considering both databases. Our results have substantially 
improved a previous study of Kim et al. [22], who recognized only 17 proteins using 
MALDI-TOF MS. The low rate of identified species was probably due to lack of 
ginseng genome DNA sequence database. Also for this reason we have decided to 
perform a search by considering the databank of plant species mostly used as model 
organism. In order to increase protein identification, Kim et al. have performed a 
BLAST search of amino acids sequences using the ginseng EST databases, finally 
recognizing 87 unique gene products. Our quite large discovery has been made 
possible thanks to very sensitive high resolution and high mass accuracy of the 
Orbitrap mass spectrometer, as well as to the use of CPLLs, which have enhanced 
by more tha 20% the final discovery. Indeed, as reported in the lower Venn diagram 
of Figure 3, the adopted strategy has been indispensable to capture 13 more proteins, 
via identification by the Panax db, and 43 more proteins, via the Arabidospis Thaliana 
db. Even if these numbers are not too high, we believe that the CPLLs technology 
has contributed to proteome knowledge of this perennial plant whose genome is not 
fully sequenced. Moreover the strategy to use different pHs incubations has 
contributed to capture specific unique gene products, setting up the most performant 
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conditions for a more efficient interaction between ginseng’s proteins and 
hexapeptides chains.  
 
4.2. Protein functional data 
To gain further knowledge of the Panax ginseng proteome functionality, the 206 
identified proteins were analysed by Gene Ontology, ascertaining their molecular 
function, and all GO categories were described in a pie chart of Figure 4. The most 
enriched protein classes were: structural  (19.2%) and oxidoreductase (19,5%). The 
first category was probably a consequence of tissue type considered in this study. In 
fact roots are a very simple plant tissue, consisting of a central vascular system 
surrounded by a large storage parenchyma cells on the outside protective layer. So 
this sample type has justified the discovery of large amount of proteins with structural 
function. In fact, for example, proteins of cytoskeleton, like tubulin alpha-3 and tubulin 
beta-4 identified by MS analysis (TBA3_ARATH, TBB4_ARATH), and pectins are 
involved in the cell wall structure and the changes in structure/chemistry of cell walls 
directly affect the ripening and senescence of plants [40-41].  Moreover 
oxidoreductases are enzymes able to catalyse the transfer of electrons from one 
molecule to another one and they are normally involved in different metabolic 
processes like signalling and regulation of growth [39], transport activities and 
defense against pathogens [42]. Another large percentage of identified proteins 
belongs to the class of dehydrogenases (7.6%), enzymes able to interconvert 
alcohols into aldehydes or ketones with the reduction of nicotinamide adenine 
dinucleotide (NAD+ to NADH), like our identification NADH dehydrogenase iron-
sulphur protein 3 (NDUS3_ARATH). They are expressed at low levels in roots of 
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young plants grown on agar and at a high level in lack of oxygen or water and in low 
temperatures [43]. In addition, a particular dehydrogenase, the glyceraldehyde 3-
phosphate dehydrogenase, identified via MS in our Panax extracts (Q6VAL5_PANGI, 
D0VFU1_PANGI), is involved in glycolysis, a pathway able to break starch into 
glucose. We speculate that this result could indicate that ginseng mainly absorbs 
energy as vegetative storage for ginseng root survival, which is destroyed through 
glycolysis to release the energy required for root maturation in slow-growth period 
[24]. Another major functional class of proteins is represented by synthases (9.0%), 
which catalyzes numerous synthesis processes. For example, the overexpression of 
Panax ginseng squalene synthase causes a remarkable increase of phytosterols as 
well as ginsenoside contents [44]. Proteins belonging to the synthesis category such 
as granule-bond starch synthase I identified in our samples (Q6XY46_9APIA), 
increase with ginseng root age, indicating that protein synthesis enhances the 
ginseng maturation at different metabolic levels [9]. 
In order to investigate protein-protein interactions, a proteome-scale interaction 
network was created by merging all the proteins identified for the Panax ginseng 
proteome by using STRING software (Figure 7). The databases include interactions 
from published literature describing experimentally studied interactions, as well as 
those from genome analysis by using several well-established methods based on 
domain fusion, phylogenetic profiling and gene neighborhood concepts. The whole 
Arabidopsis Thaliana genome was selected as a reference set, correlating the new 
results with the previous MS analysis. This network obtained represents the first 
comprehensive interactomics map for the Panax ginseng proteome and provides an 
interesting framework for navigating through the proteome. 
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Figure 7 -  interactomics map realized by STRING v.9.1 software, showing a protein-protein 
interaction network formed by 196 nodes and 1554 interactions. Clusters realized applying 
the algorithm MCL (factor 2). 
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The topological analysis of this network has demonstrated several sparsely 
connected sub-networks, including that one corresponding to the ribosomal proteins 
with highly connected interactions (Figure 7). The KEGG-Pathway Enrichment in 
STRING has revealed the presence of the canonical pathways: energy metabolism, 
carbohydrate and lipid metabolism and nucleotide and amino acid metabolism (Table 
1). 
 
KEGG PATHWAY N° of genes 
Metabolic pathways 65.9% 
Energy metabolism   
Carbon fixation in photosynthetic organisms 10 
Oxidative phosphorylation 8 
Nitrogen metabolism 3 
Photosynthesis 2 
Sulfur metabolism 1 
Carbohydrate and lipid metabolism   
Carbohydrate metabolism  
Citrate cycle (TCA cycle) 10 
Pyruvate metabolism 8 
Glycolysis / Gluconeogenesis 8 
Starch and sucrose metabolism 8 
Glyoxylate and dicarboxylate metabolism 7 
Pentose phosphate pathway 6 
Butanoate metabolism 4 
Ascorbate and aldarate metabolism 3 
Pentose and glucuronate interconversions 2 
Galactose metabolism 2 
Fructose and mannose metabolism 1 
Sugar metabolism   
Amino sugar and nucleotide sugar metabolism 8 
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Fatty acid metabolism   
Arachidonic acid metabolism 1 
Glycan metabolism   
N-Glycan biosynthesis 1 
Terpenoid backbone biosynthesis  1 
Sesquiterpenoid biosynthesis 1 
Other terpenoid biosynthesis  
Limonene and pinene degradation 2 
Carotenoid biosynthesis 1 
Nucleotide and amino acid metabolism  
Purine metabolism 4 
Pyrimidine metabolism 1 
Amino acid metabolism   
Alanine, aspartate and glutamate metabolism 6 
Cysteine and methionine metabolism 5 
beta-Alanine metabolism 3 
Phenylalanine metabolism 4 
Arginine and proline metabolism 2 
Glycine, serine and threonine metabolism 1 
Tyrosine metabolism 1 
Tryptophan metabolism 1 
Other amino acid metabolism   
Glutathione metabolism 6 
Taurine and hypotaurine metabolism 3 
Selenocompound metabolism 2 
Cyanoamino acid metabolism 1 
Metabolism of cofactors and vitamins  
One carbon pool by folate 1 
Secondary metabolism   
Biosynthesis of secondary metabolites   
Phenylpropanoid biosynthesis 4 
Stilbenoid, diarylheptanoid and gingerol biosynthesis 3 
Flavonoid biosynthesis 1 
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Genetic Information Processing 27.4% 
Translation  
Ribosome 27 
mRNA surveillance pathway 3 
RNA transport 2 
Aminoacyl-tRNA biosynthesis 1 
Transcription  
Spliceosome 5 
RNA polymerase 1 
Folding, sorting and degradation  
Protein processing in endoplasmic reticulum 11 
Proteasome 8 
RNA degradation 3 
Cellular Processes 5.8% 
Transport and catabolism  
Endocytosis 6 
Peroxisome 4 
Phagosome 3 
Organismal Systems 0.9% 
Environmental adaptation  
Plant-pathogen interaction 2 
 
Table 1 – The KEGG-Pathway enrichment, performed by STRING software, has revealed 
the presence of canonical pathways: metabolic pathways (65.9%), genetic information 
processes (27.4%), cellular transport and catabolism (5.8%) and environment adaptation 
(0.9%). the numbers of involved genes are reported for all subcategories of enriched cell 
pathways. 
 
Among them the metabolic processes are the most relevant biological processes, 
representing the 65.9% of  global dataset. KEGG pathway data have confirmed the 
proteins identifications by MS analysis: most of interactions involved proteins of 
energy metabolisms, like oxodoreductases recognized previously, of carbohydrate 
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metabolism (glycolysis) such as glyceraldehyde 3-phosphate dehydrogenase. 
Considering another pathway map class, the Genetic Information Processes has 
included 27 ribosomal proteins, which represented the top protein class of 
interactomics map. In conclusion, the investigation of the protein network, realized by 
using MS- proteomics data, has allowed the global protein–protein interactomics 
inspection of Panax ginseng proteome, providing a first reference map for further 
proteomics studies.  
 
4.3. Analysis of proteolytic peptides  
In order to explore the possibility to identify bioactive peptides, encrypted in the global 
Panax ginseng proteome, the physiologic enzymatic digestion of proteins was 
simulated in-silico by sequential hydrolysis with pepsin (stomach) and intestinal 
enzymes (trypsin, chymotrypsin, elastase, carboxypeptidase A and B and 
aminopeptidases). Despite restricted parameters such as one missed cleavages and 
a minimum of 6 residues per peptide, smaller peptides were not considered in the 
study because their sequence might not be unique and may belong to several 
different proteins. This model could not be completely prognostic because it didn’t 
consider a lot of individual physiological factors, like pH variations, peptidase/protein 
ratio and interactions with other molecules. The predicted peptidome  resulted into 
661 different peptides, as shown in Figure 5, and it was subsequently investigated by 
using different databases that include known bioactive peptides. By using 
PeptideRanker (http://bioware.ucd.ie/~testing/ biowareweb/) the complete list of 
potential bioactive peptides was ranked using the N-to-1 neural network probability, 
which predicts more bioactive peptides (95). Among them, with a score higher than 
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0.5 (6–11 residues), the majority corresponded to peptides encrypted in the 
nucleotide/nucleoside phosphate binding proteins (Figure 6).  
Antimicrobial peptides (AMPs), characterized by score < −0.251, were identified 
using the CAMP (Collection of Anti-Microbial Peptides) database 
(http://www.bicnirrh.res.in/antimicrobial/) and applying the DAC score (Discriminate 
Analysis Classifier score). Table 2 despicts 6 potential bioactive peptides with anti-
microbial activities.  
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Table 2 –  It lists 6 
peptides 
characterized by 
antimicrobial function 
(AMP), reporting all 
parameters like 
PeptideRanker 
score, AMP 
probability,peptide 
sequence and 
length. Also other 
parameters, referred 
to the original 
proteins, like 
accession number, 
protein family and 
function, are shown. 
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Two peptides belong to traslocon protein of chloroplast membrane, involved in 
protein precursor import to chloroplasts [45]. RPDRNF is a peptide of chloroplast 
protein Ycf2 previously identified by MS analysis, whose function is still unknown 
even if it seems to be a ATPase [46]. Other two peptides (QNEWGW and ICCCNKM) 
derived from proteins involved in cell metabolism: in particular the second one derives 
from elongation factor 1-alpha recognized in Panax samples and it seems to be 
involved in protein biosynthesis inside ribosomes. The last peptide, GWNRSW, 
belongs to alpha-glucan water dikinase 2 protein, an enzyme of PEP-utilizing family. 
Although all these potential bioactive peptides need to be validated by further 
bioactivity assays using corrspondent synthetic  peptides, we believe that the 
computational methods are useful for a preliminary peptidomic analysis. In fact they 
are  fast and low cost alternatives, able to predict and reduce the number of potential 
targets to be investigated. In addition, bioinformatics-driven tools provide useful 
insights not achievable in human or animal model studies. 
 
5. Conclusions 
Up to the present the lack of complete knowledge of Panax ginseng proteome has 
contributed to a defective characterization of ginseng proteins composition and 
functions. Despite numerous efforts to sequence Panax ginseng genome [47, 48], 
most research has focused on ginsenosides investigations [49-51]. This work 
provides new insight into the proteome of the Chinese traditional medical plant root, 
coupling the power of the Combinatorial Peptide Ligand Library (CPLL) technology, 
the SDS-PAGE separation and  the high resolution nLC-ESI MS/MS. We have 
successfully identified 55 proteins belonging to Panax ginseng database and 152 
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belonging to Arabidopsis thaliana database, for a total of 207 identifications. The GO 
software has permitted a classification of proteins in order to understand the role and 
the function of the identified species. The four major classes are represented by 
oxidoreductase (19.5%), structural compound (19.2%), synthase (9.0%) and 
dehydrogenase (7.6%). In order to explore proteins interactions useful to understand 
the Panax ginseng biology, an interactomics map was built, thus obtaining a complex 
grid formed by 196 nodes connected via 1554 interactions. The protein-protein 
interaction network was simplified in a table, reporting the pathways classification, 
which has confirmed the previous GO analysis with a prevalence (65.9%) of proteins 
involved in metabolic pathways. Our proteomic research has concluded with a 
novelty in Panax ginseng studies: a peptidomic investigation by simulating in-silico 
the enzymatic protein digestion in the human gastrointestinal tract. A total of 661 
different peptides were generated, but only 95 could be considered as potentially 
bioactive, including 6 with a predicted anti-microbial function. This approach could be 
an useful novelty to evaluate a possible antimicrobial activity expressed by proteolytic 
peptides, while normally antioxidant and antimicrobial actions are mainly associated 
to ginsenosides present in Panax ginseng root. For example recently fresh root 
extracts, from 4 years old Panax ginseng plants, have been explored for the 
synthesis of silver and gold nanoparticles, characterized by potential antimicrobial 
functions against pathogenic microorganisms [52-54]. In conclusion our proteomic 
and peptidomic analysis aimed to provide a deep investigation of 
Panax ginseng components for a better understanding of ginseng metabolism 
connected with beneficial effects, which have contributed to the diffusion as the most 
valuable traditional Asian medicine. 
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Supplementary data 
Table S1: Lists of the 152 unique gene products identified by the use of Arabidopsis thaliana database, of 55 proteins identified by 
the use of Panax ginseng database and of 207 unique identifications considering both searches. 
 
Description GENE_ID 
1 PR10-2 OS=Panax ginseng PE=3 SV=1 - [E9M221_PANGI] E9M221_PANGI 
2 PR10-3 (Fragment) OS=Panax ginseng PE=2 SV=1 - [E9M220_PANGI] E9M220_PANGI 
3 Granule-bound starch synthase I (Fragment) OS=Panax zingiberensis GN=GBSSI PE=4 SV=1 - 
[Q6XY46_9APIA] 
Q6XY46_9APIA 
4 Cytoplasmic ribosomal protein S13 OS=Panax ginseng PE=2 SV=1 - [Q9MAV9_PANGI] Q9MAV9_PANGI 
5 Putative uncharacterized protein OS=Panax ginseng PE=2 SV=1 - [Q20BN0_PANGI] Q20BN0_PANGI 
6 RNase-like major storage protein OS=Panax notoginseng GN=PMP PE=2 SV=1 - [X2D3J9_9APIA] X2D3J9_9APIA 
7 60S ribosomal protein L17-like protein (Fragment) OS=Panax ginseng PE=2 SV=1 - [A9QMA3_PANGI] A9QMA3_PANGI 
8 Dehydrin 4 OS=Panax ginseng GN=Dhn4 PE=2 SV=1 - [Q1HGF4_PANGI] Q1HGF4_PANGI 
9 60S ribosomal protein L27a OS=Panax ginseng PE=2 SV=1 - [Q9MAW6_PANGI] Q9MAW6_PANGI 
10 Glutamine synthetase-like (Fragment) OS=Panax quinquefolius PE=2 SV=1 - [A9QMA5_PANQU] A9QMA5_PANQU 
11 Ribosomal protein S4 OS=Panax ginseng PE=2 SV=1 - [Q401B8_PANGI] Q401B8_PANGI 
12 ADP-ribosylation factor-like protein OS=Panax ginseng PE=2 SV=1 - [Q20BN2_PANGI] Q20BN2_PANGI 
13 Dehydrin 2 OS=Panax ginseng GN=Dhn2 PE=4 SV=1 - [Q1HGF6_PANGI] Q1HGF6_PANGI 
14 Pathogenesis-related protein 4 OS=Panax ginseng PE=2 SV=1 - [W8FMB6_PANGI] W8FMB6_PANGI 
15 Sesquiterpene synthase OS=Panax ginseng GN=STS PE=2 SV=1 - [S5RMQ6_PANGI] S5RMQ6_PANGI 
16 ATP synthase subunit alpha OS=Panax ginseng GN=atpA PE=3 SV=1 - [O47412_PANGI] O47412_PANGI 
17 Glutamate decarboxylase OS=Panax ginseng GN=GAD PE=2 SV=1 - [D3JX88_PANGI] D3JX88_PANGI 
18 Glutathione peroxidase OS=Panax ginseng PE=2 SV=1 - [U5NNF1_PANGI] U5NNF1_PANGI 
19 Dehydrin 1 OS=Panax ginseng GN=Dhn1 PE=2 SV=1 - [Q1HGF7_PANGI] Q1HGF7_PANGI 
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20 ATP-dependent Clp protease proteolytic subunit OS=Panax ginseng GN=clpP PE=3 SV=1 - [CLPP_PANGI] CLPP_PANGI 
21 Class 1 chitinase OS=Panax ginseng GN=Chi-1 PE=2 SV=1 - [C1K2M3_PANGI] C1K2M3_PANGI 
22 60S ribosomal protein L31 OS=Panax ginseng GN=RPL31 PE=2 SV=1 - [RL31_PANGI] RL31_PANGI 
23 Glutathione peroxidase OS=Panax ginseng PE=2 SV=1 - [U5NNJ1_PANGI] U5NNJ1_PANGI 
24 Glycosyltransferase OS=Panax notoginseng PE=4 SV=1 - [F4YF65_9APIA] F4YF65_9APIA 
25 Catalase OS=Panax ginseng GN=Cat1 PE=2 SV=1 - [A9Z0Q0_PANGI] A9Z0Q0_PANGI 
26 Ribosomal protein L31 OS=Panax ginseng PE=2 SV=1 - [Q20BM6_PANGI] Q20BM6_PANGI 
27 Thioredoxin (Fragment) OS=Panax ginseng PE=2 SV=1 - [A9QMA1_PANGI] A9QMA1_PANGI 
28 ATP synthase subunit beta, chloroplastic OS=Panax ginseng GN=atpB PE=3 SV=1 - [ATPB_PANGI] ATPB_PANGI 
29 PgMADS protein1 OS=Panax ginseng GN=PgMADS1 PE=2 SV=1 - [F2ZBV8_PANGI] F2ZBV8_PANGI 
30 ATP synthase subunit alpha, chloroplastic OS=Panax ginseng GN=atpA PE=3 SV=1 - [ATPA_PANGI] ATPA_PANGI 
31 Cytochrome P450 OS=Panax notoginseng PE=2 SV=1 - [F4YF81_9APIA] F4YF81_9APIA 
32 Cytochrome P450 OS=Panax notoginseng PE=2 SV=1 - [F4YF78_9APIA] F4YF78_9APIA 
33 Peroxidase OS=Panax ginseng PE=2 SV=1 - [Q401B7_PANGI] Q401B7_PANGI 
34 Cytochrome P450 CYP73A100 OS=Panax ginseng PE=2 SV=1 - [C7A10_PANGI] C7A10_PANGI 
35 Cytochrome P450 (Fragment) OS=Panax notoginseng PE=2 SV=1 - [F4YF83_9APIA] F4YF83_9APIA 
36 Glycosyltransferase OS=Panax notoginseng PE=2 SV=1 - [F4YF66_9APIA] F4YF66_9APIA 
37 Farnesyl diphosphate synthase OS=Panax quinquefolius GN=FPS PE=2 SV=1 - [G0T3G2_PANQU] G0T3G2_PANQU 
38 Putative membrane protein ycf1 OS=Panax ginseng GN=ycf1 PE=3 SV=1 - [YCF1_PANGI] YCF1_PANGI 
39 Pleiotropic drug resistance transporter 3 OS=Panax ginseng GN=PDR3 PE=2 SV=1 - [U5KP94_PANGI] U5KP94_PANGI 
40 Protein Ycf2 OS=Panax ginseng GN=ycf2-A PE=3 SV=1 - [YCF2_PANGI] YCF2_PANGI 
41 DNA-directed RNA polymerase subunit beta' OS=Panax ginseng GN=rpoC1 PE=3 SV=2 - [RPOC1_PANGI] RPOC1_PANGI 
42 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Panax ginseng PE=3 SV=1 - 
[D0VFU1_PANGI] 
D0VFU1_PANGI 
43 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Panax notoginseng PE=2 SV=1 - 
[Q3LRW8_9APIA] 
Q3LRW8_9APIA 
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44 Glyceraldehyde-3-phosphate dehydrogenase OS=Panax ginseng PE=2 SV=1 - [Q6VAL5_PANGI] Q6VAL5_PANGI 
45 Major latex-like protein OS=Panax ginseng GN=mlp151 PE=2 SV=1 - [B5THI3_PANGI] B5THI3_PANGI 
46 Heat shock protein 90-like protein (Fragment) OS=Panax quinquefolius PE=2 SV=1 - [A9LIX4_PANQU] [A9LIX4_PANQU] 
47 Superoxide dismutase [Cu-Zn] OS=Panax ginseng GN=SODCC PE=2 SV=1 - [SODC_PANGI] SODC_PANGI 
48 Peroxiredoxin OS=Panax ginseng PE=2 SV=1 - [D7RWP9_PANGI] D7RWP9_PANGI 
49 Ribonuclease-like storage protein OS=Panax ginseng PE=1 SV=2 - [RN28_PANGI] RN28_PANGI 
50 Ribonuclease 1 OS=Panax ginseng PE=1 SV=1 - [RNS1_PANGI] RNS1_PANGI 
51 Ribonuclease 2 OS=Panax ginseng PE=1 SV=1 - [RNS2_PANGI] RNS2_PANGI 
52 S-adenosylmethionine synthase OS=Panax ginseng PE=2 SV=1 - [B3GLJ1_PANGI] B3GLJ1_PANGI 
53 Cyclophilin ABH-like protein OS=Panax ginseng PE=2 SV=1 - [A5YU16_PANGI] A5YU16_PANGI 
54 Short-chain alcohol dehydrogenase OS=Panax ginseng PE=1 SV=1 - [B8YDG5_PANGI] B8YDG5_PANGI 
55 Histone H4 OS=Arabidopsis thaliana GN=At1g07660 PE=1 SV=2 - [H4_ARATH] H4_ARATH 
56 Polyubiquitin 10 OS=Arabidopsis thaliana GN=UBQ10 PE=1 SV=2 - [UBQ10_ARATH] UBQ10_ARATH 
57 60S ribosomal protein L23 OS=Arabidopsis thaliana GN=emb2171 PE=2 SV=1 - [F4J3P1_ARATH] F4J3P1_ARATH 
58 Histone H2B.1 OS=Arabidopsis thaliana GN=At1g07790 PE=1 SV=3 - [H2B1_ARATH] H2B1_ARATH 
59 40S ribosomal protein S13-1 OS=Arabidopsis thaliana GN=RPS13A PE=2 SV=1 - [RS131_ARATH] RS131_ARATH 
60 40S ribosomal protein S19-3 OS=Arabidopsis thaliana GN=RPS19C PE=2 SV=1 - [RS193_ARATH] RS193_ARATH 
61 Histone H3.2 OS=Arabidopsis thaliana GN=HTR2 PE=1 SV=2 - [H32_ARATH] H32_ARATH 
62 GTP-binding protein SAR1B OS=Arabidopsis thaliana GN=SAR1B PE=2 SV=1 - [SAR1B_ARATH] SAR1B_ARATH 
63 Putative Sar1 GTP binding protein OS=Arabidopsis thaliana GN=AT3G62560 PE=2 SV=1 - 
[Q8VYP7_ARATH] 
Q8VYP7_ARATH 
64 40S ribosomal protein S14-2 OS=Arabidopsis thaliana GN=RPS14B PE=1 SV=1 - [RS142_ARATH] RS142_ARATH 
65 40S ribosomal protein S17-2 OS=Arabidopsis thaliana GN=RPS17B PE=2 SV=3 - [RS172_ARATH] RS172_ARATH 
66 Histone H2B.4 OS=Arabidopsis thaliana GN=At2g37470 PE=1 SV=3 - [H2B4_ARATH] H2B4_ARATH 
67 Probable mediator of RNA polymerase II transcription subunit 37c OS=Arabidopsis thaliana GN=MED37C 
PE=1 SV=1 - [MD37C_ARATH] 
MD37C_ARATH 
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68 60S ribosomal protein L23a-2 OS=Arabidopsis thaliana GN=RPL23AB PE=3 SV=1 - [A8MS83_ARATH] A8MS83_ARATH 
69 Probable histone H2A variant 3 OS=Arabidopsis thaliana GN=At1g52740 PE=1 SV=1 - [H2AV3_ARATH] H2AV3_ARATH 
70 40S ribosomal protein S9-1 OS=Arabidopsis thaliana GN=AT5G15200 PE=3 SV=1 - [B3H7J6_ARATH] B3H7J6_ARATH 
71 Probable histone H2AXa OS=Arabidopsis thaliana GN=At1g08880 PE=1 SV=1 - [H2AXA_ARATH] H2AXA_ARATH 
72 40S ribosomal protein S15a-1 OS=Arabidopsis thaliana GN=RPS15AA PE=2 SV=2 - [R15A1_ARATH] R15A1_ARATH 
73 Histone H2A.6 OS=Arabidopsis thaliana GN=RAT5 PE=1 SV=1 - [H2A6_ARATH] H2A6_ARATH 
74 40S ribosomal protein S5-2 OS=Arabidopsis thaliana GN=RPS5B PE=2 SV=2 - [RS52_ARATH] RS52_ARATH 
75 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3 OS=Arabidopsis thaliana GN=NAD9 PE=1 SV=2 - 
[NDUS3_ARATH] 
NDUS3_ARATH 
76 Glyceraldehyde-3-phosphate dehydrogenase GAPC1, cytosolic OS=Arabidopsis thaliana GN=GAPC1 PE=1 
SV=2 - [G3PC1_ARATH] 
G3PC1_ARATH 
77 Eukaryotic initiation factor 4A-3 OS=Arabidopsis thaliana GN=TIF4A-3 PE=1 SV=1 - [IF4A3_ARATH] IF4A3_ARATH 
78 Probable mediator of RNA polymerase II transcription subunit 37c OS=Arabidopsis thaliana GN=MED37D 
PE=1 SV=2 - [MD37D_ARATH] 
MD37D_ARATH 
79 Phosphoglycerate kinase 1, chloroplastic OS=Arabidopsis thaliana GN=PGK1 PE=1 SV=1 - 
[PGKH1_ARATH] 
PGKH1_ARATH 
80 Mediator of RNA polymerase II transcription subunit 37a OS=Arabidopsis thaliana GN=MED37A PE=1 
SV=1 - [MD37A_ARATH] 
MD37A_ARATH 
81 Probable mediator of RNA polymerase II transcription subunit 37e OS=Arabidopsis thaliana GN=MED37E 
PE=1 SV=3 - [MD37E_ARATH] 
MD37E_ARATH 
82 Histone H2B.9 OS=Arabidopsis thaliana GN=At5g02570 PE=1 SV=3 - [H2B9_ARATH] H2B9_ARATH 
83 60S ribosomal protein L30-2 OS=Arabidopsis thaliana GN=RPL30B PE=3 SV=1 - [RL302_ARATH] RL302_ARATH 
84 Heat shock 70 kDa protein 3 OS=Arabidopsis thaliana GN=HSP70-3 PE=1 SV=1 - [HSP7C_ARATH] HSP7C_ARATH 
85 Probable histone H2A.4 OS=Arabidopsis thaliana GN=At5g02560 PE=1 SV=1 - [H2A4_ARATH] H2A4_ARATH 
86 60S ribosomal protein L11-2 OS=Arabidopsis thaliana GN=RPL11B PE=2 SV=2 - [RL112_ARATH] RL112_ARATH 
87 60S ribosomal protein L18-2 OS=Arabidopsis thaliana GN=RPL18B PE=1 SV=2 - [RL182_ARATH] RL182_ARATH 
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88 ADP-ribosylation factor 1 OS=Arabidopsis thaliana GN=ARF1 PE=1 SV=2 - [ARF1_ARATH] ARF1_ARATH 
89 AAA-type ATPase family protein OS=Arabidopsis thaliana GN=AT1G45000 PE=4 SV=1 - [B3H533_ARATH] B3H533_ARATH 
90 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase 1 OS=Arabidopsis thaliana 
GN=MS1 PE=1 SV=1 - [METE1_ARATH] 
METE1_ARATH 
91 Elongation factor 1-alpha OS=Arabidopsis thaliana GN=AT5G60390 PE=3 SV=1 - [A8MSE8_ARATH] A8MSE8_ARATH 
92 40S ribosomal protein S3-3 OS=Arabidopsis thaliana GN=RPS3C PE=1 SV=1 - [RS33_ARATH] RS33_ARATH 
93 Heat shock protein 90-1 OS=Arabidopsis thaliana GN=HSP90-1 PE=1 SV=3 - [HS901_ARATH] HS901_ARATH 
94 Tubulin beta-4 chain OS=Arabidopsis thaliana GN=TUBB4 PE=2 SV=2 - [TBB4_ARATH] TBB4_ARATH 
95 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase 2 OS=Arabidopsis thaliana 
GN=MS2 PE=1 SV=1 - [METE2_ARATH] 
METE2_ARATH 
96 40S ribosomal protein S18 OS=Arabidopsis thaliana GN=RPS18A PE=1 SV=1 - [RS18_ARATH] RS18_ARATH 
97 Phosphoglycerate kinase OS=Arabidopsis thaliana GN=T8K14.3 PE=2 SV=1 - [Q9SAJ4_ARATH] Q9SAJ4_ARATH 
98 Heat shock 70 kDa protein 5 OS=Arabidopsis thaliana GN=HSP70-5 PE=2 SV=1 - [HSP7E_ARATH] HSP7E_ARATH 
99 Adenosylhomocysteinase 2 OS=Arabidopsis thaliana GN=SAHH2 PE=1 SV=1 - [SAHH2_ARATH] SAHH2_ARATH 
100 20S proteasome alpha subunit PAD1 OS=Arabidopsis thaliana GN=PAD1 PE=4 SV=1 - [Q2V3Q0_ARATH] Q2V3Q0_ARATH 
101 Catalase OS=Arabidopsis thaliana GN=CAT2 PE=2 SV=1 - [F4JM86_ARATH] F4JM86_ARATH 
102 Chaperone protein ClpB1 OS=Arabidopsis thaliana GN=CLPB1 PE=1 SV=2 - [CLPB1_ARATH] CLPB1_ARATH 
103 40S ribosomal protein S23-2 OS=Arabidopsis thaliana GN=RPS23B PE=2 SV=2 - [RS232_ARATH] RS232_ARATH 
104 ATP synthase subunit alpha, mitochondrial OS=Arabidopsis thaliana GN=ATPA PE=1 SV=2 - 
[ATPAM_ARATH] 
ATPAM_ARATH 
105 Cell division control protein 48 homolog A OS=Arabidopsis thaliana GN=CDC48A PE=1 SV=1 - 
[CD48A_ARATH] 
CD48A_ARATH 
106 Pyruvate kinase OS=Arabidopsis thaliana GN=AT3G52990 PE=2 SV=1 - [A8MR07_ARATH] A8MR07_ARATH 
107 60S ribosomal protein L7-3 OS=Arabidopsis thaliana GN=RPL7C PE=2 SV=1 - [RL73_ARATH] RL73_ARATH 
108 Heat shock protein 90-4 OS=Arabidopsis thaliana GN=HSP90-4 PE=2 SV=1 - [HS904_ARATH] HS904_ARATH 
109 60S ribosomal protein L13-3 OS=Arabidopsis thaliana GN=RPL13D PE=2 SV=1 - [RL133_ARATH] RL133_ARATH 
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110 18.1 kDa class I heat shock protein OS=Arabidopsis thaliana GN=HSP18.1 PE=2 SV=1 - [HS181_ARATH] HS181_ARATH 
111 60S ribosomal protein L13 OS=Arabidopsis thaliana GN=BBC1 PE=3 SV=1 - [A8MQA1_ARATH] A8MQA1_ARATH 
112 40S ribosomal protein S6-2 OS=Arabidopsis thaliana GN=EMB3010 PE=2 SV=1 - [F4KGU2_ARATH] F4KGU2_ARATH 
113 60S ribosomal protein L26-2 OS=Arabidopsis thaliana GN=RPL26B PE=2 SV=1 - [RL262_ARATH] RL262_ARATH 
114 Cytosolic isocitrate dehydrogenase [NADP] OS=Arabidopsis thaliana GN=CICDH PE=2 SV=1 - 
[ICDHC_ARATH] 
ICDHC_ARATH 
115 Peptidyl-prolyl cis-trans isomerase OS=Arabidopsis thaliana GN=CYP5 PE=1 SV=1 - [A8MS66_ARATH] A8MS66_ARATH 
116 Peroxidase 72 OS=Arabidopsis thaliana GN=PER72 PE=1 SV=1 - [PER72_ARATH] PER72_ARATH 
117 Ras-related protein RABB1c OS=Arabidopsis thaliana GN=RABB1C PE=2 SV=1 - [RAB1C_ARATH] RAB1C_ARATH 
118 6-phosphogluconate dehydrogenase, decarboxylating 1, chloroplastic OS=Arabidopsis thaliana 
GN=At1g64190 PE=2 SV=1 - [6PGD1_ARATH] 
6PGD1_ARATH 
119 40S ribosomal protein S16-3 OS=Arabidopsis thaliana GN=AT5G18380 PE=3 SV=1 - [A8MRX2_ARATH] A8MRX2_ARATH 
120 6-phosphogluconate dehydrogenase, decarboxylating 3 OS=Arabidopsis thaliana GN=At3g02360 PE=2 
SV=1 - [6GPD3_ARATH] 
6GPD3_ARATH 
121 Serine hydroxymethyltransferase 4 OS=Arabidopsis thaliana GN=SHM4 PE=1 SV=1 - [GLYC4_ARATH] GLYC4_ARATH 
122 Probable fructokinase-1 OS=Arabidopsis thaliana GN=At2g31390 PE=2 SV=1 - [SCRK1_ARATH] SCRK1_ARATH 
123 26S proteasome non-ATPase regulatory subunit 14 homolog OS=Arabidopsis thaliana GN=RPN11 PE=1 
SV=1 - [PSDE_ARATH] 
PSDE_ARATH 
124 ATP-citrate synthase beta chain protein 1 OS=Arabidopsis thaliana GN=ACLB-1 PE=2 SV=1 - 
[ACLB1_ARATH] 
ACLB1_ARATH 
125 Proteasome subunit beta type-2-A OS=Arabidopsis thaliana GN=PBD1 PE=1 SV=1 - [PSB2A_ARATH] PSB2A_ARATH 
126 V-type proton ATPase catalytic subunit A OS=Arabidopsis thaliana GN=VHA-A PE=1 SV=1 - 
[VATA_ARATH] 
VATA_ARATH 
127 ATP synthase subunit alpha OS=Arabidopsis thaliana GN=AT2G07698 PE=2 SV=1 - [F4IMB5_ARATH] F4IMB5_ARATH 
128 40S ribosomal protein S25-3 OS=Arabidopsis thaliana GN=RPS25D PE=3 SV=2 - [RS253_ARATH] RS253_ARATH 
129 26S proteasome regulatory subunit 4 homolog B OS=Arabidopsis thaliana GN=RPT2B PE=1 SV=1 - 
[PRS4B_ARATH] 
PRS4B_ARATH 
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130 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform OS=Arabidopsis thaliana 
GN=PP2AA2 PE=1 SV=2 - [2AAB_ARATH] 
2AAB_ARATH 
131 40S ribosomal protein S20-2 OS=Arabidopsis thaliana GN=RPS20B PE=2 SV=1 - [RS202_ARATH] RS202_ARATH 
132 Heat shock 70 kDa protein 7, chloroplastic OS=Arabidopsis thaliana GN=HSP70-7 PE=1 SV=1 - 
[HSP7G_ARATH] 
HSP7G_ARATH 
133 60S ribosomal protein L7a-2 OS=Arabidopsis thaliana GN=RPL7AB PE=1 SV=1 - [RL7A2_ARATH] RL7A2_ARATH 
134 40S ribosomal protein S3a-2 OS=Arabidopsis thaliana GN=RPS3AB PE=2 SV=3 - [RS3A2_ARATH] RS3A2_ARATH 
135 Glutamate decarboxylase 4 OS=Arabidopsis thaliana GN=GAD4 PE=2 SV=1 - [DCE4_ARATH] DCE4_ARATH 
136 S-adenosylmethionine synthase 2 OS=Arabidopsis thaliana GN=SAM2 PE=1 SV=1 - [METK2_ARATH] METK2_ARATH 
137 Phosphoenolpyruvate carboxylase 1 OS=Arabidopsis thaliana GN=PPC1 PE=1 SV=1 - [CAPP1_ARATH] CAPP1_ARATH 
138 UDP-arabinopyranose mutase 1 OS=Arabidopsis thaliana GN=RGP1 PE=1 SV=1 - [RGP1_ARATH] RGP1_ARATH 
139 14-3-3-like protein GF14 omega OS=Arabidopsis thaliana GN=GRF2 PE=2 SV=2 - [14332_ARATH] 14332_ARATH 
140 Glutamine synthetase cytosolic isozyme 1-4 OS=Arabidopsis thaliana GN=GLN1-4 PE=1 SV=1 - 
[GLN14_ARATH] 
GLN14_ARATH 
141 UDP-arabinopyranose mutase 3 OS=Arabidopsis thaliana GN=RGP3 PE=1 SV=2 - [RGP3_ARATH] RGP3_ARATH 
142 Ribosomal protein S5/Elongation factor G/III/V family protein OS=Arabidopsis thaliana GN=AT3G12915 
PE=4 SV=1 - [F4JB05_ARATH] 
F4JB05_ARATH 
143 AT2G44100 protein OS=Arabidopsis thaliana GN=GDI1 PE=2 SV=1 - [B9DFX1_ARATH] B9DFX1_ARATH 
144 Citrate synthase 3, peroxisomal OS=Arabidopsis thaliana GN=CSY3 PE=2 SV=1 - [CISY3_ARATH] CISY3_ARATH 
145 UDP-glucose 6-dehydrogenase 2 OS=Arabidopsis thaliana GN=UGD2 PE=1 SV=1 - [UGDH2_ARATH] UGDH2_ARATH 
146 Proteasome subunit beta type-5-B OS=Arabidopsis thaliana GN=PBE2 PE=1 SV=1 - [PSB5B_ARATH] PSB5B_ARATH 
147 Uncharacterized protein OS=Arabidopsis thaliana GN=AT1G47980 PE=2 SV=1 - [F4HWR0_ARATH] F4HWR0_ARATH 
148 At1g30580 OS=Arabidopsis thaliana GN=T5I8.3 PE=2 SV=1 - [Q9SA73_ARATH] Q9SA73_ARATH 
149 26S protease regulatory subunit 6B homolog OS=Arabidopsis thaliana GN=RPT3 PE=1 SV=1 - 
[PRS6B_ARATH] 
PRS6B_ARATH 
150 HSP90-like protein GRP94 OS=Arabidopsis thaliana GN=SHD PE=2 SV=1 - [F4JQ55_ARATH] F4JQ55_ARATH 
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151 GDP-mannose 3,5-epimerase OS=Arabidopsis thaliana GN=At5g28840 PE=1 SV=1 - [GME_ARATH] GME_ARATH 
152 V-type proton ATPase subunit B1 OS=Arabidopsis thaliana GN=VHA-B1 PE=2 SV=2 - [VATB1_ARATH] VATB1_ARATH 
153 40S ribosomal protein S4-2 OS=Arabidopsis thaliana GN=AT5G07090 PE=2 SV=1 - [F4K5C7_ARATH] F4K5C7_ARATH 
154 Peroxisomal isocitrate dehydrogenase [NADP] OS=Arabidopsis thaliana GN=ICDH PE=1 SV=1 - 
[ICDHX_ARATH] 
ICDHX_ARATH 
155 ADP,ATP carrier protein 3, mitochondrial OS=Arabidopsis thaliana GN=AAC3 PE=1 SV=1 - [ADT3_ARATH] ADT3_ARATH 
156 NAD-dependent malic enzyme 2, mitochondrial OS=Arabidopsis thaliana GN=NAD-ME2 PE=1 SV=1 - 
[MAO2_ARATH] 
MAO2_ARATH 
157 Cysteine synthase, chloroplastic/chromoplastic OS=Arabidopsis thaliana GN=OASB PE=1 SV=2 - 
[CYSKP_ARATH] 
CYSKP_ARATH 
158 Clp ATPase OS=Arabidopsis thaliana GN=HSP93-III PE=3 SV=1 - [F4JF64_ARATH] F4JF64_ARATH 
159 Guanine nucleotide-binding protein subunit beta-like protein B OS=Arabidopsis thaliana GN=RACK1B PE=2 
SV=1 - [GPLPB_ARATH] 
GPLPB_ARATH 
160 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial OS=Arabidopsis thaliana 
GN=At2g20360 PE=2 SV=2 - [NDUA9_ARATH] 
NDUA9_ARATH 
161 TCP-1/cpn60 chaperonin family protein OS=Arabidopsis thaliana GN=AT3G11830 PE=2 SV=1 - 
[F4J7H2_ARATH] 
F4J7H2_ARATH 
162 Heat shock protein 60-2 OS=Arabidopsis thaliana GN=HSP60-2 PE=2 SV=1 - [F4IVR2_ARATH] F4IVR2_ARATH 
163 Glutamate decarboxylase 2 OS=Arabidopsis thaliana GN=At1g65960 PE=2 SV=1 - [Q56W28_ARATH] Q56W28_ARATH 
164 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform OS=Arabidopsis 
thaliana GN=PP2AA1 PE=1 SV=1 - [2AAA_ARATH] 
2AAA_ARATH 
165 Probable phosphoglucomutase, cytoplasmic 1 OS=Arabidopsis thaliana GN=At1g23190 PE=2 SV=2 - 
[PGMC1_ARATH] 
PGMC1_ARATH 
166 Succinate-semialdehyde dehydrogenase, mitochondrial OS=Arabidopsis thaliana GN=ALDH5F1 PE=1 
SV=2 - [SSDH_ARATH] 
SSDH_ARATH 
167 60S ribosomal protein L4-1 OS=Arabidopsis thaliana GN=AT3G09630 PE=4 SV=1 - [Q2V3X4_ARATH] Q2V3X4_ARATH 
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168 Alpha-glucan phosphorylase 1 OS=Arabidopsis thaliana GN=PHS1 PE=1 SV=1 - [PHS1_ARATH] PHS1_ARATH 
169 40S ribosomal protein S2-4 OS=Arabidopsis thaliana GN=RPS2D PE=2 SV=1 - [RS24_ARATH] RS24_ARATH 
170 60S ribosomal protein L5-2 OS=Arabidopsis thaliana GN=RPL5B PE=2 SV=3 - [RL52_ARATH] RL52_ARATH 
171 Sucrose synthase 3 OS=Arabidopsis thaliana GN=SUS3 PE=1 SV=1 - [SUS3_ARATH] SUS3_ARATH 
172 Polyadenylate-binding protein 8 OS=Arabidopsis thaliana GN=PAB8 PE=1 SV=1 - [PABP8_ARATH] PABP8_ARATH 
173 Phenylalanine ammonia-lyase 3 OS=Arabidopsis thaliana GN=PAL3 PE=1 SV=3 - [PAL3_ARATH] PAL3_ARATH 
174 Aconitate hydratase 1 OS=Arabidopsis thaliana GN=ACO1 PE=1 SV=2 - [ACO1_ARATH] ACO1_ARATH 
175 26S proteasome non-ATPase regulatory subunit 2 homolog A OS=Arabidopsis thaliana GN=RPN1A PE=1 
SV=2 - [PSD2A_ARATH] 
PSD2A_ARATH 
176 Aldolase-type TIM barrel family protein OS=Arabidopsis thaliana GN=T22N19_70 PE=2 SV=1 - 
[Q9LYR4_ARATH] 
Q9LYR4_ARATH 
177 Aminopeptidase family protein OS=Arabidopsis thaliana GN=AT2G24200 PE=2 SV=1 - [F4INR3_ARATH] F4INR3_ARATH 
178 Pyruvate kinase OS=Arabidopsis thaliana GN=AT5G63680 PE=3 SV=1 - [Q9FFP6_ARATH] Q9FFP6_ARATH 
179 Tubulin alpha-3 chain OS=Arabidopsis thaliana GN=TUBA3 PE=2 SV=2 - [TBA3_ARATH] TBA3_ARATH 
180 UDP-glucose 6-dehydrogenase 3 OS=Arabidopsis thaliana GN=UGD3 PE=1 SV=1 - [UGDH3_ARATH] UGDH3_ARATH 
181 60S acidic ribosomal protein P0-1 OS=Arabidopsis thaliana GN=RPP0A PE=1 SV=1 - [RLA01_ARATH] RLA01_ARATH 
182 NADP-dependent malic enzyme 1 OS=Arabidopsis thaliana GN=NADP-ME1 PE=1 SV=1 - 
[MAOP1_ARATH] 
MAOP1_ARATH 
183 Clathrin heavy chain 2 OS=Arabidopsis thaliana GN=CHC2 PE=1 SV=1 - [CLAH2_ARATH] CLAH2_ARATH 
184 Isocitrate dehydrogenase [NAD] regulatory subunit 3, mitochondrial OS=Arabidopsis thaliana GN=IDH3 
PE=1 SV=1 - [IDH3_ARATH] 
IDH3_ARATH 
185 Glucose-6-phosphate isomerase, cytosolic OS=Arabidopsis thaliana GN=PGIC PE=2 SV=1 - 
[G6PI_ARATH] 
G6PI_ARATH 
186 Glycine--tRNA ligase 1, mitochondrial OS=Arabidopsis thaliana GN=GLYRS-1 PE=2 SV=1 - 
[SYGM1_ARATH] 
SYGM1_ARATH 
187 HEAT SHOCK PROTEIN 89.1 OS=Arabidopsis thaliana GN=Hsp89.1 PE=2 SV=1 - [F4JFN3_ARATH] F4JFN3_ARATH 
188 Phosphoglucomutase, chloroplastic OS=Arabidopsis thaliana GN=PGMP PE=1 SV=2 - [PGMP_ARATH] PGMP_ARATH 
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189 Pectinesterase/pectinesterase inhibitor 3 OS=Arabidopsis thaliana GN=PME3 PE=2 SV=2 - 
[PME3_ARATH] 
PME3_ARATH 
190 Heat shock 70 kDa protein 14 OS=Arabidopsis thaliana GN=HSP70-14 PE=2 SV=1 - [HSP7O_ARATH] HSP7O_ARATH 
191 At1g56070/T6H22_13 OS=Arabidopsis thaliana GN=At1g56075 PE=2 SV=1 - [Q9ASR1_ARATH] Q9ASR1_ARATH 
192 Alpha-glucan water dikinase 2 OS=Arabidopsis thaliana GN=GWD2 PE=2 SV=3 - [GWD2_ARATH] GWD2_ARATH 
193 Chaperonin 60 subunit alpha 1, chloroplastic OS=Arabidopsis thaliana GN=CPN60A1 PE=1 SV=2 - 
[CPNA1_ARATH] 
CPNA1_ARATH 
194 Chaperonin 60 subunit beta 2, chloroplastic OS=Arabidopsis thaliana GN=CPN60B2 PE=1 SV=1 - 
[CPNB2_ARATH] 
CPNB2_ARATH 
195 Chaperonin 60 subunit beta 3, chloroplastic OS=Arabidopsis thaliana GN=CPN60B3 PE=1 SV=1 - 
[CPNB3_ARATH] 
CPNB3_ARATH 
196 Malate dehydrogenase OS=Arabidopsis thaliana GN=mMDH2 PE=3 SV=1 - [A8MQK3_ARATH] A8MQK3_ARATH 
197 Prohibitin-6, mitochondrial OS=Arabidopsis thaliana GN=PHB6 PE=1 SV=1 - [PHB6_ARATH] PHB6_ARATH 
198 Malate dehydrogenase, cytoplasmic 1 OS=Arabidopsis thaliana GN=At1g04410 PE=1 SV=2 - 
[MDHC1_ARATH] 
MDHC1_ARATH 
199 Malate dehydrogenase, cytoplasmic 2 OS=Arabidopsis thaliana GN=At5g43330 PE=2 SV=1 - 
[MDHC2_ARATH] 
MDHC2_ARATH 
200 Malate dehydrogenase, chloroplastic OS=Arabidopsis thaliana GN=At3g47520 PE=1 SV=1 - 
[MDHP_ARATH] 
MDHP_ARATH 
201 Bifunctional enolase 2/transcriptional activator OS=Arabidopsis thaliana GN=ENO2 PE=1 SV=1 - 
[ENO2_ARATH] 
ENO2_ARATH 
202 ATP synthase subunit beta-1, mitochondrial OS=Arabidopsis thaliana GN=At5g08670 PE=1 SV=1 - 
[ATPBM_ARATH] 
ATPBM_ARATH 
203 Fructose-bisphosphate aldolase OS=Arabidopsis thaliana GN=AT2G36460 PE=2 SV=1 - [Q9SJQ9_ARATH] Q9SJQ9_ARATH 
204 Proteasome subunit alpha type-6-A OS=Arabidopsis thaliana GN=PAA1 PE=1 SV=2 - [PSA6A_ARATH] PSA6A_ARATH 
205 Actin-7 OS=Arabidopsis thaliana GN=ACT7 PE=1 SV=1 - [ACT7_ARATH] ACT7_ARATH 
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206 NAD(P)H oxidoreductase, isoflavone reductase-like protein OS=Arabidopsis thaliana GN=T22F8.130 PE=2 
SV=1 - [Q9T030_ARATH] 
Q9T030_ARATH 
207 Formate dehydrogenase, mitochondrial OS=Arabidopsis thaliana GN=FDH1 PE=1 SV=1 - [FDH_ARATH] FDH_ARATH 
208 CBS domain-containing protein CBSX3, mitochondrial OS=Arabidopsis thaliana GN=CBSX3 PE=1 SV=1 - 
[CBSX3_ARATH] 
CBSX3_ARATH 
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Table S2: Lists of 95 potential bioactive peptides, generated by in-silico enzymatic digestion.  
PeptideRanker 
Score  
Peptides 
Sequence 
Peptides 
Lenght 
Class  
AMP Probability 
(CAMP_Analysis) 
Accession 
Number 
Protein Description 
0.93 CCSEFGW 7 NAMP  0.081 P19171 Basic endochitinase B 
0.92 DGQFRW 6 NAMP  0.001 Q9M111 Sucrose synthase 3 
0.89 NGFCDRM 7 NAMP  0.001 P92549 ATP synthase subunit alpha, mitochondrial 
0.85 NTWDRF 6 NAMP  0.003 Q9STY6 40S ribosomal protein S20-2 
0.85 GWNRSW 6 AMP  0.603 Q9STV0 Alpha-glucan water dikinase 2 
0.83 QNEWGW 6 AMP  0.774 P25696 Bifunctional enolase 2/transcriptional activator 
0.82 QQCDRF 6 NAMP  0.048 Q8L7K9 NAD-dependent malic enzyme 2, mitochondrial 
0.82 DNCCMQL 7 NAMP  0.135 O81796 Isocitrate dehydrogenase [NAD] regulatory subunit 3, mitochondrial 
0.81 YQNRGCF 7 NAMP  0.056 Q0WLB5 Clathrin heavy chain 2 
0.81 NSFRGDF 7 NAMP  0.003 Q9LSY8 UDP-glycosyltransferase 71B2 
0.81 ICCCNKM 7 AMP  0.699 A8MSE8 Elongation factor 1-alpha  
0.8 NGTCRWL 7 NAMP  0.019 P17562 S-adenosylmethionine synthase 2 
0.79 EKNDFCF 7 NAMP  0.208 P56785 Protein TIC 214 
0.78 GGCDKQGFP 9 NAMP  0.168 P51430 40S ribosomal protein S6-2 
0.78 GGCDKQGF 8 NAMP  0.041 P51430 40S ribosomal protein S6-2 
0.75 SKEQGFF 7 NAMP  0.003 P56786 Protein Ycf2 
0.75 GGQRQFNGM 9 NAMP  0.088 O49447 ADP,ATP carrier protein 3, mitochondrial 
0.74 QQCDRFI 7 NAMP  0.054 Q8L7K9 NAD-dependent malic enzyme 2, mitochondrial 
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0.74 DFDNRM 6 NAMP  0.003 O65719 Heat shock 70 kDa protein 3 
0.73 RWCSCNI 7 NAMP  0.128 Q9LK36 Adenosylhomocysteinase 2 
0.73 RPDRNF 6 AMP  0.88 P56786 Protein Ycf2 
0.73 QNTWGQF 7 NAMP  0.115 Q7PC86 ABC transporter G family member 35 
0.73 NQWKNW 6 AMP  0.989 P56785 Protein TIC 214 
0.73 MCQGGDF 7 NAMP  0.002 P34790 Peptidyl-prolyl cis-trans isomerase CYP18-3 
0.73 GQSKGYGF 8 NAMP  0.201 Q9FXA2 Polyadenylate-binding protein 8 
0.73 DNFTKW 6 NAMP  0.026 Q2V3X4 60S ribosomal protein L4-1 
0.73 CSCGDRPI 8 NAMP  0.01 Q9MAH0 Phosphoenolpyruvate carboxylase 1 
0.72 QNRGCFN 7 NAMP  0.497 Q0WLB5 Clathrin heavy chain 2 
0.72 QFNNGTW 7 NAMP  0.029 Q7XA90 At1g14210 
0.71 NDNQLRF 7 NAMP  0.28 Q9MAQ0 Probable granule-bound starch synthase 1, chloroplastic/amyloplastic 
0.71 DKSFDCL 7 NAMP  0.005 Q84UU4 Alpha-humulene/(-)-(E)-beta-caryophyllene synthase 
0.7 CVQQCDRF 8 NAMP  0.016 Q8L7K9 NAD-dependent malic enzyme 2, mitochondrial 
0.69 NGNDFRY 7 NAMP  0.006 P92994 Trans-cinnamate 4-monooxygenase 
0.69 MGGCDKQGF 9 NAMP  0.024 P51430 40S ribosomal protein S6-2 
0.69 GQMDRTF 7 NAMP  0.006 P56786 Protein Ycf2 
0.69 FNKDTGF 7 NAMP  0.01 Q8L7K9 NAD-dependent malic enzyme 2, mitochondrial 
0.69 DGSHNRW 7 NAMP  0.001 Q9STV0 Alpha-glucan water dikinase 2 
0.67 NNCQSNCWGS 10 NAMP  0.01 P43082 Hevein-like preproprotein 
0.67 GQTCDWI 7 NAMP  0.003 Q0WLB5 Clathrin heavy chain 2 
0.67 CSPNEKW 7 NAMP  0.003 Q0WLB5 Clathrin heavy chain 2 
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0.66 NNCQSNCW 8 NAMP  0.106 P43082 Hevein-like preproprotein 
0.66 GDLGCQGM 8 NAMP  0.003 O82191 NADP-dependent malic enzyme 1 
0.66 EGRSGCGF 8 NAMP  0.003 Q84UU4 Alpha-humulene/(-)-(E)-beta-caryophyllene synthase 
0.66 CDSQKGCCPP 10 NAMP  0.42 Q7XA90 At1g14210 
0.66 CDSQKGCCP 9 NAMP  0.454 Q7XA90 At1g14210 
0.65 PQTDRW 6 NAMP  0.432 Q9LK36 Adenosylhomocysteinase 2 
0.65 DGTQNEWGW 9 NAMP  0.186 P25696 Bifunctional enolase 2/transcriptional activator 
0.65 CCSQYGY 7 NAMP  0.019 P43082 Hevein-like preproprotein 
0.65 CCCNKMD 7 NAMP  0.133 A8MSE8 Elongation factor 1-alpha  
0.64 DQRQFL 6 NAMP  0.116 P56786 Protein Ycf2 
0.63 RSGGHDF 7 NAMP  0.002 Q9FKV0 Berberine bridge enzyme-like protein 
0.63 DDQGINF 7 NAMP  0.059 Q9SID0 Probable fructokinase-1 
0.63 DCYNQRSF 8 NAMP  0.003 P19171 Basic endochitinase B 
0.62 RGCFNEL 7 NAMP  0 Q0WLB5 Clathrin heavy chain 2 
0.62 KSCWDK 6 NAMP  0.049 Q7PC86 ABC transporter G family member 35 
0.62 ESCFRDP 7 NAMP  0.001 P56786 Protein Ycf2 
0.61 DFGNENCL 8 NAMP  0.012 Q9S7C0 Heat shock 70 kDa protein 14 
0.6 SEHGNRF 7 NAMP  0.005 Q95748 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3 
0.6 GNQSFRI 7 NAMP  0.04 Q0WRS4 Putative heat shock protein 
0.59 SQCRQM 6 NAMP  0.006 Q9SAK4 Succinate-semialdehyde dehydrogenase, mitochondrial 
0.59 FDSRGNP 7 NAMP  0.006 P25696 Bifunctional enolase 2/transcriptional activator 
0.58 GQPDSRNM 8 NAMP  0.012 P43082 Hevein-like preproprotein 
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0.58 FCDQTNL 7 NAMP  0.205 Q7XA90 At1g14210 
0.58 EDFKCSW 7 NAMP  0 Q43315 Farnesyl pyrophosphate synthase 2 
0.58 CCCNKMDA 8 NAMP  0.256 A8MSE8 Elongation factor 1-alpha  
0.57 RGSGGNML 8 NAMP  0.002 P56786 Protein Ycf2 
0.57 QQSDFR 6 NAMP  0.05 P56785 Protein TIC 214 
0.57 NRCQSMM 7 NAMP  0 P34795 Glucose-6-phosphate isomerase, cytosolic 
0.57 GQQCGRQGGG 10 NAMP  0.002 P43082 Hevein-like preproprotein 
0.57 EGRSGCGFH 9 NAMP  0.002 Q84UU4 Alpha-humulene/(-)-(E)-beta-caryophyllene synthase 
0.57 DSQKGCCPP 9 NAMP  0.26 Q7XA90 At1g14210 
0.56 DSQKGCCP 8 NAMP  0.15 Q7XA90 At1g14210 
0.56 DACDRNL 7 NAMP  0.001 Q9C522 ATP-citrate synthase beta chain protein 1 
0.55 RNCDPNGP 8 NAMP  0.003 Q9ASR1 elongation factor EF-2-like protein LOS1 
0.55 EFGQTCDW 8 NAMP  0.001 Q0WRS4 Putative heat shock protein 
0.55 DCSQFDN 7 NAMP  0.013 P56786 Protein Ycf2 
0.54 GGNMRDSF 8 NAMP  0.003 Q9SF16 T-complex protein 1 subunit eta 
0.54 EHGNRF 6 NAMP  0.005 Q95748 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3 
0.53 SGDGRYY 7 NAMP  0 O49299 Probable phosphoglucomutase, cytoplasmic 1 
0.53 QCRQMSM 7 NAMP  0.001 Q9SAK4 Succinate-semialdehyde dehydrogenase, mitochondrial 
0.53 GSEGFQKL 8 NAMP  0.034 Q9C522 ATP-citrate synthase beta chain protein 1 
0.53 DNCRENMM 8 NAMP  0 Q9ZPS3 Glutamate decarboxylase 4 
0.53 CTKDWY 6 NAMP  0.002 Q9STV0 Alpha-glucan water dikinase 2 
0.53 AGQQCGRQGGG 11 NAMP  0.005 P43082 Hevein-like preproprotein 
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0.52 NGKNTCPL 8 NAMP  0.012 O22850 Probable glutathione peroxidase 3, mitochondrial 
0.52 GGSCFQKDI 9 NAMP  0.057 Q9LIA8 UDP-glucose 6-dehydrogenase 2 
0.52 ESRQWL 6 NAMP  0.009 Q43315 Farnesyl pyrophosphate synthase 2 
0.52 CRNGEW 6 NAMP  0 P57106 Malate dehydrogenase, cytoplasmic 2 
0.51 QFDTKM 6 NAMP  0.006 Q9CAI7 Eukaryotic initiation factor 4A-3 
0.51 FCEQCGV 7 NAMP  0.015 P56763 DNA-directed RNA polymerase subunit beta' 
0.5 QNRGCFNEL 9 NAMP  0.039 Q0WLB5 Clathrin heavy chain 2 
0.5 KNNYDF 6 AMP  0.905 P56785 Protein TIC 214 
0.5 GWCGNTEP 8 NAMP  0.003 P19171 Basic endochitinase B 
0.5 DSCMERI 7 NAMP  0 Q38876 Agamous-like MADS-box protein AGL8 
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Conclusions  
The present study provides new insight into the proteome of two amazing sources of 
bioactive proteins (Bovine Colostrum and Panax Ginseng), that could be exploited in 
the nutraceutical and pharmaceutical filed, coupling the power of the Combinatorial 
Peptide Ligand Library (CPLL) technology, the SDS-PAGE separation and the high 
resolution nLC-ESI MS/MS. The potentialities of ProteoMiner technique deserve 
special mention, for its capability in greatly expanding the visibility of low- to very-low 
abundance species, up to now unexplored. Overall, it has been underlined the 
importance of proteomics in the pharmaceutical field and in particular for elucidating 
the biological effects of complex protein matrices. 
Moreover, the proteomic research has concluded with a novelty in Panax ginseng 
studies: a peptidomic investigation by simulating in-silico the enzymatic protein 
digestion in the human gastrointestinal tract, to evaluate a possible antimicrobial 
activity expressed by proteolytic peptides.  
This work contributes not only to mapping the Bovine Colostrum and Panax 
Ginseng proteome, but also to setting-up a suitable analytical platform aimed at 
achieving an high standardization and an in-depth quality profiling of bovine 
colostrum in the manufacture of food supplements. 
Such an approach also permits the exploration of novel biological functions of Bovine 
Colostrum and Panax Ginseng by searching in the “homemade” database for the 
presence of proteins characterized by innovative functions. 
This knowledge can be used in the future for further "explorations" of different natural 
sources of bioactive macromolecules, known to be effective in several claimed 
healthy effects.   
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